This stock is WAY underpriced. Equity per share is $16.07, and yet the price is below $5! Having shares of DSS will give you two shares of the Impact IPO that will be released in 2021.
Update (12/22/20): Still holding strong! I believe the price of this stock will come close to doubling in the coming months.
Update (1/19/21): Nothing has changed yet. I’m awaiting news on the Impact Bio IPO shares that we will obtain for holding this stock.
Update (1/26/21): Blegh. DSS had an offering, but the stock price has gone up since then. It’s a nice time to buy low, especially with shares of Impact IPO coming soon.
Update (1/31/21): No real update. Waiting on Impact IPO news.
Update (2/7/21): DSS had a second offering, which sucks in the short term, but the money will likely be used to make an acquisition of some sort. This is one of my least-favorite stocks right now; I’m only holding on for the Impact IPO shares.
Update (2/15/21): Just a reminder that the float here is just 4.35 million shares, and this stock is 14.7-percent shorted. This could blow at any moment.
Update (2/21/21): This continues to be undervalued. Be patient, and it’ll pay off.
Update (2/28/21): This stock was hurt by the market crash and the Bitcoin drop – they handle blockchain security – which would explain why it dropped to $3.50. This is very undervalued. Increasing to two stars.
Update (3/5/21): There’s no news here, but the $3 price is way too low. This is a bargain right now, but I wouldn’t be surprised to see this go to $2.50.
Update (3/14/21): DSS is approaching $4 again, and I’m bullish on it eclipsing that figure this week. With Bitcoin soaring, blockchain plays should do well, and this is one of them.
Update (3/21/21): DSS had a nice week, closing at $4.26. It sounds like Impact Bio IPO share distribution will be in Q2. For every share of DSS you own by a certain date, you’ll get two shares of Impact. I currently have 3,500 shares, and I’m looking to add more if this dips under $4.
Update (3/28/21): It’s not shown above, but I bought some DSS under $4. This is an NFT play that hasn’t spiked yet.
Update (4/4/21): Some of my DSS shares were borrowed, but not all of them. This is a cheap buy with tons of upside. Now that this is well under $4, I’m bumping it up to three stars.
Update (4/11/21): DSS dropped on low volume this past week. It’s insanely cheap at the moment.
Update (4/18/21): DSS continues to fall because of manipulation. It’s extremely oversold and will have a huge bounce once there’s some news.
Update (4/25/21): DSS announced that they are moving to a huge facility (150,000 square feet), which could come with some other news. There are so many catalysts with this company. Given the new short-selling rules, this could squeeze sooner than expected.
Update (5/8/21): A 13F filing revealed Friday that Blackrock bought 525,000 shares of this company at $4.67. Think of how undervalued DSS is at the moment.
Update (5/16/21): Here’s another nice 13F filing: Vanguard bought 435,000 shares at $4.92. DSS continues to be a heavily shorted undervalued stock.
Update (5/23/21): Goldman Sachs used to own a position in DSS, but they sold off back in 2018. Well, they’re back! They just bought 131,000 shares.
Update (5/30/21): Here’s some more inside buying: The Ultra-Small Company Market Fund bought 100,500 shares of DSS at $3.61. At any rate, the CEO of DSS announced that we’ll have a record date set for the Impact IPO at the end of the second quarter, so we should have news in the next 30 days.
Update (6/6/21): We’re still waiting for Impact news, but it was nice to see a Vanguard index fund buy 26,173 shares of DSS at $3.61 per a June 1 13F filing.
Update (6/13/21): We had some good news this week on DSS. Nothing on the Impact front, but the company was added to the Russell micro cap index. That could help as a catalyst for this to squeeze, which is long overdue.
Update (6/20/21): Good news/bad news. The bad news is that DSS had an offering, which sunk the stock price. The good news is that the CEO bought 1.7 million shares after the offering. So, the CEO made money issuing new shares and then bought a bunch of shares cheaply, which I think is a good thing in the long run. Hopefully we get some great news soon (including Impact IPO.)
Update (6/27/21): Thanks to last week’s purchase by the CEO, Fintel has given DSS a 90.34 ownership score, which is 353 out of 11,725. The ownership score is a “sophisticated, multi-factor quantitative model that identifies companies with the highest levels of institutional accumulation.” The CEO bought this stock cheaply, so he obviously knows something that could cause the price to rise.
Update (7/4/21): Well, it’s July, which means that Q2 is over. And yet, we’ve heard no news on the Impact Bio IPO. However, the CEO bought a ton of shares around this price, so he expects it to rise. Also, I was looking at the filings, and I wasn’t happy to see that Citadel owned 35,000 shares of DSS. Ken Griffin will likely have to sell those shares once he gets squeezed out of AMC, but 35,000 shares won’t make or break this stock price.
Update (7/11/21): Nothing new to add this week except some chart stuff. DSS’ RSI is 28.65, which means that it’s incredibly oversold.
Update (7/18/21): DSS’ RSI is even lower than last week. It’s now 24.58. Remember, the CEO of this company recently bought a ton of shares, so he knows that the price will rise eventually. This could go once we’re out of this miserable bear market.
Update (8/1/21): This stock has been a huge turd for a while, but I’ll remind you of what I wrote two weeks ago: The CEO of this company bought lots of shares, so he’s expecting something good to happen with it soon.
Update (8/8/21): Nothing changed this past week – there weren’t any new filings of note either – but I will once again point out that the CEO bought 350,000 shares, so he expects this stock to rise.
Update (8/15/21): Vanguard Group bought 1.4 million shares of DSS at an average price of $2.70! Between this, as well as the CEO’s purchases, someone knows something.
Update (8/22/21): Nothing new to add at the moment. As I’ve been writing, the CEO bought lots of shares recently, so something’s going to happen soon.
Update (8/29/21): Morgan Stanley bought 90,000 shares of DSS, and there was a report about Impact BioMedical reporting psitive test results. That’s great and all, but I’d love to get some news on Impact BioMedical’s IPO so we can get some free shares.
Update (9/5/21): Zzzzz…
I have nothing to say about this right now. The CEO bought shares, so he’s expecting something good to happen.
Update (9/12/21): It appeared as though we had a glimmer of hope when DSS jumped from $1.33 to $1.41 one day, but then it went back to $1.33. The news here was that DSS invested $40 million into American Pacific Bancorp (APB), becoming a majority shareholder. APB will issue 6.7 million shares of its common stock to DSS at $6 per share. This could be why the CEO was buying his shares earlier. And speaking of, let’s see what the CEO did this week…
Wow, a 12 million-share purchase! That’s some major conviction. I’ll be buying more shares this upcoming week.
Update (9/19/21): I bought more shares as promised, though I waited until the end-of-week dip. It dawned on me that the CEO buying all of those shares could mean that he expects the Impact BIO IPO to happen soon.
Update (9/26/21): I bought even more shares this past week after the Monday market crash. News has to be coming soon because the CEO bought so many shares.
Update (10/3/21): There are dumb FUD bears spreading dilution scares on StockTwits, but that doesn’t seem likely because of all the shares the CEO has purchased. It’s more likely that big news is coming soon.
Update (10/10/21): We’ve reached a lower price compared to where the CEO bought shares of this company. This seems like a bargain, but I can understand why people would be skeptical, given this company’s dilution-crazed past.
Update (10/17/21): Here’s a good summary of why I like DSS right now:
The CEO bought tons of shares. That has to mean the Impact Bio shares are coming soon. I bought more shares Friday.
Update (10/24/21): Spire Wealth Management bought 30,000 shares of DSS, effective Sept. 30. Like the CEO, this hedge fund realizes something big will happen here soon.
Update (10/31/21): DSS popped a bit this past week, but it seems as though there’s more to come. Check out this nice DD that I found:
Update (11/7/21): Breaking news: DSS Acquires Three Established Acute Care Hospitals in Texas and Pennsylvania.
Update (11/14/21): You better believe there will be some tax selling here, thanks to the multiple offerings from this company this past year. However, as mentioned repeatedly, the CEO bought tons of shares around this price, so he expects this stock to increase in price at some point.
Update (11/21/21): It’s hard to believe that this dropped below $1 when the CEO bought shares at a higher price. According to FinViz, DSS book value is $4.80, which just shows how undervalued this stock is.
Update (11/28/21): I still can’t believe that this stock is so cheap after the CEO bought above $1. I purchased more shares this week at 86 cents.
Update (12/5/21): I keep saying this, but the CEO bought above $1. I don’t think he’s going to dilute more after doing so. I would expect more share repurchasing than anything.
Update (12/12/21): DSS had a nice run this past week, at least until Thursday. This is still a great price, as RSI is at 34.
Update (12/19/21): There was more inside buying this week from DSS owners. Like CLOV, this too has a no-buy 30-day window at the moment.
Update (12/26/21): DSS had a nice move from 67 cents to 78 cents this past week, but the price is still way below at which the CEO bought. DSS has some gaps to fill, so perhaps we’ll get there at some point in 2022. It would help if we got some Impact Bio news!
Update (1/9/22): DSS is back to 67 cents, so perhaps this is the bottom of the chart. I suspect we’ll go above $1 again once the small-cap shorting stops, which should be soon.
Update (1/16/22): DSS’ market cap is $56 million, and their annual revenue is $19 million. There’s a bit of a disparity there, but the CEO bought shares above $1.
Update (1/30/22): DSS’ market cap is down to $33.8 million. Their revenue last year was half of that. Unfortunately, there’s nothing of note related to on-balance volume.
Update (2/6/22): DSS’ cost to borrow has doubled from 0.6 to 1.3 percent. That’s not a high number, but at least it’s something…
Update (2/13/22): The borrowing fee has remained stagnant, much like the price. Remember, the CEO bought shares at a much more expensive price than this.
Update (2/27/22): Nothing new thee past two weeks. Waiting for this company to release news is like watching grass
Update (3/6/22): DSS rose twice to around 60 cents because the CEO published a letter to shareholders. There were plenty of big promises in this letter. This could be more talk, no walk, but the insiders bought lots of shares at a higher price than this.
Update (3/13/22): DSS had an amazing week, with the CEO of this company buying $4 million shares! Something is going down soon, perhaps regarding the Impact Bio shares.
Update (3/27/22): Will Meade highlighted DSS in a tweet last week:
I honestly didn’t even know that DSS was that heavily shorted, so I was glad to see this.
Update (4/3/22): Nothing new this week. This is still undervalued.
This stock fell from $60 to $35 because of the 180-day lockdown period, plus election week. This is a great buy-low opportunity for a company with a billion in cash and no debt. DraftKings is the future of fantasy football and gambling. It will be $100 one day.
Update (12/22/20): Andrew Cuomo has destroyed New York, so he may be forced into legalizing gambling. If so, we may see a $100 price.
Update (1/19/21): We’re still waiting on New York to legalize gambling. It’s going to happen sooner or later because the dumb politicians in New York have bankrupted the state. Hey New Yorkers, you may want to vote these idiots out at some point.
Update (1/26/21): No change. Come on New York, legalize sports gambling!
Update (1/31/21): These are so many $60 calls of DraftKings expiring Friday, Feb. 5:
If the stock price closes above $60 next week, this will skyrocket the following week. Look for the scumbag shorts to keep this below $60 with all their might.
Update (2/7/21): The stock closed above $60, so it should continue to rise. DraftKings remains a strong play until some of the major states legalize sports betting.
Update (2/15/21): The most Feb. 12 calls were at $60 and $61, and they all finished in the money, which provides a nice outlook for the coming week. The most Feb. 19 calls are currently for $65, so let’s see if this trend continues.
Update (2/21/21): The most Feb. 19 calls ended up being at $60, which were in the money. I don’t see why this wouldn’t keep going up. We’ll see $100-plus at some point.
Update (2/28/21): DraftKings just had a great earnings report, and they just increased their revenue guidance. There’s no reason this should be trading for less than $100 per share.
Update (3/5/21): DraftKings should have soared in the wake of their great earnings, but the market crash prevented that from happening. We’ll see this approach $100 once everything returns to normal.
Update (3/14/21): DraftKings crossed $70 for the first time this past week. With Penn running to $130, we should see DraftKings make a run to triple digits soon.
Update (3/21/21): DraftKings had a strong close to the week, finishing at $71.98. DraftKings basically just prints money, so the sky is the limit for this company.
Update (3/28/21): DraftKings dropped along with everything else last week. Anything less than $60, and you could be looking to double your money within a year.
Update (4/4/21): No DraftKings shares were borrowed (see CLOV for details.) There’s some negativity here, however, because Major League Baseball engaged in SJW nonsense by moving the All-Star game out of Atlanta. I don’t think it was a coincidence that none of DraftKings’ MLB contests filled that day.
Update (4/11/21): There are rumors of sports betting being legal in New York by the beginning of the NFL season. If that happens, this will take off toward $100.
Update (4/18/21): DraftKings has partnered with the NFL to be their sports betting partner. You’d think this would cause its stock price to skyrocket, but it barely moved.
Update (4/25/21): I still have no idea how DraftKings is under $100, let alone $60. I have no news to report, but this continues to be undervalued.
Update (5/8/21): I wrote above that the market felt like a bottomless pit this past week. Companies with great earnings tanked, and that includes DraftKings. It beat revenue estimates, yet lost money because they spent a ton on advertising. This reaction might be the dumbest thing ever. Why would DraftKings be punished for advertising in an attempt to recruit future customers? It makes no sense. They basically print money, and they should be over $100 right now.
Update (5/16/21): I don’t understand how DraftKings fell to $41 at some point this week, but it jumped back up on Friday. This is still a nice time to get into DraftKings, which should be at least $100.
Update (5/23/21): We don’t have 13F filings for what has transpired since DraftKings dipped into the $40s, but I imagine plenty of institutions have been loading up on this very cheap price.
Update (5/30/21): DraftKings had a nice rally this week, shooting back up into the $50s. This is still an undervalued company with tons of cash and no debt.
Update (6/6/21): DraftKings remained stagnant this past week. A Vanguard index fund bought 113,340 shares at $61.13, according to a June 1 13F filing.
Update (6/13/21): DraftKings moved from $50 to $56 early in the week, but then fell to $53 on Friday. There are no new filings to speak of, save for 14,842 shares purchased by some entity called Prentice Wealth Management.
Update (6/20/21): DraftKings has been heavily shorted recently. There was a bogus hit piece that dropped the share price. DraftKings is now 9.8-percent shorted, which doesn’t sound like very much unless you factor in the large float. There are 33 million or so shares shorted, so we’ll have a squeeze at some point.
Update (6/27/21): DraftKings had a nice week, as sports betting will likely be legalized in Canada soon. Now that they’re done throwing healthy people into gang-run hotels, they’re finally concentrating on improving their economy.
Update (7/4/21): DraftKings remained steady this week, at least until Friday, which was a very red day for most of the market. At any rate, DraftKings has become more shorted recently, with the short interest rising to 10.5 percent. That may not sound like much, but DraftKings’ float is 366 million shares, which means 36.6 million shares will be bought by short-selling scum at some point.
Update (7/11/21): There was some major insider selling at the end of the week, which was disappointing to see. This has happened often, so I think DraftKings would’ve cracked $100 already if that didn’t happen. On the bright side, State Street bought 220,000 shares at an average price of $53.94, per a July 9 13F filing.
Update (7/18/21): A week after State Street bought 220,000 shares, Addison Capital purchased 56,000 shares at an average price of $56.69. DraftKings’ RSI is 29.49, making it extremely oversold.
Update (8/1/21): I mentioned Alliancebernstein earlier. They bought 283,000 shares of DraftKings on June 30 at an average price of 56.71.
Update (8/8/21): DraftKings had a nice earnings report, prompting the largest volume Friday that we had seen in about a month. This continues to be undervalued, as DraftKings basically just prints money.
Update (8/15/21): I’m grouping DraftKings and Golden Nugget together because DraftKings bought Golden Nugget! Those who have GNOG shares will receive .365 DKNG shares for each one at some point during Q1 of 2022. Thus, DraftKings and Golden Nugget will move together until then. I haven’t sold any of my GNOG shares in the wake of the news. I believe DraftKings should be at least $80, which would make Golden Nugget worth $29. At $100, which is reasonable as well, Golden Nugget would be $36.50.
Update (8/22/21): And so we wait. I believe DraftKings will be a $100 stock one day. I have no new updates this week, as we’re just waiting on news.
Update (8/29/21): DraftKings had a great week, so Golden Nugget did as well because they are moving together. There was awesome news Friday that ESPN is exploring a sports-betting deal worth at least $3 billion with Caesars and DraftKings. Also, we had another big buy: Morgan Stanley bought 600,000 shares of DraftKings.
Update (9/5/21): The bad news is that the hedge funds dropped this below $61, so lots of call options at that price finished out of the money. The good news is that there were slightly more in the money at $60:
It was nice to see this, so perhaps we’ll continue our trajectory up toward $100 soon.
Update (9/12/21): Perhaps getting some momentum from the start of the NFL season, DraftKings had a nice run up to $64 before it was rejected into the $62-63 range to end this week. Why did it fail to reach $64? Market manipulation, of course! The market makers certainly couldn’t allow those $64 call strikes to finish in the money:
Nevertheless, we have some big news:
The sports betting market is growing every year, and I’m glad I’m along for the ride.
Update (9/19/21): Macquarie issued a price target of $75 for DraftKings. We’ll go beyond that if ESPN news is officially released.
Update (9/26/21): DraftKings and Golden Nugget shares fell this weekend because DraftKings put in an expensive bid offer for another company. I saw speculation that DraftKings was simply doing this to drive up the price for its competitor, but this is all just speculation. There’s a nice dip buy opportunity with these companies right now, as DraftKings is basically printing money this football season.
Update (10/3/21): The down market and the nonsense bid offer I wrote about last week caused DraftKings to drop to $48. I considered buying more shares, but I thought it might drop lower. That didn’t happen, as DraftKings rose on Friday.
Update (10/10/21): The deal referenced on Sept. 26 hasn’t been canceled yet, which is why DraftKings is hovering below $50. This stock price will rise again if that bogus deal is nullified.
Update (10/17/21): There were tons of calls at every price at $50 or above, which is why the market makers dragged DraftKings down late in the week:
If you know some poor soul who buys calls each week, please send them here so they can see all the blatant market manipuation that happens all the time.
Update (10/24/21): The dropped price on Friday seems to be in relation to growth stocks taking a hit from interest rates. DraftKings is cheap, however, and definitely worth buying at this price.
Update (10/31/21): The deal has been nullified, yet this stock didn’t recover. It remains a nice value at the current price. Earnings, by the way, will be on Friday.
Update (11/7/21): The stock market is stupid sometimes, or maybe all the time. DraftKings plummeted Thursday because Penn posted disappointing earnings. DraftKings’ Friday earnings were fine, but the guidance was great. The CEO discussed a great 2022 and even said he expects a trillion dollars in revenue in the 2030s.
Update (11/14/21): DraftKings continues to tank, as the earnings report revealed that they’re burning through cash. Yes, it’s called spending money to make money, which is what growth companies do! DraftKings is very cheap right now, but I think we could see a drop into the $30s. Just a guess.
Update (11/21/21): DraftKings and Golden Nugget plummeted all week, with the former hitting the high $35s on Friday. We’re at a 52-week low for DraftKings, making it a great bargain at this price.
Update (11/28/21): I bought more shares of Golden Nugget this week at $12.50. There’s no reason it or DraftKings should be this low. The entire sector is down, so it’ll bounce back soon.
Update (12/5/21): I don’t think I’ve seen an RSI 16 except during March 2020. It would be crazy not to buy DraftKings at this level.
Update (12/12/21): DraftKings/Golden Nugget ran well early in the week, but collapsed along with the market by Friday. Penn is also down, as the entire sports-betting market is down for some reason. Everything is dirt cheap. It looks like we have resistance on DraftKings at around $27.50, so I have a buy order in place at that price.
Update (12/19/21): I bought more DraftKings shares at $27. The entire betting sector is laughably oversold. I like PENN in addition to DKNG and GNOG.
Update (12/26/21): There looked to be some momentum for DraftKings early last week, but that changed. I think DraftKings has left a bad taste in people’s mouths after all the inside selling it did earlier this year. However, it’s still oversold with an RSI of 39.
Update (1/9/22): DraftKings hit as low as the high $23s, but it has since rebounded a bit. We have multiple instances of the gambling stocks not moving with the overall market, so like the BANG KEN stocks, these could rise while everything owned by the hedges plummets.
Update (1/16/22): I can’t believe DraftKings dropped to $22 on Friday. The entire betting sector has been shorted, from DKNG, to PENN, to FUBO, to CZR. It seems as though some hedge fund managers had one of their fancy dinners at some point during the summer and colluded to bring down the betting sector. Everything is super cheap and heavily shorted now. I bought more DKNG at $22.60 on Friday.
Update (1/30/22): I bought more DraftKings shares at $17. The stock price rose later in the week on news of a price target increase, with Morgan Stanley upgrading its target price to $31.
Update (2/6/22): Morgan Stanley upgraded DraftKings’ target price to $31. Its merger with Golden Nugget should occur soon.
Update (2/13/22): The betting sector continues to be on sale. There’s no reason DraftKings should be this cheap.
Update (2/20/22): DraftKings’ earnings were released Friday. It beat revenue and raised its 2022 revenue guidance. All of this is great, yet the stock dropped 21 percent because, as some dumb Stocktwits bears said, “DraftKings burns through money.” Uhh… yeah. That’s what growing companies do. They spend money to acquire new customers. And yes, new customers for a company that has been around so long because they’ve moved into new markets recently like New York. This stock price drop is completely unwarranted.
Update (2/27/22): DraftKings rose about $5 this past week. As I’ve been saying, the entire gambling sector took a dive in recent months, so it appears as though this is the beginning of a reversal.
Update (3/6/22): DraftKings looked to continue its reversal, but the end of the week was brutal. There was some major selling on Thursday and Friday, which was discouraging.
Update (3/13/22): DraftKings continues to plummet for some reason. The CEO, Jason Robins, tweeted this on March 8: “If you sold #DKNG today, just be aware that my team and I are on a mission to make you regret that decision more than any other decision you’ve ever made in your life.” Oh, really? Then why did he and his board members sell tons of shares before that? Robins spent the rest of the week making a Ukraine logo for his Twitter bio and tweeting about International Women’s Day, as if anyone cares. I love DraftKings, but this Jason Robins guy can’t be trusted with his constant virtue signaling and lying.
Update (3/27/22): We’re still waiting to see how Jason Robins will make sellers regret selling. This stock has been frustrating, but the entire gambling market is in shambles. Take a look at PENN if you want to see a blood bath.
Update (4/3/22): Q1 is over, and yet there has been no merger. Meanwhile, the gambling stocks continue to fall. I suppose the bear thesis is that people won’t gamble in a recession, but degenerates will always gamble.
I’m not a big penny stock guy, but this should be $2 at least. They’re the only company with at least a billion in revenue ($1.3 billion in 2020) trading below 50 cents. Debt is the big issue, but they just received a huge contract from the VA and a deal with Mastercard to pay off the debt. With that, and other big contracts, debt will be a thing of the past. This company is expecting a great earnings report for Q4.
Update (12/8/20): This stock hasn’t moved much since posting, but we’re waiting on what should be an outstanding Q4 earnings report.
Update (12/22/20): I sold my shares when this hit the 50-cent range on Friday. I’m interested in re-buying in the low 40s.
Update (1/19/21): This hit $1.10. I put in a stop loss at $1, and it sold once the stock fell back to that price. I’ll be interested in re-buying if this falls again.
Update (5/30/21): I’m back in XELA. This has been shorted into oblivion. Take a look:
The black line is the stock price. It reached close to $5 in March, but then the cockroach shorts infested this company. The borrowing fee, depicted by the red line, rose in response. It’s now in the 30-percent range, so it’s becoming harder to short this company. Exela produces a billion-plus in annual revenue, and they tend to receive big contracts, so their next deal could have the scumbags scrambling to cover.
Update (6/6/21): If you’re in AMC, you might be familiar with naked shorting and fails-to-deliver. There’s some of that in this stock as well, so XELA is a huge candidate for a squeeze.
Update (6/13/21): I’ve heard that this stock has gained some traction on WallStreetBets. It’s a highly shorted stock, so it’s only a matter of time before the WSB crew really finds it.
Update (6/20/21): Exela isn’t heavily shorted, but the borrowing fee is high, so the shorts will be pressured to cover at some point. Exela is good for some big news about once per quarter that will cause the price to shoot up.
Update (6/27/21): Some clarification on the past two entires. I wrote Exela was highly shorted on June 13 and then not so highly shorted on June 20. This sort of data can be imprecise, and I was looking at two sets of numbers. Ortex says Exela isn’t heavily shorted, and yet the borrowing fee is very high, which is confusing.
Update (7/4/21): I sold half my Exela when it reached $2.50, and I plan on buying those shares back if it falls a bit more. I can now confirm Exela is heavily shorted. It’s 35.6-percent shorted, according to Ortex, and it’s the No. 1 squeeze candidate on Fintel:
It should be noted that Exela diluted its shares when it rose above $2.50, but I’m not very upset about that because they needed to address their debt. With less debt, the stock price is bound to increase eventually.
Update (7/11/21): Exela closed just shy of $3. It’s still heavily shorted – it is currently second on the Fintel Short Squeeze Explorer – so we still have some room to rise. My conservative price target is $5, but it could easily go higher.
Update (7/18/21): I sold half my shares at around $4.50. I’m still holding the rest for an even greater run. The price could drop, and if it goes below $2, I’ll add to my position.
Update (8/1/21): We remain in limbo with Xela. It’s too cheap to sell, but a bit too expensive to buy.
Update (8/8/21): Nothing has changed with Xela. We’re still in limbo. That said, the short interest is still very high (23%), so this company will squeeze eventually.
Update (8/15/21): Will Meade, a former portfolio manager at a hedge fund, tweeted that S3 has Exela as the most shorted stock in the market, percentage-wise. I still think it’s a bit too expensive to buy at the moment.
Update (8/22/21): There were some big buys reported this week. Luminus Management bought 437,000 shares of Exela, while Davidson Kempner Capital bought 550,000 shares of Exela. They did so cheaper – the filings are as of June 30 – so I don’t think we’re in buy territory yet, but we’re close.
Update (8/29/21): I came close to buying Exela on Thursday, but I wanted to see if the price would fall below $2 on Friday. Instead, the price rose. As I’ve mentioned previously, I lend my shares so I can further understand the borrowing fee and the demand for shorted shares, and none of my Exela shares have been borrowed for at least two weeks. That tells me there’s more room for the downside on this stock, but I’m not bearish on it. This company has immense potential, but the bears have a legitimate case because of the debt.
Update (9/5/21): We’re still in no-man’s land regarding buys and sells. I’d love to see the borrowing fee rise into the 30-percent range once again to put pressure on the short sellers, but it’s very low at the moment.
Update (9/12/21): I’m going to say the same thing as last week, though I’d like to point out that utilization reached 80 percent on Tuesday before falling down. There’s also this:
If this drops a bit more, I will buy more shares.
Update (9/19/21): Utilization is down in the dumps at 50 percent. I’ll buy more shares of this stock when the price drops below $1.80 and the utilization reaches 80 percent again.
Update (9/26/21): I came close to pulling the trigger at the end of the week, but I’m still waiting for $1.80. Utilization, however, has risen to 70 percent.
Update (10/3/21): Utilization is now up to 80 percent. I had a buy order of $1.80 on Friday that didn’t fill.
Update (10/10/21): I know I had a $1.80 buy order last Friday, but I couldn’t pull the trigger on $1.65 this week. I think there’s more downside coming in this crappy economy before we rip. I want to see utilization climb to about 90 percent.
Update (10/17/21): Utilization dipped a bit this past week, dropping to 76 percent. I still haven’t bought any shares.
Update (10/24/21): Xela’s short interest just hit a yearly high:
Also, Evanson Asset Management bought 37,243 shares of XELA, effective Sept. 30. I finally picked up more shares on Friday at $1.52.
Update (10/31/21): I’m glad that I picked up those Exela shares because the stock rose this past week. This as because Exela announced a partnership with CareSource, one of the nation’s largest Medicaid managed care plans.
Update (11/7/21): Exela posted a positive earnings report that featured a 25 percent reduction in debt, which is the major issue holding this company back from being a double-digit stock. I put in a buy order for Exela for $1.74 on Friday, but it never filled. I’ll try again next week.
Update (11/14/21): There was a nice insider buy of 100,000 shares done Friday. I put in a buy order for mor shares at $1.58 during the afternoon, but it didn’t fill.
Update (11/21/21): Despite there being a 100,000-share buy from an insider last week, Exela’s stock price dropped this past week along with everything else. I bought more shares at $1.39.
Update (11/28/21): This stock is way too cheap now. I bought more shares at $1.29 on the 23rd.
Update (12/5/21): Exela’s RSI is 29. The last time it was this low, the stock price was $1.40, and it immediately popped back up to $2.38.
Update (12/12/21): Exela got a nice bump early in the week, but fell a bit at the end, just like everything else. I put in a buy order at $1.09.
Update (12/19/21): I actually just put in a buy order for Exela at $1.05, so you’ll see that next week if it’s not filled. There was more inside buying from the board members of this company. We’re currently at 52-week lows.
Update (12/26/21): I ended up getting more shares at $1.05. Again, we’re near all-time lows, making this a great value buy right now.
Update (1/9/22): I added more shares in the 60s and 70s. Excluding March/April 2020, we’re at all-time lows. The RSI is 20! There’s no reason this stock should be so low. Exela’s market cap is $132 million, and yet the yearly revenue is $1.1 billion! Sure, they have debt, but they make enough money to eventually pay it.
Update (1/16/22): Exela’s market cap has collapsed to $102 million, yet their annual revenue is $1.1 billion. This could 10x, and yet it would still be undervalued. I bought more shares this week.
Update (1/30/22): Exela had some amazing news this week, with the company purchasing up to 100 million shares (likely a third of the float) for $1 per share. Yes, the company is buying its own shares for $1, and yet the stock price isn’t even close to that!
Update (2/6/22): Exela looked like it would be hitting $1, but short sellers beat it down late in the week. I guess those idiots didn’t see the news that Exela is buying back its own shares for $1. The on-balance volume didn’t change very much, so you can be sure that normal people weren’t selling this stock.
Update (2/13/22): Here’s a very bullish article on Exela. I bought more shares this past week before even seeing this!
Update (2/20/22): There was a lot of momentum for Exela before the market crashed late in the week. On the bright side, Exela’s borrowing fee increased recently. With the company buying back shares, and institutions buying in, this one seems like a no-brainer.
Update (2/27/22): I can’t believe this was at 35 cents recently. RSI is currently at a middling 46, so there’s some room for the downside before the stock price rises. I’m waiting for a dip before I buy more.
Update (3/6/22): Exela is closing a preferred share exchange offer at $1.25. This will decrease the float by 30 percent. Exela continues to be severely undervalued.
Update (3/13/22): I was thinking about selling some of my Exela shares when it skyrocketed on Thursday. I did not, and the company plummeted Friday. Ugh. Earnings did not meet expectations, which is why the stock price fell. This could continue to drop back to 34 cents, which is where I’ll be buying.
Update (3/27/22): Exela announced that there will be a vote on a reverse split. This is extremely disappointing. I’m thinking about giving up on this one.
Update (4/3/22): The ATM offering is over, so this is expected to climb a bit. It really looked like it was going to move on Friday morning (it was at 50 cents at pre-market), but the red day ruined any chance of this rising. I’ll probably get out of this at the next surge.
Henrik Fisker’s EV company (just switched from SPAQ to FSR.) I think this will be $50 minimum one day, but may take a while. Fisker has a billion dollars, so this stock is worth $18.18 in cash. It’s extremely undervalued at $10.
Update (12/8/20): Fisker is now trading at $17.24. There’s still plenty of room for growth.
Update (1/19/21): Fisker has fallen a couple of bucks since my previous update. It’s a bit disappointing, but I’m still very bullish on the company.
Update (1/26/21): No change since last week. I’m still bullish here. Patience.
Update (1/31/21): Still no change. Fisker will be bringing lots of cars to the market in the coming future.
Update (2/7/21): No change. Fisker will skyrocket in the future, but not anytime soon, barring unexpected big news.
Update (2/15/21): If you didn’t believe in market manipulation, take note that there were 24,436 Feb. 12 calls at $19, and this stock closed at $18.99. Fisker closing above $19 would’ve meant that 2.4 million shares would’ve been bought, which would’ve been huge. Still, the outlook for Fisker is very bright, with Morgan Stanley issuing a $27 price target.
Update (2/21/21): It was disappointing to see this stock drop $1 last week, but it’s not a big deal. This company has huge upside for the long term.
Update (2/28/21): Apple deal! Fisker exploded this past week, rising to $28.50 by the end of the week. This stock is still cheap, however, as Morgan Stanley has given it a regular price target of $40 and a bullish price target of $90. I can’t blame them, given that Apple manufacturer FoxConn will be producing their vehicles. Everyone who was chasing the CCIV crooks should be interested in Fisker instead.
Update (3/5/21): Fisker has fallen to $21 because of this crash. It hasn’t helped that shorts have been attacking this company because the cars won’t be coming for a while. And here I thought the stock market is supposed to look ahead… At any rate, this company has a bright future with Apple manufacturer FoxConn making the cars.
Update (3/14/21): The Bank of Norway added 1.1 million shares of Fisker in the mid-$20s. They are very well aware of Fisker’s potential once the cars begin to go to market. Be patient with this one. There’s enormous upside.
Update (3/21/21): Fisker is very undervalued again. It’s currently trading at 0.5x 2025 projected revenues. Nio, by comparison, is trading at 3.25x 2025 projections. Even just doubling it to 1x would bring Fisker into the $40s. My price target remains $50, though it may take a year to get there.
Update (3/28/21): Henrik Fisker announced a date when they’ll be showing off the Fisker Ocean production vehicle. That date is Nov. 17. That may seem like a while from now, but time will fly by quickly.
Update (4/4/21): No Fisker shares were borrowed from me (see CLOV for details.) This was surprising to me because automobile companies dropped because of the chip shortage. Fisker will rebound and eventually skyrocket in seen months.
Update (4/11/21): Fisker plummeted down to the 200-day moving average ($15.39), so this is likely its floor. RSI is 34 and Slo Stochastics are the lowest it has ever been:
This is a great buying opportunity, given the major potential of this company. There’s been lots of institutional buying at this range, so the sharks agree.
Update (4/18/21): Invesco bought nearly three million shares of Fisker at $15.03. Think this is undervalued right now?
Update (4/25/21): Fisker was beginning a nice reversal last week, but crashed on one of the days before rebounding. If you’re wondering what that was about, a short-selling scum put out a hit piece on Fisker, all while touting Tesla. The hit piece was nonsense, so it’s not a surprise that Fisker bounced back well.
Update (5/8/21): Tech stocks were shorted heavily these past two weeks, and Fisker is no exception. I’m sure Fisker will have another violent spike once they release more news. We still have to wait a bit until they release their product, but it’ll be coming eventually.
Update (5/16/21): Fisker and Foxconn had a nice announcement on Thursday where they promised to deliver an EV priced at $30,000. I expect the EV market to be on fire soon in the wake of the gas shortage.
Update (5/23/21): Moore Capital Management filed a 13G that shows they increased their share count in Fisker from 9.465 million to 11.828 million. Fisker had a nice week, climbing up into the mid $12s from the $10s.
Update (5/30/21): Fisker rose to the $13 range this week. I expect all good EV companies to do well in the near future because of the gas shortage.
Update (6/6/21): Fisker had a nice week, rising to the $15 range. I expect it to keep moving up because EV stocks figure to do well amid the gas shortage. It was also nice to see the borrowing fee move into the 3-4 percent range. That said, the borrowing fee was in the 60-80 range back in November and December, so we need to see that level for a huge squeeze.
Update (6/13/21): Fisker continued to increase in price this week, while the borrowing fee has remained steady. The higher this goes, the more shorts who are going to be underwater, so a squeeze appears to be brewing.
Update (6/20/21): If you have any doubts that Fisker is heavily shorted, check out the tweet from S3’s Ihor Dusaniwsky, which contain stocks not named AMC that have 100/100 short squeeze scores:
Update (6/27/21): Fisker rose at the end of the week because of its new index inclusion. The increased price will put pressure on shorts to cover, and there are many of them, as 30 million shares are on loan.
Update (7/4/21): I wrote last week that there 30 million shares on loan. There are now 40 million shares on loan, according to Ortex! An increase in 33 percent in such a short span is ridiculous, and it would explain the negative price action we saw this past week.
Update (7/11/21): Fisker dropped this week because so many of the small- and mid-cap stocks plummeted. However, it rebounded a bit on Thursday, indicating that it could be in the beginning of a reversal.
Update (7/18/21): EVs got crushed this past week, which would explain Fisker’s price drop. The RSI is now 37.6, indicating that it’s oversold, though we already knew that.
Update (8/1/21): Alliancebernstein bought 1.5 million shares of Fisker on June 30 at an average price of 18.25.
Update (8/8/21): Swiss National Bank bought 312,900 shares of Fisker. There were some other big buys as well. This one will pay off huge, but it’ll take some time.
Update (8/15/21): Good news, bad news this week. The good news is that Morgan Stanley raised its price target of Fisker to $40, with $90 bullish potential. The stock price rose as a result, but then plummeted when the CEO announced a $625,000 notes offering. This greatly pissed me off because Fisker has a billion in cash, so money wasn’t an issue for them. Nevertheless, the news dropped the price, but Fisker now has $625,000 more in his coffers than he did a week ago when this stock was the same price. It’s weird to think about it that way.
Update (8/22/21): Fisker’s very cheap, and if it drops to the low $12s, I will buy more. The price drop wasn’t warranted. Production will begin in a few months, which is when this stock could rise.
Update (8/29/21): Fisker never fell into the $12s, but I bought more. Why? Morgan Stanley bought 588,000 shares of Fisker, and Fisker is now more shorted than it has ever been:
I always liked Fisker as a long hold, but this is also turning into a major short squeeze play.
Update (9/5/21): Fisker is still heavily shorted, and the interest I receive for lending out my shares doubled on Friday, which was nice to see. It’s just a matter of time.
Update (9/12/21): Fisker looks primed for a squeeze. Take a look at the utilization, shares on loan and short interest, all of which have skyrocketed recently:
Update (9/19/21): Fisker dipped during the week, then rose on Friday. Here’s a very bullish article on Fisker from Seeking Alpha.
Update (9/26/21): Fidelity bought 1.16 million shares of Fisker as of July 31. Fisker shares has a nice bump late in the week because of a press release saying that Fisker vehicles will be displayed at the 2021 L.A. Auto Show.
Update (10/3/21): We had some good news:
When this goes to production, we’re going to have lots of people asking themselves why they didn’t buy when the stock price was in the low teens.
Update (10/10/21): I was talking to a long-time trader friend of mine who is also in FSR. We agreed that $13 is a bargain, but here’s what he said: “FSR long term will be great, but I think we can get an $11 price to buy more shares.” I think he’s right, given the state of this economy.
Update (10/17/21): The market makers wanted Fisker under $14.50 because that’s where a chunk of calls were. I don’t know how many times I have to repeat this, but by shares; not weekly options!
Update (10/24/21): Another growth stock that plummeted Friday because of interest rates. This is a fine price to buy, but it’s possible that we could see $11 at some point, as written two weeks ago.
Update (10/31/21): Fisker rose this past week for two reasons. First, it was a sympathy play to Lucid, which spiked to $37 because of their announcement that they will be delivering their vehicles soon. Second, there was some delta hedging because lots of future call options were being bought. Fisker is going to have a Lucid-type announcement soon, and the stock is still incredibly cheap right now.
Update (11/7/21): What a great finish to the week! Closing above $19 was a rare moment in which plenty of call options finished in the money. There might be resistance in the $19.40-$20.60 range, but there’s nothing but clear skies if we soar past that area.
Update (11/14/21): Fisker had another monster week, rising as high as $22.25 before consolidating in the $21s on Friday. It was a great week for EV stocks in general. It’s a reminder that Fisker has some amazing potential.
Update (11/21/21): Fisker dipped a bit this week, but given how bad the market was, it wasn’t too bad. EV stocks continue to be hot. More good news: Insider Mark Hickson bought 44,900 shares between $21.19 and $22.84:
Update (11/28/21): A down week for Fisker, but inconsequential in the long term. Production begins about a year from now.
Update (12/5/21): Fisker’s RSI is relatively high compared to the rest of the market (43). However, this could dip a bit because Lucid is going to fail to deliver the number of cars it promised.
Update (12/12/21): Fisker showed a sign of strength late in the week by not collapsing like everything else. There’s a lot to be optimistic about regarding this company with production beginning in 2022.
Update (12/19/21): Fisker doesn’t follow the market, so it was up on Friday. It’s just a waiting game for production to begin.
Update (12/26/21): I’ve seen some rumors that Fisker filed for a $2 billion shelf offerings. I’m not sure if it’s true or not, as the two sites that have posted that info look sketchy as hell. Shelf offerings are actually good because it means the company believes the stock price will rise, but it’s a bad thing in the short term because people don’t seem to understand the difference between shelf offerings and direct offerings.
Update (1/9/22): We’re in 2022, which means production will begin this year! If you look at Lucid’s chart, that’s the type of movement we should be expecting, except Fisker has 1/6th of the float of Lucid!
Update (1/16/22): Fisker has no revenue yet because their cars haven’t been released yet, but we can compare their market cap with Lucid’s, two similar companies where Lucid’s timeline is ahead of Fisker’s. Fisker’s market cap is $4.5 billion, while Lucid’s market cap is $62 billion. I don’t think it’s out of the question that Fisker’s stock price could 10x in the future.
Update (1/30/22): Fisker is near all-time lows, with its market cap now below $2 billion. It won’t be too long before this takes off. I purchased more shares this week.
Update (2/6/22): Fisker’s market cap is at $1.8 billion. This is a company with about a billion in cash alone. Many of the large-cap stocks have insane valuations – see Palantir for example – but the small and mid caps have the opposite effect where their valuations make no sense because they’re too low.
Update (2/13/22): Henrik Fisker teased something about the Super Bowl on Twitter. I wonder if this means there will be a Fisker commercial during the game.
Update (2/20/22): Fisker is another stock that was hot during the middle of the week, but fell because of war fears at the end of the week.
Update (2/27/22): I hope you caught the dip on Thursday when Fisker dropped to $9.99! I didn’t get more shares, unfortunately.
Update (3/6/22): I thought Fisker would fall as a sympathy to Lucid’s bad news last week. That didn’t happen, but Fisker plummeted anyway with the rest of the market. This is cheap at the moment, but could go lower because the RSI is 39.
Update (3/13/22): Fisker’s stock price waffled around the $11 range all week, with the RSI settling in at 42. I haven’t bought or sold shares for a while.
Update (3/27/22): Nothing new here. Production will begin soon enough.
Update (4/3/22): This was another stock that looked like it was going to run on Friday, but the red day ruined it. The good news is that we’re another month closer to production.
I’ve heard this described as the Michael Jordan of stocks. FUBO has millions of subscribers and will soon be integrating sports betting with their streaming abilities. This stock is like PENN/DKNG and ROKU had a baby. I think this could be $200 one day. (New 11/20/2020)
Update (12/22/20): Wow, I hope all of you bought this! It went as high as $51 on Monday.
Update (1/19/21): I sold some of my shares at $60, but I’m still holding a position. The stock is now 40-percent shorted, so it’s going to happen an awesome squeeze once they have some great news/earnings.
Update (1/26/21): FUBO is beginning to squeeze. I believe we’ll be back at $60 soon.
Update (1/31/21): The squeeze continues! FUBO is one of the stocks restricted by Robinhood, so once the nonsense ends, and the floodgates open, FUBO’s ascent should continue.
Update (2/7/21): I’m looking forward to seeing what FUBO’s short interest is during the next update. It’s likely still very high, and if so, we could see it squeeze to $100.
Update (2/15/21): There are currently 14,900 Feb. 19 $50 calls, so if the stock price finishes above $50 at the end of the week, this will skyrocket. That’s going to happen eventually anyway, as there’s a 50 million float with high short interest. Also, Goldman Sachs and Vanguard bought a combined nine million shares.
Update (2/21/21): We had some great news last week. Check it out:
Six institutions just gobbled up nearly half the float. FUBO is going to skyrocket in the near future. We should see $100 at some point.
Update (2/28/21): The stock price is now $35.30, which is an incredible bargain. Buy the dip! Remember, six institutions ate up half the float last week. They know big things are coming.
Update (3/5/21): Here are FUBO’s killer earnings. Tell me if that warrants a drop from $47 to $31:
Even better, look at institutional ownership:
Wow, 90-percent institutionally owned! The public float is less than seven million shares, and it’s heavily shorted. The big-money people know where this is going.
Update (3/14/21): FUBO dipped in after hours heading into the weekend. The reason was because the president of the company resigned, but he’ll be taking another role within FUBO. This drop isn’t warranted, so I’ll be buying dips this upcoming week. Remember, this is 90-percent owned by institutions, so the real float is very small.
Update (3/21/21): Will Meade, who worked for a billion-dollar hedge fund, shorted this stock when it was $60 several months ago. Meade just announced that he’s now long on FUBO. Meade was all over GameStop back in August when the company was in the $4s all month.
Update (3/28/21): What the shorts did to this stock on Friday was disgusting. Viacom plummeted, and the shorts used that as an excuse to sink this stock. We were able to pick up some incredibly cheap shares, however.
Update (4/4/21): No FUBO shares were borrowed (see CLOV for details), though I imagined that wouldn’t have been the case a week ago. FUBO appears to be in reversal, thanks in part to the news that FUBO will carry Marquee Sports Network. The two parties reached a deal on Thursday, which is a big deal. FUBO figures to have more Chicago viewership as a result.
Update (4/11/21): FUBO skyrocketed on Friday, moving from $20 to $25 before dropping to $23.31 during the sell-off. The big news was that FUBO will be broadcasting the next World Cup. Many people watch soccer for some reason, so this will obviously help the company.
Update (4/18/21): I can’t believe FUBO is under $20. So many institutions bought in at the high $20s, $30s and even low $40s. I don’t think they’re going to take a big loss on this promising stock.
Update (4/25/21): I still can’t believe this was under $20. It finally passed that number during the reversal, and it’s not a coincidence that this happened once naked shorting was curbed.
Update (5/8/21): Scumbags have been shorting this into oblivion recently. They’ll be sorry if Tuesday’s earnings report is positive. We’re looking to see if FUBO added lots of new customers. Needham’s Laura Martin speculated that FUBO would add two million customers per year. She has given FUBO a $60 price target.
Update (5/16/21): Stocks have been dropping on good, and even great earnings. FUBO’s earnings were incredible! This is why it shot up after being crushed into the teens by the shorts. FUBO is incredibly underpriced right now, and we’re beginning to see the borrow rate rise a bit. It just reached 4.7 percent, which is triple from where it was a week ago.
Update (5/23/21): FUBO spiked to $22 on Tuesday, but was shorted back down to $20. I would love to see the borrowing fee increase to squeeze these shorts out of their positions. The borrowing fee is now 2.3 percent, which is a drop from last Friday, but is still better than the sub-1 percent we saw for a while.
Update (5/30/21): What a rally for FUBO! It was having a great week until Friday, when it opened at $26 but then consolidated to the mid $24s. Still, it was nice to see this strong company bounce back after getting crushed the past couple of months.
Update (6/6/21): Former hedge fund PM Will Meade, who was once shorting this stock, predicted that FUBO will squeeze soon. The borrowing fee has begun inching upward, moving close to three percent from its previous sub-one range.
Update (6/13/21): FUBO was in the $30-32 range for most of the week, but the shorts dropped it to sub-$30 to close Friday because there were tons of expiring calls at $30. If the SEC actually cared about marketing fairness, they would do something about this blatant manipulation, but they’re either sleeping or siding with the enemy.
Update (6/20/21): FUBO is heavily shorted as well, so I’m sticking with it. Check out the Ortex data:
We have a stock 28.5-percent shorted with 36.25 million shares on loan and a 100-percent utilization rate. Those numbers will increase by Tuesday because the hedge funds killed a ton of $30 call options.
Update (6/27/21): FUBO had a great week, as some shorts covered. Despite this, there are still 34.8 million shares on loan, so plenty of dumb short sellers will still have to buy shares. You may have noticed that FUBO touched $35 on Friday, but was pushed down immediately. The hedge funds and market makers did this to kill $35 options.
Update (7/4/21): FUBO’s price decreased this week because of insider selling. David Gandler sold 88,642 shares at $35, which was very disappointing to see because this highly shorted stock had some great momentum going for it. Perhaps Gandler needed this money for taxes or emergency purposes, but had he waited, he likely could’ve gotten more money for his shares. I’m currently neutral on FUBO after this occurred. I still like the company, but bears might use this insider selling as FUD to drop the price.
Update (7/11/21): I sold some shares of FUBO, but only 20 percent of my shares. I’m still bullish on this heavily shorted company, but I thought it would drop because of the insider selling.
Update (7/18/21): FUBO’s earnings are coming up soon, and I can’t wait to see if their subscriber number beat expectations. State Street is optimistic. Thy bought 82,000 shares at an average price of $25.07, per a July 9 13F filing. If this drops a bit more – RSI is 39.7 right now – I’ll buy back the shares I sold.
Update (8/1/21): Alliancebernstein bought 196,000 shares of FUBO on June 30. It appears to be entering positive MACD territory on the chart, and the last time that happened, the price rose to $35.
Update (8/8/21): There were some big institutional buys for FUBO in recent filings, including six-figure share buys from Swiss National Bank and Rhumbline Advisers. FUBO, which is still very shorted, was upgraded to a hold by Zacks Investment Research.
Update (8/15/21): Good news, bad news. The good news was that FUBO crushed earnings. This prompted an increase to $31. That’s when the bad news arrived, which was a secondary offering. While this is bad for the short term, I think it’s bullish for the long haul because FUBO will have more money for purchases and expansion. No new shares were even issued yet. I believe this stock could drop a bit more, which will make this an interesting value play.
Update (8/22/21): I would have bought more FUBO this past week if I were eligible to do so. My loss expiry ends Sept. 6, so I will be buying more FUBO at this level. Remember, they destroyed earnings. This price is very cheap.
Update (8/29/21): Marshall Wace North America bought 410,000 shares of FUBO. Again, FUBO destoryed earnings, so it’s about to rise soon.
Update (9/5/21): FUBO spiked to $31 heading into Friday, as news of their sportsbook opening soon was released. Of course, the hedge funds couldn’t let this rise too quickly because of the call options:
This market is completely rigged, which is why FUBO closed the week just under $30.
Update (9/12/21): We had some exciting news this week, with FUBO partnering with the New York Jets. FUBO continues to be undervalued at this price because it never recovered from the selling induced by one of the hedge funds imploding. The only reason it finished below $30 is because market makers didn’t want these call options in the money:
Please, once again: Do. Not. Buy. Weekly. Options. The stock market is heavily manipulated and the SEC does nothing about it, so you will lose your shirt with weekly options.
Update (9/19/21): Utilization took a nose dive here as well. It’s down to 62 percent. I don’t understand how utilization is down across the board for most stocks. Perhaps Ortex changed how they report their data. It’s also possible that there’s disgusting manipulation happening once again. But that can’t possibly occur in the stock market, right?
Update (9/26/21): FUBO’s price sunk this week, making it a great value purchase at the moment. The FUBO Sportsbook app is now available in the app store, so you’d think that would have created some momentum for this stock.
Update (10/3/21): FUBO plummeted this past week. It’s truly baffling how low this stock is right now, given its immense potential. All growth stocks have taken a major hit since March, but they will recover at some point.
Update (10/10/21): This stock rose in the middle of the week because FUBO and the Cleveland Cavaliers agreed to a multi-year partnership. Of course, FUBO fell Friday along with the rest of the market. A price of $24 is a steal.
Update (10/17/21): A week after FUBO signed a deal with the Cavaliers, FUBO Sportsbook was named authorized gaming operator of NASCAR. This is why the stock rose late in the week. It’s still far below levels before it plummeted during the margin call sell-off earlier in the year.
Update (10/24/21): This growth stock took a hit Friday along with the rest of the market, which is a shame because it reached $30 earlier in the week. FUBO has had so much great news recently, however, that’s bound to take off soon.
Update (10/31/21): There were plenty of FUBO purchases per the Fintel page. I didn’t see anything crazy, but this is still bullish as we continue to see higher lows.
Update (11/7/21): FUBO had a great week, hitting resistance at $35. Earnings are on Tuesday, so hopefully we get a great report!
Update (11/14/21): FUBO had a great earnings report. Revenue beat with $156.7 million over the estimated $143.55 million. EBITDA beat expectations as well. Total subscribers is now close to a million. Despite this, FUBO plummeted from $33 to $24. I believe this is a combination of factors. Tax selling is definitely a contributor. Also, some didn’t like the purchase of Molotov for $190 million. Still, FUBO is incredibly underpriced at the moment for its huge growth. I sold some shares at $33 for taxes (not too many, unfortunately), and I’ll be re-buying in the mid $20s once the 30 days are up.
Update (11/21/21): Man, I wish my 30-day period was expired so I could buy more shares at this level. I can’t believe how cheap FUBO is at the moment.
Update (11/28/21): I was really kicking myself for not being able to buy at $19 on the 23rd. This price is absurd, but as mentioned in the DraftKings write-up, the entire sector is down.
Update (12/5/21): There’s no reason FUBO should be this low. RSI is 24. I’d buy more if I weren’t locked out of this for 30 days.
Update (12/12/21): FUBO is dirt cheap right now with an RSI of 33. It fell along with the entire betting market and should bounce back when the rest of that sector does.
Update (12/19/21): FUBO is another heavily oversold gambling stock. Its RSI is 31. I will put in buy orders when my tax-selling lockup is expired.
Update (12/26/21): FUBO made a nice move from $15 to $17 this past week, but continues to be oversold. The entire betting sector is down, but that could change soon with bowl season and the NFL playoffs upon us.
Update (1/9/22): I was able to get back into FUBO at $13/$14 after tax-loss selling. We currently sit at 12-month lows. I expect FUBO to rebound along with the rest of the gambling sector.
Update (1/16/22): As mentioned in the DraftKings entry, the entire betting sector is undervalued. As you can see above, I have an open order for more FUBO shares.
Update (1/30/22): FUBO’s market cap is down to $1.5 billion even though annual revenue is a third of that. I put in a $7.99 buy order for FUBO that didn’t fill yet.
Update (2/6/22): FUBO’s market cap is now $1.31 billion. Its earnings are on Feb. 23, so maybe that’ll make people realize what an incredible value this stock is right now.
Update (2/13/22): FUBO’s short interest is now the highest it has ever been:
Hopefully the low borring fee rises to put pressure on these a**hole shorts.
Update (2/20/22): FUBO dropped Friday because of DraftKings and Roku’s earnings. It’s not cheaper than when Zack Morris recommended it last fall.
Update (2/27/22): FUBO’s earnings were this past week. EPS missed by 2.6 percent, but revenue beat by 8.3 percent. The best news is that FUBO now has a record 1.13 million subscribers. I don’t think EPS missing is meaningful because FUBO is a growing company, and it’s using its money to obtain more subscribers. That’s what growing companies do.
Update (3/6/22): As a reminder, FUBO was $35 five months ago. What happened that its share price was reduced to $7? Nothing, that’s what. In fact, FUBO reported a record number of subscribers. This company is a steal right now, as its RSI is only 32.6.
Update (3/13/22): I bought more shares at $6.99 on Friday morning, thinking I got a great deal. Whoops. FUBO closed at $6.60, but the RSI is 31, so we’re in the oversold buy zone.
Update (3/27/22): As mentioned under DraftKings, the entire gambling market has been in a huge downtrend. It’ll have to come to life at some point. The last time the RSI has been above 50 on this ticker is November!
Update (4/3/22): It’s a bad look for FUBO that they didn’t air the Final Four. That, combined with the downtrend in gambling stocks, has caused this to fall further. I think this could continue to drop.
How can you not like a company called Thunderbird, which was the toughest boss in Zelda II? OK, this is Thunder Bridge and not Thunderbird, but still. At any rate, here’s a semi-conductor play. This is intriguing because there’s a global shortage in semi-conductor chips, so there could be lots of interest in this one. There was a $1.2 million buy at $14 on this stock, so someone with a ton of money agrees. This stock is heavily shorted (26.64%), so this one will shoot up when we get some news. (New 1/19/2021)
Update (1/26/21): This dipped a bit this past week, but that’s a good thing. There’s some serious consolidation happening. This company has very high potential.
Update (1/31/21): Consolidation and shorting. This stock has dipped, but there’s a $10 floor because it’s a SPAC. This company has enormous potential.
Update (2/7/21): No update. Buy the dip!
Update (2/15/21): The government has acknowledged the shortage of semiconductors, which caused the stock price to rise on Thursday. It dropped back down on Friday. The stock is still criminally underpriced and heavily shorted.
Update (2/21/21): We’re still waiting an announcement from the vice president’s administration on the shortage of semiconductors. Thunder Bridge is extremely underpriced right now.
Update (2/28/21): Several car companies had to shut down production due to a lack of semiconductors. I’m not sure why the government hasn’t asked for companies like THBR to ramp up their production, but it should happen soon.
Update (3/5/21): Vice President Joe Biden will talk about semiconductors one day, mark my words. He’ll have to wake up from one of his five daily naps, but I’m confident he’ll get to it sooner or later. Until then, anything under $11 is a steal.
Update (3/14/21): Thunder Bridge eclipsed $12 at one point on Friday, ultimately finishing at $11.79. Are people finally beginning to realize that semiconductor stocks are undervalued because of the shortage? This company has received $20 price targets, which isn’t high enough, as far as I’m concerned.
Update (3/21/21): Roth starts THBR at Buy with a price target of $20. That’s nice, but $20 is still too cheap!
Update (3/28/21): Nio has stopped production due to a chip shortage. With that in mind, how has this chip company bottomed out? It makes no sense!
Update (4/4/21): Jim Cramer talked about Thunder Bridge on his show, which sparked this stock to climb up to the $11 range. I still don’t understand why this hasn’t gotten more attention, given the chip shortage. Oh, and none of my THBR shares were borrowed.
Update (4/11/21): It’s crazy that this stock price can’t hold. Every time it looks like it’s making a move, it comes crashing back down to the low or mid $10s. Yet, there are two legitimate price targets of $20 and $17 on this stock.
Update (4/18/21): Another SPAC that is getting crushed. Everything is cylical, so THBR will have its day.
Update (4/25/21): THBR is one of many SPACs that had to re-file papers because of the warrants rule change, stemming from the CCIV fraud. We’ll see what happens, but there’s no downside here because THBR can’t go below $10.
Update (5/8/21): Let’s give a shout out to the CEO of this company for delaying the merger; otherwise, the stock price would’ve gone below $10. With the bear market for SPACs coming to an end soon, THBR could run eventually.
Update (5/16/21): We have a nice IBorrowDesk chart on THBR. Shares to borrow are disappearing, and the borrow fee skyrocketed from 0.5 percent to 7.9 percent. The short-selling scum have pinned down this stock to $10 – it can’t go lower because it’s a SPAC – but perhaps this is a sign that it’s close to finally moving.
Update (5/23/21): THBR’s borrowing fee is down to 2.2 percent, but it’s still much better than the 0.5 we saw earlier. Shares to borrow are lower than before as well. I think this stock will squeeze eventually, but we might be a couple of months away from that.
Update (5/30/21): Thunder Bridge is being manipulated so much, it’s ridiculous. I’d love to see the borrowing fee skyrocket to make these scumbags pay, but it’s still rather low.
Update (6/6/21): Nothing new to say this week. This continues to be highly manipulated. The merger is coming soon, so perhaps that will spark some price movement.
Update (6/13/21): After barcoding for months, THBR merged into Indie Semiconductor. The price actually moved for once, though not very drastically. Car chip stocks should be going through the roof right now, but this has been held down by scumbag manipulators. The good news is that the borrowing fee has risen to 13.2 percent, so there could be a squeeze on the horizon.
Update (6/20/21): Indie just had its merger, so I’m not seeing any short data on it from Ortex. However, iBorrowDesk is showing just 4,000 shares available to short, so this could be heavily shorted.
Update (6/27/21): We still don’t have data from Ortex – and likely won’t for a couple of months – but it’s a good sign that the borrowing fee has reached double digits. Given the chip shortage and increased borrowing fee, we should see the stock price rise soon.
Update (7/4/21): There’s not much to say this week. There’s a semiconductor shortage, and this company makes them. I don’t understand why this stock price is less than $10.
Update (7/11/21): Indie was trending on Stock Twits all day Friday, when it rose nearly 10 percent. This upcoming week should be nice.
Update (7/18/21): There were no shares available to short for several hours on Friday, according to iBorrowDesk. Indie is extremely underpriced right now. Barring dilution, this could be $100 stock in a few years.
Update (8/1/21): Indi earnings are on Aug. 10, so hopefully we get some good news in nine days!
Update (8/8/21): The administration that believes it is in power is stressing EVs, and Indie’s earnings are in two days. Here we go!
Update (8/15/21): Indi beat revenue but lost on earnings. That’s not a big deal because this is a 2- or 3-year play.
Update (8/22/21): Holy crap, look at these buys!
George Soros bought 2.5 million shares. Luxor and Ghisallo each bought a million. Summit bought two million. Bamco bought 1.74 million. And yet, this price is near an all-time low? WTF. This company makes semiconductor chips, and there’s a chip shortage. Hello!? I bought more shares this week, if you couldn’t tell.
Update (8/29/21): Here’s another seven-figure purchase: Barons Investment Funds Trust bought 1.25 million shares of Indie.
Update (9/5/21): No new filings were released, but we had some positive price action throughout the week. We should be in the teens soon.
Update (9/12/21): Indi had a nice close to the week. There were no new filings, but we probably won’t see any until October because that’s when the Q3 purchases will be revealed.
Update (9/19/21): Motley Fool published a short-term bearish article on Indie, yet George Soros bought seven figures’ worth of shares. I’m sure they know more than he does.
Update (9/26/21): My INDI shares were lent out for the first time in quite a while. This means that utilization is rising, which is good news for us.
Update (10/3/21): There must have been a major buy this past week because INDI finally broke out of its $10-11 trend and rose to $12. Again, George Soros bought 1.5 million shares of his company.
Update (10/10/21): INDI is the type of company that won’t collapse during a crash because they’re going to make so much money selling semiconductor chips, which are in very high demand. Soros knows what he’s doing; he helped orchestrate this economic collapse, which is why he bought 1.5 million shares of this company.
Update (10/17/21): This is a long hold, so there are weeks in which I won’t have a substantial update. This is one of those weeks.
Update (10/24/21): Nothing to update again, save for the great Thursday we had in which we ran up to $12.30. This stock is still incredibly cheap.
Update (10/31/21): INDI had a nice week, rising into the $13s. Even better, Fidelity bought 435,000 shares of INDI, effective on Aug. 31.
Update (11/7/21): We had some more big INDI buys. Tygh Capital bought 454,000 shares, while Sycamore Asset bought 255,000 shares.
Update (11/14/21): INDI’s price action was great this week. Here’s another reason to be positive: Vanguard bought 1.795 million shares of INDI, effective Sept. 30.
Update (11/21/21): INDI had a nice week, especially when considering the horrible stock market. There are no new significant buys to report, unfortunately.
Update (11/28/21): INDI had a green day on Friday, which is telling. The stock price dropped a couple of bucks during the week, but that only allowed the RSI to cool off. The RSI is now 49, which makes INDI a compelling buy again.
Update (12/5/21): Ah, the power of George Soros. INDI’s stock price didn’t fall that much compared to the rest of the market. INDI is 30th on the Fintel Short Squeeze list (you need a subscrption to see it, but I can show you the proof here):
Update (12/12/21): PIPE selling knocked this price down to $12, and I’m kicking myself for not knowing about it. Had I known the date, assuming it was even available to the masses, I would have sold and then re-bought at $12. Nevertheless, this is a great price to buy into this company.
Update (12/19/21): The PIPE selling really hurt this stock. It now has an RSI of 36. I find it hard to believe George Soros is not going to make a ton of money on this stock.
Update (12/26/21): Someone is making a bet against George Soros because they shorted this stock. Short interest and utilization are high:
INDI is now 70th on the Fintel short squeeze list.
Update (1/9/22): We’re near levels at which George Soros purchased 2.5 million shares. This is a play for the long haul.
Update (1/16/22): Like Fisker, Indie is a great investment for the future. This is the buy zone.
Update (1/30/22): Indie’s market cap is now under $1 billion, making it very cheap. Blackstone purchased 200,000 shares of Indie.
Update (2/6/22): This stock has become highly shorted. FinViz has the short interest at 36 percent. I don’t understand why short sellers are shorting a stock in which George Soros invested at a higher price than it is currently.
Update (2/13/22): FinViz has reduced INDI’s short interest to 11.4 percent. I’m not sure what happened, but it’s still a great value.
Update (2/20/22): Earnings are on Tuesday. With all the institutional money in this stock, I expect good news.
Update (2/27/22): I missed this a couple of weeks ago, but George Soros bought one million more shares, giving him 3.5 million shares. That’s the good news. The bad news is that a Google search is saying that Indi missed on revenue and EPS. This is not true. Revenue beat and EPS was as expected. Guidance was solid as well. There’s plenty to be bullish about with this company.
Update (3/6/22): Nothing new here. RSI is 38.7, so there’s still a bit of room to the downside to create a great buying opportunity.
Update (3/13/22): I keep waiting to see something that says George Soros sold his shares, but no such filing has been made. I have to think this will explode eventually.
Update (3/27/22): Nothing new to add. The RSI has moved close to 50, but the stock price hasn’t moved very much.
Update (4/3/22): Earnings were announced for May 12. Perhaps we’ll finally have some movement then.
I’m introducting iSpecimen as a new play this week. This is a shorted stock with a very low float of 6.96 million shares. Its market cap is $65.4 million, and according to some of their recent filings, they have revenue of $350 million coming into the company. Despite this, the stock has been shorted down from $28.98 to the high $5s/low $6s. The shorts are paying an expensive price to do this right now. The borrowing fee is 114.8 percent! With the short thesis dying from the increased revenue, and the expensive price to maintain the shorts, this company could squeeze violently. (New 1/14/2022)
Update (1/30/22): Here’s another extremely manipulated stock. Take a look at the on-balance volume and the lack of red volume days:
Update (2/6/22): ISPC had a nice close to the week, finishing above $5. There’s still a long way upward to go, as this was trading for more than $25 at one point in December.
Update (2/13/22): ISPC dropped a bit this past week, but that’s fine. The float is only seven million shares, so it could explode at any moment.
Update (2/20/22): This is the lowest ISPC has ever been. There’s nowhere to go but up, right? Remmeber, this is a low float with a high borrowing fee.
Update (2/27/22): I picked up more shares of ISPC when the RSI reached about 30 on Wednesday. Despite the price drop, the on-balance volume hasn’t fallen at all.
Update (3/6/22): ISPC hit $4.24 this past week, but fell to $3.83 to close Friday’s trading. On-balance volume remained very high. RSI is 37.5, so you can wait a bit to add more shares.
Update (3/13/22): ISPC rose to $4 earlier in the week, but closed at $3.88. On-balance volume remains high.
Update (3/27/22): ISPC finished at $4.04 this past week, so perhaps we’ll finally have a leg up next week.
Update (4/3/22): We had our leg up, hitting $5.40 at one point on Thursday. This moves with LGVN, which has been ripping lately.
Two people just bought 50 percent of this company, including Alex Denner, who used to run healthcare investments for Carl Icahn. Just like that, half the float disappeared, and this was already a low-float stock! $ITRM just filed for an NDA (new drug application), and they’re expected to be approved in seven or eight weeks. This stock has a huge gap to fill to $4, and the short squeeze could take us into the $6-$10 range. (New 12/8/2020)
Update (1/19/21): We’re still awaiting news on their NDA. There’s a 60-day window, so we’ll hear something soon.
Update (1/26/21): We had a nice week with this, as the stock rose from $1.30 to $1.90. We should be getting big news this week.
Update (1/31/21): Zack Morris posted a tweet he regretted regarding ITRM not being an overnight play. Naturally, some people sold. Morris, however, said that he expects this stock to be at least $5 by the summer, which is a good, albeit conservative price target.
Update (2/7/21): This stock dropped to $1.25 last week, but only because the company offered more shares to Denner. There was some confusion about it being a regular offering, but that was not the case. Denner invested even more money into this company, which was a very bullish indicator. I increased my position by 50 percent on the dip.
Update (2/15/21): This stock shot up to $2.60 this past week, but dropped to $2 after hours on Friday because Denner sold his shares. That was huge, but all hope is far from lost. Denner has received royalty-linked notes that will net him 15-20 percent of U.S. sales, so he was taking profits and moving on and spending all his money on something else. I wonder if his move means that he wanted a buyout, but Iterum was unwilling to move in that direction. Meanwhile, Sabby, a notorious short seller, bought 7.75 million shares, while New Leaf Ventures, which specializes in buyouts, purchased 5.3 million shares. Zack Morris, meanwhile, remained bullish on the company, purchasing 50,000 shares on the dip to $2. The target price here remains around $5.
Update (2/21/21): We got some great news Friday afternoon, as Iterum closed their offering with a $35 million purchase. Last week, I wrote that Alex Denner sold out of his shares, but other big buyers have replaced him. I’m still confident we’re heading to $5-plus territory.
Update (2/28/21): No update this week except for the reduced share price as the result of the market crash and more short interest. Short interest here is now above 10 percent, so we’ll get a nice squeeze soon.
Update (3/5/21): The price of $1.36 ($1.29 after hours) is insanely cheap. We’re waiting on FDA news in the summer, so we weren’t expected to see this fly at the moment anyway.
Update (3/14/21): Iterum said that it hasn’t had any issues with the FDA yet, so potential approval of their drug by the summer is looking good.
Update (3/21/21): Beth Hecht was named to the board of directors of Iterum. She’s an attorney who specializes in intellectual property and corporate transactions. This goes with the theory that Iterum is bound for a merger or a buyout.
Update (3/28/21): We’re just biding our time until there’s a buyout or FDA approval. Canaan Partners, the largest institutional holder of Iterum, has an extensive history of being involved in buyouts.
Update (4/4/21): All of my ITRM shares were borrowed instantly (see CLOV for details.) I can’t say I’m surprised, given that the shorts have been attacking this company ever since Alex Denner sold his shares. Of course, Denner will still get 15-20 percent of U.S. sales, so this shouldn’t have mattered too much. At any rate, we’re still waiting for June-July for FDA approval.
Update (4/11/21): Iterum dropped 18 percent Friday because of the FDA delay. The FDA is backed up, which is hardly a surprise because the Covid vaccines haven’t even been approved by them yet. I don’t see this as a reason to sell. I’ve seen other bio stocks have FDA delays, only to be approved in the future.
Update (4/18/21): This stock price continued to fall because of the FDA delay. This just created a great buying opportunity for us. Unfortunately, I put in a buy order at $1.03, and it didn’t fill. It could still happen though because we’ll have to wait for a few months for the FDA approval. It’ll happen at some point.
Update (4/25/21): I managed to buy more shares at $1.03 early last week before ITRM rose to $1.20. This is only the beginning, as FDA approval will quadruple this price at the very least.
Update (5/8/21): Nothing new to report with Iterum. We’re waiting on results that should be available in July.
Update (5/16/21): I’m not happy to see the borrowing fee decrease, but to make up for it, we have lots of institutional buying for ITRM, as all of these entities are fully expecting ITRM to explode upon FDA approval.
Update (5/23/21): There were numerous 13Fs filed again. Nothing huge, with the largest filing I see being 430,000 shares from Two Sigma Investments. Still, it’s a good sign as we wait unti July.
Update (5/30/21): There was an FDA update about an announcement being made at the end of July. Basically, an announcement for an announcement. This pumped up the share price quite a bit, but the real fireworks will come in late July if there is FDA approval.
Update (6/6/21): We’re continuing our ascent to the July FDA announcement, as many buyers are loading up on shares.
Update (6/13/21): We’re getting closer and closer to FDA approval, which would explain the recent surge in price. If the drug is approved, this stock will skyrocket. Note that there is some risk here, and approval could be denied. This is the general risk that bio stocks have. There’s enormous upside, but there’s more risk than with normal stocks.
Update (6/20/21): I’m obviously holding on to Iterum through the FDA announcement. I’ve seen speculation that there’s a 75-to-80-percent chance of FDA approval. However, I want to warn you that there is some risk. If Iterum’s drug doesn’t get approved, well, just look at what happened to Orph on Friday.
Update (6/27/21): The FDA approval date is in about a month. Hopefully we get positive news!
Update (7/4/21): Wow, what a crazy turn of events. This stock price plummeted 38 percent Friday on news that wasn’t bad, but not quite ideal. The FDA reached out to Iterum and told them that they had a labeling issue. This was not a denial. Iterum has to change some paperwork before possibly being approved by the FDA. This could mean that the FDA approval date will be extended, but holding a bit longer isn’t a reason to sell. In fact, with this lower price, it’s a nice opportunity to buy. I’ve been asked if I’m concerning that this will lead to FDA denial, and I’m thinking about it this way: If the FDA was going to deny the drug, wouldn’t they just have done so? All they asked Iterum to do was change the labeling. That doesn’t seem like a huge deal.
Update (7/11/21): Iterum rebounded nicely on Friday, rising 9.2 percent, up to $1.31. Congrats if you bought the sub-$1.20 dip!
Update (7/18/21): I bought a couple hundred more shares at $1.11 this week. My plan is to buy many more if the price drops at the end of July if no FDA approval is announced. Many are expecting a late July announcement, but the labeling mistake may have pushed back the date. Impatient people will sell, creating a great buying opportunity.
Update (7/26/21): Iterum’s drug was not approved by the FDA, but all hope isn’t lost. I haven’t sold my shares because there’s still plenty of upside. Consider that the FDA acknowledged in their letter that Phase 3 trials demonstrated a statistical difference in overall response rate of the drug, but it determined that additional data was necessary. The FDA recommended that Iterum conduct at least one additional adequate and well-controlled clinical trial.
This doesn’t sound that bad. Consider the possibilities:
1. After another trial, Iterum is approved and skyrockets.
2. Iterum appeals the FDA approval and has its drug approved (this has been known to happen.)
3. With the diminished stock price, another company buys them out.
All three are real possibilities, which is why I haven’t sold any shares. I haven’t bought the dip either, however, because there could still be a sell-off. I will let you know if/when I buy the dip.
Update (8/1/21): Iterum received an upgrde from Gabelli, which was part of the reason it bounced back at the end of the week. I was thinking it might go to the 50-cent range, which was where I was planning to buy. I missed out on the low price, but hopefully you bought at the 60-cent range. I’m still bullish on Iterum because they need just one trial to potentially be approved. They could also be a part of a buyout.
Update (8/8/21): Bragar Eagel & Squire PC has announced a class action lawsuit being filed against Iterum. You may have seen this news, but it’s not very significant. Any time a stock drops rapidly, a lawfirm swoops in and does this. It’s not a bad thing for the company, but it could scare some people into selling. We can use this to our advantage and buy when it drops.
Update (8/15/21): The FDA will work with ITRM on a plan for their trials. I believe this will be approved in the future, so patience is needed. I want to buy more shares, but I think this could drop a bit more.
Update (8/22/21): I was so close to buying more on Thursday. I was hoping for something in the high-50s like 58 cents, but it never got there. I still may buy sometime soon.
Update (8/29/21): Again, I’m waiting for a price in the high-50s to buy more shares. This stock won’t rise significantly until there is A) news, or B) a huge purchase. There may not be any news dropping until mid or late September, so there will be plenty of time to find a good deal.
Update (9/5/21): Nothing to report. We’re still waiting on news, and I’m hoping to scoop up shares in the high-50s.
Update (9/12/21): Iterum notified its investors that it received a compliance letter from the SEC, stating that it will risk delisting if it remains below $1. It can avoid this with a reverse split, but it won’t need to do that if some major news breaks to push this over $1.
Update (9/19/21): Iterum spiked Friday, likely because of major buying. It’s possible that this big buyer knows something about either FDA approval or a buyout. Or, they’re just hopeful bulls like the rest of us! I finally bought more shares, so here’s to hoping we get some great news soon!
Update (9/19/21): I picked up some more shares of Iterum in the 55-cent to 59-cent range. We’re bound to hear some FDA news from this company in the coming weeks.
Update (10/3/21): I missed an update here last week. Iterum had an update for us instead, citing that they had a positive meeting with the FDA. “We are currently evaluating the optimal design for an additional Phase 3 uUTI study to be conducted prior to the potential resubmission of the NDA,” said CE Corey Fishman. This caused the stock to rise from 55 to 60 cents.
Update (10/10/21): If you wanted to buy Iterum, here you go. The 50-55 cent range is a great opportunity if you think this company has a good chance for FDA approval. I believe it does.
Update (10/17/21): Once again, this is a great buying opportunity because any sort of news will send this stock skyrocketing.
Update (10/24/21): We’re still waiting on Phase 3 news. Once that’s released, this stock will rise. This feels like the bottom.
Update (10/31/21): I don’t know what happened this past week. ITRM rose into the 70-cent range suddenly, but then came crashing down into the 50s again. Either someone bought a ton of shares, or there was some short covering, followed by more shorting. I was hoping to find news for this spike, but I didn’t see any.
Update (11/7/21): Iterum announced that they are dropping some news this upcoming Friday before market open. They have until March for the reverse split, so it shouldn’t be that. They’re also doing it before the market opens, as opposed to after the closing bell, so it should be bullish news.
Update (11/14/21): So much for news this Friday. Nothing happened, causing Iterum to drop five cents. I imagine there will be tax selling here as well.
Update (11/21/21): No news plus a bad market caused this stock to drop to 52-week lows, hitting 49 cents. I’m personally torn on what i want to do. I’d like to buy more shares, but I also want to take a loss for tax purposes. I’m terrified that ITRM will get FDA news in those 30 days, plus it’s foolish to sell at a 52-week low.
Update (11/28/21): ITRM didn’t crash along with the rest of the market on Friday, which was encouraging. However, we’re still waiting on news, which will hopefully come soon.
Update (12/5/21): RSI and charts don’t matter here because this is news-driven. If there was talk of FDA approval, the price would have skyrocketed this past week.
Update (12/12/21): Zacks Investment Research upgraded this as a buy. I would agree, as any sort of FDA news will send this upward.
Update (12/19/21): I’ll have a buy order on this when my tax-selling window is closed. FDA news could break any week.
Update (12/26/21): No news to report. Hopefully we get it soon.
Update (1/9/22): I’m going to buy more shares once my tax-loss selling window is closed. Any news will send this stock soaring. FDA approval will send it to the moon.
Update (1/16/22): Nothing new here. We’re still waiting for news.
Update (1/30/22): No news yet. Iterum should hire someone from Pfizer so they can instantly get FDA approval.
Update (2/6/22): I don’t know what happened, but there were some major buys late in the week, but there was no news yet. Someone may know something, or it could be someone is buying in anticipation of news breaking.
Update (2/13/22): For those of you who are still believers in Zack Morris, he tweeted this week that he’s back in ITRM because “news should be coming soon.” That may have been why this stock rose to the 45-cent range. I bought more shares in the low 40s.
Update (2/20/22): I guess I should’ve waited until the mid-30s to pick up more shares. Either way, this will skyrocket once we get news, which could come at any time.
Update (2/27/22): I put in a buy order for Iterum this past week, but it didn’t fill. It dropped to around 32 cents, but I was hoping to get shares at 29 cents. Either way, this company is a steal at the moment because they were so close to FDA approval.
Update (3/6/22): No new news. Hopefully we get some before a potential reverse split. I don’t even know if that’s on the table, but it could be. If it happens, I would just cut my losses and then buy back cheaper a month later because everyone sells into a reverse split.
Update (3/13/22): There’s good news, which is that Iterum was granted an extension for the reverse split. They now have about six more months to send the stock price over $1, and FDA approval would easily do that.
Update (3/27/22): Iterum will have a call Monday with some sort of announcement. Hopefully it’s about FDA approval!
Update (4/3/22): I got out of this one. Sorry, guys. The call sucked, and the CEO sounded depressed. I think they’ll have to reverse split before FDA approval, which makes me wonder why they even got an extension in the first place. I’ll buy back in later after the price plummets following the R/S.
Borrowing this one from Will Meade. Kempharm is a heavily shorted pharmacutecal company. According to Market Watch, Kempharm is 61-percent shorted! Despite this, Kempharm has $78 million in cash and no debt. They have an FDA-approved adderall-type pill for children. The ADHD market was valued at nearly $18 billion in 2019, so there’s a ton of potential here, especially if KMPH squeezes. (New 3/28/2021)
Update (4/4/21): A grand total of five of my 1,250 KMPH shares were borrowed (see CLOV for details.) This is surprising, given how shorted this company is.
Update (4/11/21): Here’s some positive KMPH news. Despite this, the stock price dropped to $9.15.
Update (4/18/21): Despite the good news last week, this stock price is down to the mid $8s. As I wrote above, it’s a rough, bear market right now for the speculative stocks.
Update (4/25/21): Samuel Braun filed a 13G with the SEC, disclosing 7.2-percent ownership of KMPH (2.06 million shares.) Braun made eight figures off GameStop, so he obviously knows a short-squeeze candidate.
Update (5/8/21): Blackrock bught 58,883 shares of KMPH per a May 7 13F filing. That’s not a huge amount, but it was nice to see. KMPH is cheap, and according to Fintel, it’s the 42nd-most likely stock to have a short squeeze.
Update (5/16/21): Vanguard bought 817,000 shares of KMPH. This was one of many institutional buys for KMPH. Look at that beautiful sea of green!
Update (5/23/21): Samuel J. Braun, who previously disclosed a 7.2-percent ownership of this company, increased his stake to 11.1 percent in a 13G filed on Monday. Braun also tweeted about more instutitional investments coming into KMPH, which could easily double from this price.
Update (5/30/21): KMPH rose on Friday because they announced that they were ahead of schedule on the Azstarys launch. This stock will triple in price at some point.
Update (6/6/21): KMPH had a strong week, moving from sub-$10 to the mid-$11s. With all the inside buying that has occurred with this stock, it’s sure to explode soon.
Update (6/13/21): What a great week for Kempharm! It closed at $14.62, then crossed $15 in the after hours. My short-term price target is $20. It could go higher in the long term, but I would take some profits at $20.
Update (6/20/21): Kempharm dropped on Friday because of some dilution. However, the dilution was just 1.5 million shares, so it shouldn’t have fallen so much. Kempharm is 26-percent shorted, and the utilzation rate is 100 percent. This is a keeper for an eventual squeeze.
Update (6/27/21): Russell index purchasing moved up this stock. Clearly, the company had some nice timing with that mini dilution. Remember, some of the institutional owners of this company were part of the GameStop squeeze, so they know what they’re doing.
Update (7/4/21): As with Jupiter, there was an after-hours dump of 3.5 percent because of a shelf offering announcement. This isn’t a big deal. GameStop announced a shelf offering when the stock price was $20. It then fell to $12, yet the company waited until triple digits to issue new shares. KemPharm knows their stock is going to squeeze because there are former GameStop people involved in this company, so they won’t offer new shares until the price skyrockets.
Update (7/11/21): Kempharm dipped a bit below $12 on July 6. If you bought then, congrats! It finished in the mid-$13s, which is a positive because it didn’t move very far following the shelf offering announcement I referenced last week.
Update (7/18/21): This stock is extremely oversold, with its RSI at 34.15. This is the lowest it has been since January, when this stock was $5.80. It still hasn’t recovered from the shelf offering announcement, but it’s not like it would have been doing well anyway, given the conditions of our miserable bear market.
Update (8/1/21): Alliancebernstein bought 22,800 shares on June 30. The RSI on this stock is very low at just 31.
Update (8/8/21): Rhumbline Advisers bought 31,832 shares on June 30. Once again, this stock is undervalued with an RSI of 33.
Update (8/15/21): This stock price dropped to the $8 range on Friday because of a 6-month delay for their drug release. That’s frustrating, but not the end of the world. Fortunately, smart people bought cheaply, prompting a rally at the end of the day.
Update (8/22/21): As written last week, we’re in a 6-month holding pattern until the drug release and some warrant expiration.
Update (8/29/21): The price dropped to $8.88 at the end of the week. I have nothing else to say, except to point out that the Russell 2000 ETF reported their stake in KMPH.
Update (9/5/21): There was an insider buy, with Travis Mickle purchasing 5,000 shares at an average price of $8.92. I love these insider buys because the people in the company know when something exciting is about to happen.
Update (9/12/21): As with Iterum, there’s no news here on this bio stock. Remember though that we had a 5,000-share purchase by an insider last week, so I can only assume that there is good news on the horizon.
Update (9/19/21): No news with KMPH this week. I was hoping for more insider buys, but we saw none of that.
Update (9/26/21): The KMPH earnings call disappointed people because the CEO didn’t discuss his plans for the company and the drug. However, he recently said, “The final strategy will be announced once the board approves” and that “We’re encouraged by many interests from big pharma.”
Update (10/3/21): No update here on this stock, but we weren’t expected to see one for a few months. There were some minor tute purchases, but nothing substantial.
Update (10/10/21): We’re now two months into the 6-month delay of the drug release. Given the small float and relatively high short interest, this will pop once there’s any news.
Update (10/17/21): There were some large buy orders this week, which is why the stock rose $1. Someone knows something is happening soon with this company.
Update (10/24/21): There was a mini squeeze of sorts on Friday, bringing this price up to $10.80. It dropped back to under $10 an hour later. I didn’t see any news, so I assume it was a large purchase and then some profit taking from someone else. We’re still waiting on the drug release.
Update (10/31/21): Someone smart has been making money all the times this has bounced between $9.50 and $10. At any rate, we’re still waiting for news that will be coming in just over three months.
Update (11/7/21): Nothing new to report here. We’re three months away from drug release.
Update (11/14/21): Vanguard bought 383,000 shares of Kempharm at an average price of $11.07, effective Sept. 30. This stock dropped Friday for no legitimate reason, so it’s currently a bargain.
Update (11/21/21): Nothing new to add here, outside of a great price being available due to the horrible market.
Update (11/28/21): Same as last week. This will move with the market as it waits for news that will be coming in about three months.
Update (12/5/21): Samuel Braun bought more shares, which was nice to see. KMPH’s RSI is 34. I put in a buy order at $7.42, which is the last level of resistance.
Update (12/12/21): No volume here as we continue to wait for news and drug release.
Update (12/19/21): What I wrote about ITRM applies to KMPH. Both are very oversold.
Update (12/26/21): Funds have added more than 350,000 shares of KMPH this past week, as the stock price had a nice rebound. We’re getting close to the drug release date.
Update (1/9/22): KMPH hasn’t done much recently, but the drug release date is approaching soon. We’re just waiting on news.
Update (1/16/22): Here’s another buy zone for a cheap company whose revenue will rise upon drug release. This stock price as $15.50 not too long ago.
Update (1/30/22): Here’s another manipulated stock per the on-balance volume:
If no one is selling, why did the stock price drop so much? It makes no sense.
Update (2/6/22): This hit all-time lows at $6.09 earlier in the week, but the on-balance volume didn’t change at all.
Update (2/13/22): This is back to being at an all-time low at $6.11, and once again, the on-balance volume hasn’t budged.
Update (2/20/22): KMPH fell along with the rest of the market late in the week. This is the lowest the stock price has been in nearly two years, and yet the on-balance volume hasn’t dropped since the stock price’s fall from $15.
Update (2/27/22): This has nothing to do with the company, but I wanted to show you an amazing post I saw on StockTwits on the KMPH board:
I look forward to drinking from the shorts’ skulls in celebration when this squeezes.
Update (3/6/22): How is this even legal?
This is the position cost distribution of KMPH. No one’s selling, yet the price keeps dropping. I hope these malicious shorters get thrown in prison one day.
Update (3/13/22): I expected more from KMPH with some of the former GameStop guys on board. This has done nothing, and there seems to be no hope.
Update (3/27/22): Nothing new to report!
Update (4/3/22): KMPH was green on a red day on Friday, so that was nice to see.
NewEgg is a major computer parts vendor. Their current market cap is $3.56 billion, but they do $2.46 billion in sales. They’ve gotten shorted into oblivion, which has caught my attention. NewEgg was as much as $80 at one point and $20 back in December, but it’s been shorted to below $10, which is a great buying opportunity. The cost-to-borrow fee is 30 percent. (New 1/7/2022)
Update (1/16/22): NewEgg continues to be shorted. If you look at the stock price history, you can see that this company tends to have some violent squeezes.
Update (1/30/22): Another highly manipulated stock whose price shouldn’t have dropped:
Yeah, stocks deserve to fall from $22 to $6 with no selling pressure, that makes so much sense.
Update (2/6/22): This stock price dropped to an all-time low of $5.68 last week, and yet on-balance volume hasn’t changed at all.
Update (2/13/22): NEGG ran to $7 this past week, but dropped back down to the low $6s at the end of the week because of nonsense.
Update (2/20/22): NEGG dropped below $6, as it fell with the rest of the market. I picked up more shares below $6. On-balance volume is at an all-time high.
Update (2/27/22): I put in a buy order under $5, but it didn’t fill. The price got to $5.01, but didn’t hit my $4.99 target. Sucks! On-balance volume remains the same.
Update (3/6/22): I bought way more shares on Friday once the RSI dipped into the 20s. This current stock price is a joke.
Update (3/13/22): I bought more shares at $4.25. RSI continues to be below 30, making this a terrific bargain.
Update (3/27/22): NewEgg shot up to $6.50 randomly this past week, but came back down to $5.18. This company remains highly shorted and extremely manipulated. On-balance volume is very high.
Update (4/3/22): I sold at $8 on Friday after the huge spike. I’ll buy back in at RSI 30 again.
Harvard professor Timothy Springer made a billion dollars by being early on Moderna. As of a few weeks ago, he disclosed a 17-percent ownership in Selecta. Will Springer be right again? I’m betting yes.
Update (1/19/21): The same applies to this as RGLS. This stock has been slowly rising in the past few weeks, but this will soar upon some great news.
Update (1/26/21): Still waiting on news for this. Be patient.
Update (1/31/21): We went up a leg, as SELB traded in the $4 range all week. This stock continues to have major potential.
Update (2/7/21): We went up another leg; SELB is now trading in the $5 range. Something big might be coming soon.
Update (2/15/21): The chart shows a bull flag, for those interested in those sorts of things. Again, this stock has huge potential.
Update (2/21/21): We’ll get some news here sooner or later, which will send this flying.
Update (2/28/21): As with RGLS, this stock price dropped along with the rest of the market. This has some great potential down the road.
Update (3/5/21): Another steal with SELB closing at $3.81 on Thursday. This stock is 60-percent owned by institutions. They know what’s up.
Update (3/14/21): This company is 60-percent owned by institutions. I’ve been hearing some rumors about shares not being available, which reminds me of what happened to GameStop before its surge. This obviously will not be GameStop, but I’m expecting Selecta to soar upon any news.
Update (3/21/21): Selecta rose 4 percent in the Friday after hours because Peter Traber increased his ownership to 26 percent. I imagine he knows of things coming that will send this soaring.
Update (3/28/21): No news to report. Selecta is very cheap right now. I’ll be buying under $4.
Update (4/4/21): None of my Selecta shares were borrowed (see CLOV for details.) Institutions have been buying instead. I hate Goldman Sachs, but they bought a million shares of SELB, which is obviously good news.
Update (4/11/21): There’s been tons of institutional buying, but no news in a while. Any positive news could cause this to skyrocket.
Update (4/18/21): Selecta has gotten hurt like all of the other bios because of the FDA delay.
Update (4/25/21): Anything under $4 is a great bargain. Again, this is another bio that has been hurt by the FDA delay, which is only temporary.
Update (5/8/21): Selecta has earnings this week, but we’re waiting on news. Given the high amount of institutional buying – Blackrock just increased to 6.2 million shares – it would be shocking if we didn’t get news at some point this year.
Update (5/16/21): Owning this stock is like watching paint dry. I have nothing to report this week, but it’s only a matter of time before we get some big news.
Update (5/23/21): Selecta was in the $2s briefly, so it was on sale. Goldman Sachs agrees. They bought 1.6 million shares of Selecta at an average price of $3.78.
Update (5/30/21): Selecta had a great week. If you’re wondering why the stock price went up so much, Timothy Springer, who became a billionaire from Moderna, bought more shares. He had owned 23.9 million shares, and he’s up to 28.6 million. He now owns 25.3 percent of this company. Something big is coming.
Update (6/6/21): This is one of the few stocks on this page that isn’t a short squeeze candidate, so I won’t be talking about borrowing fees unless that changes. This is a play on Timothy Springer, a Moderna billionaire who owns 25.3 percent of this company. It’s only a matter of time before we receive some crazy news that sends this stock skyrocketing.
Update (6/13/21): There was a ton of buying action on Thursday, so we may see a filing soon. Selecta has insane potential. To see what could happen, check out ORPH. It went from $5 to $58 this past week!
Update (6/20/21): Again, Selecta is not heavily shorted – the utilzation rate is only 1.16 percent! – but there’s bound to be a crazy catalyst on the horizon with all of the inside buying that has been happening.
Update (6/27/21): This can be a boring stock, so patience is required. But with the insane amount of inside buying, there’s bound to be news at some point that creates a huge price spike.
Update (7/4/21): As I wrote earlier, July is typically the best month for bios. Could we finally hear some news from Selecta? It’s going to happen; it’s just a matter of when.
Update (7/11/21): State Street Corp bought more into Selecta, increasing its position from 1.1 million to 1.2 million. They’re anticipating the news we’re bound to receive at some point.
Update (7/18/21): The RSI is 32.9, making this a great buy-in opportunity. This remains a great long-term hold.
Update (8/1/21): Here’s another purchase for Alliancebernstein, which purchased 28,000 shares of SELB on June 30 at an average price of $4.35.
Update (8/8/21): There were some institutional buys and sells this week, with the largest being a 50,000 buy from Rhumbline Advisers.
Update (8/15/21): Selecta rose toward the end of the week, for what I can only assume is for big purchases. This stock will skyrocket one of these days, but it could take a while.
Update (8/22/21): I have nothing to add. This is a very boring stock, but it will pay off greatly one day.
Update (8/29/21): Marshall Wace sold 800,000 shares of Selecta. Morgan Stanley sold about 400,000 shares. This isn’t ideal, but those companies still have large stakes in Selecta, owning 2 million and 484,000, respectively.
Update (9/5/21): Friday’s red market pushed this down a bit, but we’re still waiting on news. I have nothing to add otherwise, as there were no significant filings posted either.
Update (9/12/21): This is going to seem like the most boring stock of all time until it actually does something and then explodes to $50 or something. As the saying almost goes, something something, transfer of well from the impatient to the patient, something something.
Update (9/19/21): Nothing new to report this week, outside of some heavy buying on Friday. When this rips to $40-50, people will be chasing when they had so much time to load up in this range.
Update (9/26/21): I have nothing new to add here this week. This stock will not move until it does, and then it’ll skyrocket.
Update (10/3/21): TIAA-CREF bought 254,000 shares of Selecta, per a July 31 filing.
Update (10/10/21): Nothing new to report here, as usual. Again, this stock will do nothing until news sends it skyrocketing. When that will be is anyone’s guess.
Update (10/17/21): Same as last week. Nothing new. I will buy more if we go under $4.
Update (10/24/21): Something called Strs Ohio bought 29,200 shares of Selecta at an average price of $4.14, effective Sept. 30. I was looking for $3.50 to add.
Update (10/31/21): It saddens me to say this, but I sold my Selecta shares at $3.75. I did this because it was announced that they would increase their offering size by 50 percent. I’ll be looking to get back into Selecta because I’m a believer in Timothy Springer, but I’m waiting for a sub-$3 dip.
Update (3/6/22): I bought back into Selecta at the ridiculous price of $1.65. RSI is a ridiculously low 23, and it wasn’t too long ago that Timothy Springer bought more shares of this company.
Update (3/13/22): I bought more shares at $1.50 with the RSI still in the 20s. It has since popped back up to 33. Anything below $1.60 is a tremendous deal.
Update (3/27/22): Selecta is near all-time lows. Timothy Springer bought shares at a higher price, so it’s only a matter of time before this shoots up.
Update (4/3/22): It’s really amazing to me how low this stock is, given that it was trading in the $3-4 range for a year. Nothing has happened to make this move down; in fact, Timothy Springer bought more shares after the dip.
This is another Chamath play, so I can understand why you would be wary after the Clover debacle. However, SoFi is a monster company doing billions in revenue. There’s an NFL stadium named after them. I’ve been waiting for a great entry point, as IPOE – which will become SoFi following the merger – was trading at $26 in early February. It has since dropped because of both the crash and the negative sentiment about Chamath in the wake of the Clover debacle. This company is 20-percent shorted, so it’s going to explode once Clover recovers and traders have faith in Chamath again.
The only reason this is two stars at the moment is because I think this could drop to the $12 range. There’s also an unfair stench surrounding SPACs right now because of the crooks at CCIV, but people will soon forget and eventually treat SPACs favorably again. (New 3/5/2020)
Update (3/14/21): This stock hit $13 a week ago, and now it’s $19. And yet, it’s still extremely underpriced! This is a growth stock you’ll be able to hold forever in your portfolio, and yet it’s not even $20 at the moment.
Update (3/21/21): IPOE’s merger vote is April 9. Assuming the merger passes, this will be known as SOFI shortly afterward. There will be a down day to buy dips when the name transfers – some brokerages won’t have shares available for purchase – and then this company should shoot up, as people finally understand that IPOE was Sofi all along.
Update (3/28/21): Sofi put out a great tweet on Friday:
That’s the reason why Sofi was up Friday when everything was down. This is a great company that will be $100-plus one day.
Update (4/4/21): Almost all of my IPOE shares were borrowed (see CLOV for details), which is good news because the idiot short sellers are paying me 15-percent interest. Morons! At any rate, I want to correct some bad information I gave to you on March 21. I said the merger date was April 9, but that was the deadline for which IPOE would announce the merger. I saw Aug. 23 as the correct merger date. Regardless, that gives us plenty of time to accumulate.
Update (4/11/21): Sofi rose with Clov on Thursday, as some of those who shorted Chamath Palihapitiya’s stocks covered. There’s still insanely high shorting, however. Look at the information from iBorrowDesk:
There are barely any shares left to short, and the borrowing fee is now in the 40s. The short sellers are losing control of this quickly.
Update (4/18/21): SPACs like IPOE continue to get hammered, but there are barely any shares left to short. IBorrowDesk is showing just 6,000 shares remaining to be shorted. The borrowing interest is spiking. This is all music to my ears. I bought more IPOE this past week than any other company, save for CLOV.
Update (4/25/21): I posted a link of stocks most likely to squeeze. IPOE was third as of Thursday! There aren’t any shares left to short, and borrowing fee for short sellers has risen to 60 percent! With IPOE filing merger papers, this is going to squeeze rather violently. IPOE will be a triple-digit stock someday, which is why I bought aggressively when it dipped into the $14s and low $15s:
Update (5/8/21): Did you notice IPOE skyrocket late on Friday? This is because they announced their official merger and ticker-change date. IPOE will become SOFI on June 1. This stock is severely underpriced and shorted, making it my top recommendation at the moment.
Update (5/16/21): The borrowing fee has risen to 96.3 percent. Let me say that again. The borrowing fee is 96.3 percent!!! Idiots shorting this great company will have to give back all of the money they borrowed without covering within a year, so it’s just a waiting game. Seriously, just look at this:
The vertical bars are shares available to short, which have disappeared. The red line is borrowing fee. The black bar is the stock price. How does something like this not explode and squeeze violently?
Update (5/23/21): The borrowing fee is 184 percent!!!
R.I.P. Shorts.
Update (5/30/21): The borrowing fee is now 261 percent. Imagine taking out a loan in which the principal rises and you have to pay 261-percent interest. Short sellers might be the dumbest people on the planet, but I’m grateful for them because we can capitalize on their stupidity. At any rate, SoFi CEO Anthony Noto is ringing the Nasdaq bell on Tuesday with this officially switching to SoFi.
Update (6/6/21): IPOE merged with SoFi, so this ticker became SOFI on June 1. It was having a great week until some major manipulation brought down the price on Friday. I bought more shares in the $20.80-20.90 range. The borrowing fee on this stock is close to 80 percent, which is insane. I received 57-percent interest from it on Friday, which was unreal.
Update (6/13/21): We had two 13D filings! Softbank and Red Crow Capital bought 14.8 and 6.6 percent of SoFi, respectively. This company is still insanely shorting, so I’m expecting a squeeze to at least $50 in the near future.
Update (6/20/21): There’s no Ortex data on SoFi, but we know it’s incredibly heavily shorted because the borrowing fee is still 60 percent!
Update (6/27/21): There was some major selling or shorting on Friday. It’s not clear what caused the price to plummet below $19, but no shares were returned to iBorrowDesk. It costs 222 percent to short this stock, which is insane. Imagine paying 222 percent on a loan. You’d have to be an idiot to remain in that position. If the borrowing fee remains at this level, the shorts will have a permanent loss in about six months.
Update (7/4/21): SoFi dropped this week because of obligatory PIPE selling. It could drop a bit more, but that would just create a great buying opportunity.
Update (7/11/21): SoFi had another red week, closing at $16.45. The chart shows SoFi is incredibly undervalued right now. The RSI is close to 30, while Slow Stochastics are 4.61. There’s bound to be a reversal soon.
Update (7/18/21): Zack Morris tweeted his interest in SoFi this weekend, which was nice to see. SoFi is incredibly oversold right now. The RSI is 31.4, thanks to the obligatory lock-up selling. This could go down a bit more to the $10-12 range, but this is still a nice buying opportunity.
Update (8/1/21): Here’s another positive MACD cross. Again, the speculative market is so beaten up right now that it’s bound to bounce back sooner or later.
Update (8/8/21): Liberty Street Advisors bought 742,000 shares of Sofi on June 30. Perhaps they’re expecting a great earnings report, which will be released on Thursday.
Update (8/15/21): This week in the stock market, we learned that most people can’t read an earnings report. SoFi beat revenue and saw an increase in memberships of more than 100 percent, but missed earnings. The reasons they missed earnings, however, were because of deferred warrants (thanks, CCIV) and because of their Galileo purchase. SoFi is a great company, and this stock price is absurdly cheap.
Update (8/22/21): I can’t believe SoFi hit $13 after their positive earnings. I bought more shares. It was nice to see a huge purchase: Altimeter Capital bought 2.5 million shares of SoFi.
Update (8/29/21): T. Rowe Price bought 1.276 million shares of SoFi at an average price of $19.17. Morgan Stanley bought about 400,000 shares at a higher price as well. SoFi is extremely undervalued right now, and I bought more shares at the end of the week.
Update (9/5/21): The bad news is that 25,223 $15.50 call options expired out of the money. The good news is that nearly double the number of $15 call options finished in the money:
I have a feeling we’re going to see this stock rise significantly soon.
Update (9/12/21): It’s nice that the first Sunday Night Football broadcast will be at SoFi Stadium when the Rams battle the Bears. SoFi advertised during the Buccaneers-Cowboys game, which caused its app to move up 40 or so spots in the app store. All of this will bring new customers to SoFi, which has amazing potential for the long haul.
Update (9/19/21): This stock plummeted to the low $14s at one point this past week, but quickly bounced back to the $15 range. That was a good sign for this undervalued company. There were a couple of six-figure SOFI purchases reported this past week.
Update (9/26/21): SOFI shares rose this week, as there were multiple upgrades made by firms with projected prices in the mid-$20s range. I hope you picked up some shares at $14 and $15!
Update (10/3/21): We’re still waiting on a bank charter, which will send this stock skyrocketing. The CEO talked about giving away $750 million or so when the bank charter is announced, so he sounded confident about it.
Update (10/10/21): I was hoping this would run with Clover on Friday because both are shorted Chamath stocks, but SoFi remained at a cheap price in the low $16s.
Update (10/17/21): SoFi had a great week, at least until Friday when the market makers and hedge funds were up to their usual options tricks:
Still, there was plenty of institutional buying to move up the price. With bank charter news, we should hit $30 easily.
Update (10/24/21): SoFi rose to $21 during the week from what I can only assume is big buying. Of course, the market makers couldn’t allow SoFi to keep going:
So rigged. At any rate, I trimmed five percent of my position at $21. I plan to re-purchase those shares if SoFI drops to $16 again.
Update (10/31/21): There were two purchases of nearly 400,000 shares of SoFi on the SoFi Fintel page.
Update (11/7/21): SoFi’s earnings report is on Wednesday. This is going to be the first earnings report where stadium sign-ups will be incorporated into the user base. We need a huge uptick in users to really skyrocket in price.
Update (11/14/21): SoFi had terrific earnings, which is why it spiked to the low $24s before consolidating in the high $22s, low $23s on Friday. Bank charter news is coming soon, which could push this stock above $30.
Update (11/21/21): Chamath sold some shares of SoFi, but that doesn’t necessarily mean bad things for the stock because he also sold Virgin Galactic (SPCE) before it’s huge move. Besides, Chamath still has a big chunk of his position; he’s just taking profits.
Update (11/28/21): SoFi dropped a bit this past week because of the FinTech sector being down. There was no reason for SoFi to be at this price after all of their great news, so this is a good time to buy. I didn’t purchase more shares because I think we could see $16 or $17 again.
Update (12/5/21): Well, we saw $16 and $17. We also saw $14! SoFi’s RSI is 29. It’s an unbelievable bargain.
Update (12/12/21): SOFI is an amazing buy at this price. RSI is a laughable 33. Resistance is in the $14.40s, which should be the absolute lowest this should go.
Update (12/26/21): SOFI hit a double bottom at the $13.60 range, prompting a push back to $15. If we have a nice post-Christmas rally, this could head toward $20 once again.
Update (1/9/21): Like the gambling sector, the Fintech stocks have taken a beating. SOFI is trading near all-time lows, and its RSI is 37 at the moment. This is a great buying opportunity, as the Fintechs don’t move along with the overall market either.
Update (1/16/22): SoFi is now more shorted than it ever has been:
That’s 63 million shares that are shorted. AMC is considered extremey shorted at 95 million (though we all know that number is really much higher), so SoFi is about two-thirds of the way there.
Update (1/30/22): SoFi got its bank charter! And yet, the stock price dropped this week. The market makes no sense.
Update (2/6/22): SoFi had a bad week because Paypal’s bad earnings crashed fin-techs. SoFi now has a bank charter, so it shouldn’t completely follow Paypal and the like.
Update (2/13/22): SoFi has a bank charter, and yet it can’t get above $13. None of this makes any sense, though the publicity from the Super Bowl being at SoFi Stadium should help.
Update (2/20/22): SoFi has been barcoding between $11 and $13 for the past couple of months. I still can’t believe the stock price hasn’t gone up since the bank charter.
Update (2/27/22): This is frustrating. SoFi spent a tenth of its market cap buying a software company to handle their banking. Couldn’t they just hire five or six coders to do that at a much cheaper price? That would explain why this stock price dropped this past week. Earnings are on Tuesday.
Update (3/6/22): SoFi had great earnings, yet dropped at the end of the week after rising a couple of days earlier. This made no sense, as usual.
Update (3/13/22): SoFi had great earnings and became a bank, and yet the stock price has done nothing but fall. There’s more good news: CEO Anthony Noto bought 15,000 shares of SoFI. He already had 2.8 million shares, so it’s nice to see him be so bullish on his company. It seems insane to me that a bank would have a market cap of just $7.5 billion.
Update (3/27/22): Here’s another frustrating ticker. With the crooked fed raising rates, that should help SOFI.
Update (4/3/22): I thought about taking a loss at $10.50 when the RSI was at 50, only because I need to pay taxes on my GameStop shares, and I need to sell something. I’m now regretting not doing so because this dropped to $9.33. If I sell, I’ll repurchase the shares at RSI 30.
If you don’t believe in Bitcoin, you’ll want to skip this one. If you do, strongly consider Bit Digital as a stock that could 3X-6X in the coming months. Bit Digital is a Bitcoin miner whose stock price has collapsed because the price of Bitcoin has fallen. This happened back in the summer, and look what happened after that:
If you have a sharp eye, you may have seen that there is hardly any volume to justify the stock price drop from $14 to $3. That is reflected in the on-balance volume:
This stock is heavily shorted. The borrowing fee is about 50 percent, and the utilization is 99.48 percent, per Ortex. It is 20th on Fintel’s short squeeze list. If the price of Bitcoin rises, there will be a major short squeeze. (New 1/30/2022)
Update (2/6/22): Bit Digital recovered to $4 on Friday, thanks to the rising price of Bitcoin. Hopefully we see another spike to $10 or higher.
Update (2/13/22): Bit Digital had a nice week, hitting $5 before the stock market dropped and Bitcoin fell.
Update (2/20/22): Like NILE, BTBT dropped because of Bitcoin’s decreased price. I was not happy to see that Jim Cramer is bullish on Bitcoin, but I’m still holding.
Update (2/27/22): As with NILE, this company’s outlook is bright because Bitcoin increased in value as a result of Russia legalizing it. It should only be a matter of time before the stock price reflects that.
Update (3/6/22): Bit Digital’s price dropped because Bitcoin fell. I didn’t buy more shares because I was waiting for an RSI of 30 or less. It’s currently at 33.7.
Update (3/13/22): Much like NILE, this moved along with the price of Bitcoin. I have buy orders set up below $3.
Update (3/27/22): So much for those sub-$3 buy orders. BTBT moved closer to $4, and with Bitcoin now trading at $44,000, this price should continue to rise.
Update (4/3/22): It was frustrating to see GREE run on Friday, and not BTBT or NILE. BTBT dropped at the end of the week along with the price of Bitcoin.
Blackberry? Don’t they make outdated phones!? Most people think so. I asked a dozen people this week what they thought Blackberry does as a company, and all 12 told me that Blackberry makes phones.
Blackberry hasn’t made phones in years. It is now a software company. One thing they do is write the software for smart cars. In fact, Blackberry signed a partnership with Amazon for this very reason.
Furthermore, Blackberry announced a partnership with Baidu, the Chinese version of Google, for similar reasons.
You can read more about Blackberry on Reddit. Yes, Reddit. This is one of many meme stocks that were banned/restricted on Robinhood. This is why it fell from $27 to $14 last week after it skyrocketed. Shorts were aggressively shorting Blackberry to keep it below $15 because so many $15-plus calls would have created a monstrous gamma squeeze.
Now with that over, Blackberry could continue to ascend. It could dip in the next couple of days if the Robinhood people haven’t moved their funds yet, but there’s no reason for the buying not to commence once people can actually buy this stock. (New 1/31/2021)
Update (2/7/21): As expected, Blackberry dipped from $14 to $11, but went back up to $13. Going above $13 was important, as lots of $13 calls were in the money. This should cause the price to rise, along with the fact that Zacks just raised their price target for Blackberry to $29:
That’s not even including the impending short squeeze. I’m interested to see what the updated number is, given that this was heavily shorted down from $27.
Update (2/15/21): More than 10,000 $13 calls printed, so the stock price should rise this week. Also, there’s been a ton of institutional buying, as you can see here. This company has a ton of promise, and we have a large gap to fill up to $27.
Update (2/21/21): It was a rough week for the market, and one hedge fund likely shorting this stock paid to have this downgraded. This is still a great company with an outstanding CEO. With AMC and GameStop bound to bounce back soon, Blackberry should match the price movement as one of the BANG stocks.
Update (2/28/21): I thought Blackberry would go with GameStop and AMC, but after an initial surge, it dropped a bit. Don’t worry though because Blackberry is still a great company that should be worth more. If you’re worried, check out this article: Why Your Stock is Always Red. It’s a fantastic read. If you’re the least bit concerned about Blackberry, or any other of your stocks constantly falling, you must check out this article.
Update (3/5/21): Blackberry finished below $10 on Thursday, and it went down to $9.61 in after-hours training. Tech sell-off has hurt this stock, but it’ll run eventually. I’ll be aggressively buying if this drops into the $8 range.
Update (3/14/21): Blackberry made a nice move up this week with tech recovering, closing at $11.85. It’s amazing how many people don’t even know what Blackberry does. It should be trading close to $30.
Update (3/21/21): Blackberry’s earnings are next Tuesday. An earnings blowout could shoot this stock up, as it could make people examine this company and realize that it doesn’t make phones anymore.
Update (3/28/21): Blackberry dropped because the SEC told them it has to report its earnings differently than it has in the past. Ah, so the SEC is actually doing something even though the hedge funds are getting away with blatant criminal behavior, I see. Earnings may not look as great as a result, so it might be a viable strategy to sell and then buy back in cheaper. I don’t think I will be doing this because Blackberry seems to be getting more hype on WSB at the moment. Regardless, this is still a great play for the long term because autonomous driving is the future, and Blackberry has a stranglehold on the software side of that industry.
Update (4/4/21): I can’t say I’m surprised that Blackberry reported poor earnings. I thought there would be more hype from it from WSB, so I should’ve listened to my own advice and sold, then re-bought. Blackberry’s success will be recognized in the future. They have partnerships with Amazon and Baidu that will pay off in the future, which is why Zacks released a $29 price target on this company.
Update (4/11/21): Blackberry bounced back a bit, going to the mid-9s before closing at $9.13 for the week. This is still severely undervalued. We just need some major news for this to rocket.
Update (4/18/21): Nothing new to add at the moment. We’re waiting on some news that we’ll get this quarter.
Update (4/25/21): There were 5,500 Jan 2022 $40 call options purchased this past week. Yes, someone, or some people, believe that Blackberry will hit $40 by January!
Update (5/8/21): Blackberry has been shorted over the past couple of weeks. This is good news for the long run. We know Blackberry is not going bankrupt, so every short seller on this company is a future buyer.
Update (5/16/21): There was some nice inside buying on Blackbeery at cheap prices. Credit Suisse bought 400,000 shares at $7.53. Vanguard purchased about 700,000 shares at the same price. Hopefully we get to profit along with these hedge funds as the BANG KEN stocks explode once again.
Update (5/23/21): I hate to root for Citadel because of what they did to ruin the true GameStop squeeze, but it was nice to see them buy about 1.3 million shares of Blackberry at an average price of $7.53. They now own 2.19 million shares of Blackberry, which only adds to the institutional investing I mentioned earlier.
Update (5/30/21): Blackberry had a great week, as did all of the BANG KEN stocks. Here’s a great aticle on why Blackberry is undervalued.
Update (6/6/21): Blackberry had another great week, and yet it’s still underpriced. My target is somewhere in the mid-high $20s. I sold five percent of my stake at $16 to raise capital for other purchases, but I’m holding strong otherwise. The short sellers, meanwhile, are attacking the stock. The iBorrowdesk date shows that they borrowed 425,000 shares on Friday afternoon.
Update (6/13/21): Blackberry hovered in the $15-16 range for the first three days of the week before plummeting to $13 as a result of a huge short attack on all of the “meme” stocks on Thursday. It’s no surprise that it pulled back and consolidated in the $13-14 area. We’re just getting ready for the next spike.
Update (6/20/21): Blackberry had a rough Friday. Coincidentally, there were a ton of options at $13 and $13.50. Market manipulation by these hedge funds killed those options. If the SEC were paying attention, they would arrest these scumbags.
Update (6/27/21): We experienced another Friday in which Blackberry was pushed down by hedge funds and market makers to avoid paying out $13 and $13.50 calls. I hope options players one day will realize why they should just buy shares. You can get lucky with options, but more often than not, those in control of the market will find a way to screw you.
Update (7/4/21): What a coincidence that Blackberry finished the week at $11.99 when there were tons of $12 call options! I wonder if the SEC was monitoring this illegal activity. Yeah, right. There’s more of a chance they were picking dingleberries out of their buttocks than tracking illegal price manipulation.
Update (7/11/21): Nothing new for Blackberry this week. It rose early and finished 20 cents below where it started. Once people realize that Blackberry doesn’t make phones anymore, its stock price will rise considerably.
Update (7/18/21): Once again, a quiet week for Blackberry. There were a ton of $11 call options, so the hedge funds pushed the price below that figure. It’s a reminder that it’s better to buy shares than options because the market is so manipulated. Short interest, by the way, is about 30 million shares.
Update (8/1/21): Blackberry was trending on Stocktwits a couple of nights this past week, but I’m not sure why. I’m still bullish on the stock, especially when looking at the chart, which shows a switch to a positive MACD. The last time this happened, Blackberry hit $20 after a few weeks.
Update (8/8/21): Swiss National Bank bought 140,000 shares of Blackberry at an average price of $10.31. They now own 2.29 million shares. They know big news is coming with Blackberry. It’s just a matter of time before this pops.
Update (8/15/21): Two pieces of good news despite this stock being in the $9s on Friday. One, the State of Wisconsin Investment Board bought 127,000 shares of Blackberry at an average price of $10.31.
Second, the number of shares on loan is the highest it has been since the pop to $16 in early June. The more shares on loan, the greater the squeeze will be.
Update (8/22/21): Millennium Management bought 514,000 shared of Blackberry at an average price of $10.32. Meanwhile, shares on loan are now up to 33 million, which is just shy of the 35 million we had before the early June pop.
Update (8/29/21): Another big purchase was reported this past week, with Morgan Stanley buying 288,000 shares of Blackberry. Blackberry rose with the other meme stocks Monday, but didn’t have a red Friday like AMC or GameStop. Because the price finished above $11, 13,597 call options finished in the money, which is great news for this stock.
Update (9/5/21): There were lots of $12 call options expiring Friday, so Blackberry was going to be pinned down at the $11 range.
Update (9/12/21): Blackberry had a chance to finish above $11 for the week, but not really because there were so many $11 call strikes. This is a weekly reminder never to buy weekly OTM call options because you will get burned almost every single time.
Update (9/19/21): Primecap Management sold 2.4 million shares of Blackberry, but they still own 39.2 million shares. Meanwhile, we had a bad 13F reported this week, with Virtu Financial selling 141,000 shares of Blackberry. However, Virtu reported selling many stocks this week, so perhaps they needed to liquidate.
Update (9/26/21): Blackberry had a great week, beating both revenue and EPS in their latest earnings report. I hope we rise to $15 soon and establish that as our new floor.
Update (10/3/21): The down market caused Blackberry to drop below $10 even though their earnings report was outstanding. I bought some more shares in the $9.60 range.
Update (10/10/21): It’s amazing that we’re in lower $9 range after such a great earnings report. This is a great entry point for a stock that will run once AMC and GameStop pop.
Update (10/17/21): In addition to a great earnings report from earlier, Blackberry partnered with Google and Qualcomm. With AMC set to have a big run soon, Blackberry will squeeze along with it.
Update (10/24/21): If you’re wondering why Blackberry dropped below $11 on Friday despite the amazing news it received last week:
Again, remember that comic. It’s all rigged, particularly the options market. I’ll say this for the 716th time: DO NOT PLAY WEEKLY OPTIONS!!!
Update (10/31/21): Despite all the great news, Blackberry dropped below $11 this week. Want to guess why?
Dear options traders: The market is rigged. Do not, for the 719,511th time, buy weekly options!
At any rate, this is a nice entry point for Blackberry because when AMC ultmately runs, this will, too.
Update (11/7/21): Blackberry opened the week at $10.90 and rose to $12.25 as a part of the BANG KEN movement. Yet, it collapsed late in the week due to the usual manipulation:
There’s no way the market makers would ever allow this price levels to hit. This is the 716,511th reminder that you should only buy shares and way out-of-date options. Do not play weekly options ever! These scumbags will take your money 99 percent of the time!
Update (11/14/21): Goldman Sachs bought 1.3 million shares of Blackberry at an average price of $10.98. They know very well that when AMC/GME go, Blackberry will as well.
Update (11/21/21): It was odd to see Blackberry not rise along with AMC and GameStop on Friday. This will squeeze along with those two, however. In other news, Davide Leone Partners Investment bought 406,000 shares of Blackberry at an average price of $10.51.
Update (11/28/21): It’s insane that despite all the positive news and earnings this company has had in recent months, it dipped below $10 on Friday. Blackberry is a bargain at this price.
Update (12/5/21): Once AMC shoots up from the eventual NFT dividend, Blackberry will skyrocket as well. Blackberry’s RSI is 32, which is the lowest it has been since I began tracking this stock.
Update (12/12/21): Blackberry fell along with GameStop and AMC late in the week. Again, once they run, Blackberry will as well.
Update (12/19/21): Blackberry rose with GameStop and AMC as part of the BANG KEN brigade. When AMC has its next ladder up, Blackberry will skyrocket.
Update (12/26/21): Blackberry had strong earnings yet again, beating revenue and EPS expectations. This could be in the $10s next week with a positive rally, but what really matters is the squeeze when AMC begins running.
Update (1/9/22): Blackberry moved with AMC and GME in Thursday’s after hours, confirming that it’s stil heavily shorted in the same BANG KEN basket. Once AMC and/or GME go, Blackberry will rise with them.
Update (1/16/22): I bought some more Blackberry in the $8s this week. It will skyrocket when AMC does, so it’s just a matter of time.
Update (1/30/22): It should come as no surprise that Blackberry’s on-balance volume has remained the same as well. Take a look:
All of these stocks are heavily manipulated, which is why Blackberry will soar when AMC and GME skyrocket.
Update (2/6/22): Blackberry sold a patent for $600 million, and yet its stock price went down this past week. Unreal. We’re still waiting on the inevitable squeeze of GameStop and AMC for this to rise because it’s shorted by the same scumbags.
Update (2/13/22): It’s amazing to me that Blackberry’s stock price has done nothing but go down since they sold a $600 million patent. I suppose we’ll have to wait for that to be reflected in the earnings for people to pay attention.
Update (2/20/22): Blackberry is currently at a 52-week low, yet its on-balance volume has barely changed. Its RSI is only 29. I picked up more shares on Friday.
Update (2/27/22): I added more shares of Blackberry on Thursday morning because the RSI was so low. As stated numerous times, when AMC goes, this will as well.
Update (3/6/22): Blackberry’s RSI is currently 34.7, which is low, but could drop a bit more. I’ll be a buyer if it gets to RSI 30.
Update (3/13/22): Blackberry’s RSI has remained the same (35), so I’m still waiting for the price to drop a bit before I buy more shares.
Update (3/27/22): Blackberry’s stock price rose earlier in the week, but it was disappointing to see it not move with AMC and GME on Friday. I don’t know why the price didn’t rise at the end of the week.
Update (4/3/22): Blackberry’s earnings dropped the price on Friday, as guidance was a bit disappointing. It wasn’t too long ago that GameStop had a disappointing ER (with no guidance), and yet it has doubled in price since. Granted, Blackberry doesn’t have Ryan Cohen, or even Adam Aron, but it will move with GME and AMC.
You may have noticed that I bought shares of BGI. Birks Group, a jewelry chain, is a reopening stock that could hit triple digits upon a short squeeze or buyout. It’s not even trading at double cash per share ($1.77). It’s very heavily shorted – IBorrowDesk is slapping this with a 106-percent borrowing fee and there are only 150,000 shares remaining to borrow – and the float is miniscule. There are only 4.32 million outstanding shares. Some rich shark could just spend $14 million to buy up the entire float and then recall his borrowed shares to create a violent spike. This could actually happen if there’s an acquisition, which seems likely. (New 4/4/2021)
Update (4/11/21): This fell hard this past week, and I think it’ll drop to $2. However, it has major potential for the future, especially as Q4 approaches and people realize that the pandemic is over.
Update (4/18/21): Parts of Canada going into extreme lockdown for a virus with a 99.98-percent survival rate is really hurting this stock right now. That said, this company is trading around its cash per share, which is just ridiculous. This is extremely oversold at the moment. The RSI (32) is the lowest it’s been in a year.
Update (4/25/21): BGI had a nice surge on Friday, rising 27.5 percent during regular hours and 19.37 during after hours. It seems to me that some shorts are trapped. No shares are available to short anymore, so this could squeeze hard soon.
Update (5/8/21): BGI has fallen on hard times recently with some growing concerns about its debt, coupled with draconian Canadian lockdowns. The borrowing fee has fallen as well. This could squeeze hard if the company can show that it’s turning things around, but I wouldn’t blame anyone for getting out of this.
Update (5/16/21): I sold because I was too concerned with BGI’s debt. It ended up being a mistake because BGI shot up on Friday, but as Cam Newton once said, hindsight is 50-50.
Update (12/8/20): People within the company have continued to buy back their shares. I believe we’ll see the share price above $90 in a few months.
Update (12/22/20): I’ve closed my position for now. I may re-buy at a lower price, but I’m concerned that many insiders have sold shares in the previous week.
A beaten-down retailer expanding its e-commerce exponentially, all while being heavily shorted by people not paying attention to the dynamics of the company. Sound familiar?
Express is a mini-GameStop. It will not hit $100, but it should be trading in double digits. Express is doing a great job of building up their e-commerce, all while closing stores that aren’t profitable, which is exactly what GameStop did last year. Their guidance during their earnings call was great, so this cheap company will rebound. Again, Express is heavily shorted, and it’s 60-percent owned by institutions. The float isn’t very large (60 million), which once again matches GameStop. (New 3/11/2021)
Update (3/21/21): It seems as though people are catching on to Express, with it closing at $5.33 on Friday. I expect this to hit $10 at some point. I’m dropping this from four to three stars because of the price increase.
Update (3/28/21): Momentum stopped on Express because of the red market. It’s still very shorted – only 200,000 shares left to short – so we could see a spike to $10 at any time.
Update (4/4/21): No Express shares were borrowed from me (see CLOV), which was absolutely shocking. There are now 300,000 shares left to short, per IBorrowDesk. I’m still bullish on this.
Update (4/11/21): Express really pissed me off last week. Part of the reason why GameStop skyrocketed is because they never had an offering. Express, however, issued a shelf offering of 25 million shares. It’s going to be difficult for this to squeeze as a result.
Update (12/8/20): Congrats to those who bought at $8-$9! I’ve sold two-thirds of my shares. I think we could see $15. $HPE had a great earnings report.
Update (12/22/20): HPE filed for a shelf offering. That’s not the worst thing in the world, but I’ve decided to close my position. If the price drops, I may buy back in, as this still offers a great dividend.
CarLotz is criminally underpriced because, you guessed it, the company is heavily shorted.
CarLotz is an online car vendor, much like Carvana and Vroom. However, unlike Carvana and Vroom, which trade at 6x and 2.2x forward sales, respectively, Lotz only trades at 0.7x sales because the price has been crushed by the shorts. If it traded similarly to Vroom, Lotz would be $34 right now. If it traded similarly to Carvana, it would be $88!
CarLotz is well off right now and has tons of potential. It currently possesses $300 million in cash and has just $6.6 million in debt. Its visitors have tripled to 189,000 per month. They expect sales growth of more than 500 percent within the next two years, and sales of a billion by 2022.
Half of LOTZ’s float of 117 million is owned by insiders and institutions. They know how profitable this will be for them, so I’ve been buying aggressively in the $8 range. (New 3/11/2021)
Update (3/21/21): There have been big buys coming in on Lotz, yet the price keeps dropping. This is because the stock is being manipulated so that the hedge funds can load up and make tons of money on this company. Lotz should be $34 at the very minimum, for reasons discussed above.
Update (3/24/21): CarLotz has a new price target from a premium analyst. Barrington Research initiated a buy rating with a price target of $22 for LOTZ. I still think that’s too cheap, but it’s a great start. It’s ridiculous that LOTZ is trading at $8. It reminds me of when GameStop was spinning its wheels in the $4 range throughout the month of August, and then it eventually took off. You just have to be patient with these plays. The old saying is that the stock market is the transfer of wealth from the impatient to the patient.
Update (4/4/21): None of my LOTZ shares were borrowed (see CLOV for details.) I don’t have much to add this week, but I thought it was cool that the CarLotz in Seattle, which just opened, already has 75 Google Reviews with an average rating of 4.8 stars.
Update (4/11/21): Nothing crazy this week, except that the Q1 earnings date was announced. It’s about a month away from now, on May 10.
Update (4/18/21): SPACs and former SPACs have been getting crushed ever since Chamath Palihapitaya’s interview on CNBC following the GameStop spike. The good news is that one of these former SPACs, Clover, is now beginning a huge short squeeze. LOTZ will have one as well in the future. For now, this stock is extremely undervalued.
Update (4/25/21): Former hedge fund portfolio manager Will Meade posted about LOTZ on Twitter this past week, identifying it as a potential squeeze with a $22 price target.
Update (5/8/21): Carlotz’s earnings are on Monday, and I’m expecting positive things from this growing, yet heavily shorted company.
Update (5/16/21): Carlotz had good earnings, but plummeted because the market was crashing for small- and mid-cap stocks. However, Vanguard bought 3.2 million shares of Carlotz, so it’s nice to know that they agree that this company is undervalued.
Update (5/23/21): I’m not sure what Tremblant Capital is, but they bought 5.5 million shares of Carlotz in a May 17 13F filing. This stock continues to be undervalued and oversold.
Update (5/30/21): I have nothing positive to say about Carlotz. Their CEO misled the investors. It was reported Wednesday that their largest provider paused consignments due to the chip shortage, which is why the stock price dived. The CEO had to know about this, but didn’t say anything during the earnings report. This could be only temporary, but it might hurt Carlotz enough if the pause lasts a while. I’d ordinarily advise buying the dip, but I can’t do that with Carlotz right now. The company could recover, but this is a huge gamble.
Are you looking to buy stock from a cheap company that cured cancer? Then, Clovis Oncology is for you!
Yes, you read that correctly. Clovis has a drug called Rubraca, which is nearly FDA approved (in Stage 3.) It kills cancer cells. You’d think this would generate more fanfare, but short sellers have infested this company. This stock is 42-percent shorted, and the float isn’t very large (86.43 million). And you wonder why I hate short sellers so much. They’re literally trying to put a cancer-curing company out of business so they can take tax-free profits for themselves? What evil scumbags.
When this gets some attention, it’ll squeeze. Clovis is 55.6-percent owned by institutions, so they’re well aware of the potential with this company. The most recent price target we have is from H.C. Wainwright, which is $33. However, it could go higher with a major squeeze. (New 3/11/2021)
Update (3/21/21): Clovis had a 50-percent run on Friday, going as high as $8.90 before falling below $8. It ran on great news, as Clovis took a step closer to FDA approval for their ovarian cancer drug. What a great company. I bet everyone wants them to succeed.
Well, not quite. Clovis fell from $8.90 to the high $7s because Goldman Sachs reiterated a sell rating on Clovis despite the great news. Why did they do this? Because they have a huge short on Clovis.
That’s right – Goldman Sachs wants a company working hard and successfully to cure ovarian cancer to go bankrupt.
I can’t believe how disgusting this is. I mentioned avarice in the AMC entry, but this is the prime definition of it. If you still think short selling should be legal, you should have your head examined, because it allows scumbag hedge funds like Goldman Sachs to attempt to force good companies like Clovis into bankruptcy, just so they don’t have to pay taxes on their short. These people are gross.
This needs to be discussed publicly. Tweet @GoldmanSachs and ask them why they’re trying to destroy a company working to cure women’s cancer. If we put enough public pressure on them, perhaps they’ll cover their short and allow this good company to thrive.
Either way, this got attention from Wall Street Bets, so it sounds like more people will be jumping into this stock this upcoming week.
Update (3/28/21): The short sellers continue to pile into Clovis. There is going to be an absolute bloodbath once there’s FDA approval for their new drug, or if there’s a buyout. Meanwhile, HC Wainwright issued a price target of $13.
Update (4/4/21): As I explained in the Clover write-up, I allowed eTrade to lend my shares. My Clovis shares were snatched up immediately as well. It’s amazing how many evil people there are out there who don’t want women’s cancer to be cured. At any rate, Clovis will squeeze upon FDA approval or buyout, so just be patient with this one.
Update (4/11/21): Clovis dropped to $6.23. This is market manipulation/short sellers trying to drop the price. If you can be patient, you’ll be rewarded.
Update (4/18/21): There’s some negative sentiment here regarding a 250 million share shelf offering vote that will take place soon. I don’t necessarily think this is a bad thing, outside of it being an opportunity for scumbag bears being able to spread FUD (fear, uncertainty, despair). A shelf offering allows a company to issue shares whenever it needs to, and I imagine Clovis will want to do this once the share price skyrockets in a GLSI- or SAVA-type fashion.
Update (4/25/21): Earnings are coming up on May 5, but the big news we’re waiting for is FDA approval of one of Clovis’ drugs. The FDA has been slowed down with trying to approve the Covid vaccine, which is why all bios have taken a hit recently. Things will eventually revert to normal; just be patient.
Update (5/8/21): This was shorted into the mid $5 range since my previous update. Nothing has changed with this company, which remains a huge squeeze candidate.
Update (5/16/21): Vanguard bought 1.3 million shares of Clovis at an average price of $5.91. They now own 7.6 million shares. I would love to see the borrowing fee (1.6%) explode on this heavily shorted stock to finally push the shorts out of their position.
Update (5/23/21): There was some dilution here, but not a significant amount to push the stock heavily downward. We’re still waiting for one of three things: FDA approval, a buyout, or a short squeeze. I believe one of these three things will happen eventually.
Update (5/30/21): Here’s another heavily shorted stock that needs the borrowing fee to rise. The last time the borrowing fee was high (40%), the price spiked from $4 to $10 weeks later. The borrowing fee is just 1.3 percent right now.
Update (6/6/21): Clovis moved up a bit this past week, but there’s not much else to say. The borrowing fee has remained the same, and there were no new major buys.
Update (6/13/21): Clovis was strong early in the week, rising to $6.95 on Wednesday. However, yet another short attack brought it back down to the mid-$5 range. The shorts can only keep doing this for so long, though an increase in borrowing fee would help a ton.
Update (6/20/21): I wrote that I was looking into dumping non-shorted stocks. That doesn’t apply to Clovis. Take a look at the Ortex data:
Clovis is 44-percent shorted with 45 million shares on loan, and the utilization rate is 100 percent. It’s unreal how the short-selling scum are trying to sabotage a company trying to cure cancer. It just goes to show you how evil these people are. Anyway, expect these numbers to rise (Ortex data is two days behind.) The shorts did their best to crush the many $6 call options.
Update (6/27/21): There’s a long history of me chronicling stocks that finish the week below their popular option pricing, as hedge funds love rigging the stock market. However, they let this one get away. There were plenty of call options at $6 and $6.50, and yet Clovis ended the week at $6.54. Those shares will have to be bought Monday, which is great news for this stock. There are still 45 million shares on loan, so hopefully these calls being in the money will be the catalyst for the short squeeze we’ve been anticipating.
Update (7/4/21): The Vanguard Explorer Fund bought about 500,000 shares of Clovis per a June 29 13F filing. Clovis continues to be heavily shorted, especially recently when the bears pushed this under $6 to close out the week.
Update (7/11/21): Clovis continued to move between $5 and $6.50. As I’ve written before, July is usually a big month for bios, so perhaps the heavily shorted Clovis will squeeze soon. It could also continue to trade in the same range. Clovis will squeeze eventually; it’s only a matter of when.
Update (7/18/21): This has nothing to do with the stock, but I had a dream that Tucker Carlson said that Clovis saved his wife’s life. I would’ve bought the stock regardless in the low $5s, but I was more motivated to do so. Clovis was trending a lot on StockTwits this past week, so retail is trying hard to make it squeeze. The hedge funds have been fighting hard to suppress this stock, but they can’t do that forever.
Update (8/1/21): I don’t know what Alliancebernstein LP is, but they bought about 130,000 shares of Clovis on June 30. We now have an excellent entry point with Clovis’ RSI being 37.
Update (8/8/21): E-mailer Patrick P. sent over this DD on Friday, which I will share with you:
Update (8/15/21): Vanguard Group now owns 9.9 million shares of Clovis, which continues to be shorted into oblivion. Finviz has Clovis has 33-percent shorted. The criminals shorting this will have to cover eventually. It’s just a waiting game at this point.
Update (8/22/21): We had some big buys filed this week: Morgan Stanley bought 550,000 shares of Clovis at an average price of $6.41. Ikarian Capital bought 450,000 shares of Clovis at $6.41 as well. With this decreased price, I could see a buyout on the horizon.
Update (8/29/21): Clovis had a nice week, bouncing from the low $4s to the mid $4s. Even better, Morgan Stanley bought 580,000 shares of Clovis. I believe there will be a buyout of this company at some point.
Update (9/5/21): Vanguard bought more than a millin shares of Clovis per the Aug. 30 filing, effective June 30. It looked like Clovis would approach $5, but a Friday market-wide sell-off (thanks to the crappy jobs report) dropped it from its $4.82 open.
Update (9/12/21): Nothing really to report this week. This stock reminds me of GameStop back in August 2020 when it was trading all over the $4 range, but would never break below $4 or rise above $5. This stock is very manipulated.
Update (9/19/21): Here’s a stock that Virtu Financial bought. Virtu bought 172,000 shares of Clovis. Unfortunately, it’s not all good news. Utilization is the lowest it’s been in a year:
This is bad news for the squeeze, though the price of this stock rose this past week, as MACD crossed into positive territory. There was a ton of buying late on Friday, so perhaps someone knows something about upcoming news.
Update (9/26/21): Fidelity increased its shares in Clovis from 644,582 to 736,219 as of July 31.
Update (10/3/21): Vanguard increased its shares in Clovis from 615,246 to 761,044 as of July 31. Big money is buying.
Update (10/10/21): I don’t know how it happened, but short interest hs dropped to a low:
I don’t understand how shorts legally covered with the price steadily dropping. If there’s a silver lining, the lower we go, the more likely we are to seeing a buyout.
Update (10/17/21): The reported short interest rose from last week’s update, which was nice. However, it wasn’t nearly enough. The CEO, who has mismanaged this company, should do something to shrug off all the short sellers, but he has done nothing.
Update (10/24/21): Nothing new to add this week. Earnings are on Nov. 3, so perhaps something will happen then.
Update (10/31/21): Clovis’ earnings report is on Wednesday. It’s possible that we could have some short covering leading up to it, but I’m sure more shorts will pile in after the ER, even if it’s a positive one.
Update (11/7/21): There were five-figure 13Fs that were posted this week. Nothing crazy. Unfortunately, utilization hit a yearly low.
Update (11/14/21): I believe Clovis dropped because of tax-selling purposes as well. Everyone is underwater on this stock. I sold 25 percent of my shares for this reason as well. If I’m still bullish on this stock in a month, I’ll repurchase them, but I have to say that I’m very frustrated with the management of this company. They have a great drug that saves cancer patients, but they can’t seem to make money off of it. However, if this stock continues to drop, Clovis will be more and more attractive as a buyout candidate.
Update (11/21/21): There’s a lot of red on the filings page, which makes sense, given the severe price drop. Making matters worse, SVB Leerink gave Clovis a sell rating with a $3 target price. This company’s management is a disaster, but they have a good product and could be a buyout target. If that were to happen, Clovis’ price would continue to drop. Then again, RSI is at an all-time low, so there could be a small pop soon if you’re looking to exit this stock.
Update (11/28/21): I sold some of my shares on the sole green day this week for tax purposes. I can’t say I really wanted to at this price, but there are only a few weeks remaining.
Update (12/5/21): Again, I sold most of my shares, but the RSI here is 28. At this price, Clovis is ripe for a buyout. They have a great product, but s**t management.
Here’s another heavily shorted weed stock. Corbus is 20-percent shorted, and it recently closed an offering of $6 per share. Despite the $6 per share offering, this stock is trading at $3, which makes no sense. There’s a huge gap to fill to $9, and this should run with the other weed plays. (New 2/21/2021)
Update (2/28/21): Bumping this up to four stars on this insane dip. Again CRBP had a $6 per share offering, and it’s now trading above $2. That makes zero sense. Also, the MJ ETF – the largest marijuana sector ETF – just increased its ownership of CRBP by 122 percent.
Update (3/5/21): The marijuana sector hasn’t been immune to the crash, with CRBP closing at $1.88 on Thursday. Again, they did an offering at $6, so this price doesn’t make any sense.
Update (3/14/21): This moved up to $2.33 this past week, but it’s still underpriced. Once again, Corbus did an offering at $6. There’s no reason it should be trading this low.
Update (3/21/21): Corbus has been upgraded to buy by Zacks. In fact, it’s Zacks’ No. 2 stock in terms of estimate revisions. Again, there was an offering at $6, so there’s more than a 50-percent discount on this stock right now.
Update (3/28/21): As you can see above, I bought some Corbus under $2, which is a steal.
Update (4/4/21): As I explained in the Clover write-up, I allowed eTrade to lend my shares. All of my Corbus shares were borrowed as well. Corbus is in Phase 3 of a clinical trial, so we’re just waiting on news.
Update (4/11/21): This stock moved well on Thursday because of the new Corbus marijuana patent. It then dropped on Friday along with the market sell-off. This company should be much higher than it is at the moment.
Update (4/18/21): Marijuana stocks have been getting hammered for nearly two months now. BlackRock owns 5.6 million shares of CRBP, so enjoy the great buying opportunity.
Update (4/25/21): Another bio hurt by the FDA delay. I think this will hit $6 eventually, but it may take a while.
Update (5/8/21): Corbus is awaiting Phase 3 trials, which are due sometime this quarter. Blackrock continues to own 5.6 million shares of this company, so they’re optimistic.
Update (5/16/21): I think people are beginning to catch on how cheap these bio stocks are. Corbus had a nice rally on Friday, as did most of the weed stocks.
Update (5/23/21): Morgan Stanley bought 3.2 million shares of Corbus at $1.61 per share. I imagine they’re anticipating positive Phase 3 results, which are due by the end of June.
Update (5/30/21): Looks like Morgan Stanley knew what they were doing! Corbus just had a great week, rising into the low $2s. This stock will soar if positive Phase 3 results are announced.
Update (6/6/21): Corbus spiked to $2.20 early Monday and then hovered around $2 the rest of the week. We’re still waiting on Phase 3 results.
Update (6/13/21): Nothing new to note this week with this having the same sort of price action as last week.
Update (6/20/21): This stock is shorted, but not very heavily. However, this is a bio waiting on news, so if/when we get that, we’ll see some good price movement.
Update (6/27/21): Corbus plummeted early Thursday because of a misleading headline that hinted that their Phase 3 results were poor. That was not the case, which is why it rebounded well. At any rate, short interest is up to 12.4 percent, so hopefully we have some sort of a squeeze soon.
Update (7/4/21): I’m not sure what happened, but the short interest plummeted to about 4.8 percent. This is less appealing now, especially with the Phase 3 results not being a great success (but not a failure either.) That said, July is usually the best month for bios, and Corbus could have news that sends this above $2 again.
Update (7/11/21): State Street bought 210,000 shares of Corbus at an average price of $1.61 in a July 9 13F filing. This is why the price rose 3.6 percent on Friday.
Update (7/18/21): This price is now below the 210,000-share State Street purchase. This is the lowest the RSI has been (31.54) since November 2020 when the stock price was $1.15.
Update (8/1/21): I was higher on marijuana stocks before, but not so much after hearing MeetKevin discuss them. For those of you who don’t know MeetKevin, he has a large YouTube following, and he’s running for governor of California. He gave out a great fact that even though marijuana is legalized in California, 80 percent of marijuana sales in the state are illegal because people don’t want to follow the cumbersome regulations. That said, a fund called POTX bought 1.15 million shares on or around May 31.
Update (8/8/21): I’ll share positive institutional purchases with you, so to be honest, I must also show you the negatives. Rhumbline Advisers and Alliancebernstein sold approximately 150,000 shares of this company, which would explain the drop this past month. There were institutions buying earlier, but it’s possible that they sold as well because they didn’t see the news they wanted out of this company. We might have another Neptune on our hands, so I’m going to consider taking a loss this week.
Update (8/15/21): I sold and ate the loss. I’m sorry for those who followed me on this. I should have sold when their Phase 3 results weren’t very good. Lesson learned.
If you’re familiar with Support (SPRT), this is the same company. It turned into GREE, and the stock price plummeted because no one could buy the stock for a while. That has changed, as you can see by the insane volume this had on Friday. The volume was 28 million, and yet the float is just 10 million. This stock rose 33 percent, and yet it’s still undervalued. It had a 10/1 reverse split from SPRT, meaning this stock price would currently be just $2.72 right now if it were SPRT, and SPRT rose as high as $54! There are several price targets in the $50-$70 range of this eco-friendly bitcoin miner. (New 10/31/2021)
Update (11/7/21): GREE had a nice volume day on Friday. It’s a shorted, small-float stock that could have another violent squeeze if Bitcoin runs.
Update (11/14/21): Volume has dried up for now, and Bitcoin’s price decrease didn’t help at the end of the week. Also, there’s bound to be some tax-selling here, as the merger was messy and people weren’t able to buy on the crash down from $100.
Update (11/21/21): Bitcoin’s drop hurt this stock. I picked up more shares at sub-$21.
Update (11/28/21): Again, Bitcoin dropping hurt the stock price. I put in some buy orders at $18.50, but they never filled.
Update (12/5/21): This price is now the lowest it has ever been, even before the run up to $519.
Update (12/12/21): This fell in relation to Bitcoin’s price dropping. I actually bought some Bitcoin at $47K, so I’m bullish on these two entities.
Update (12/19/21): My shares were not being borrowed, indicating that the utilization is low. This could continue to drop.
Jupiter Wellness is a CBD company, but I’m in this for the squeeze. Take a look at this:
The shares to borrow (blue rectangles) have decreased, while the borrowing fee has skyrocketed to 30 percent. Jupiter has an extremely low float (4.25 million shares), so some heavy volume could send this stock soaring into the double digits. (New 5/21/2021)
Update (5/30/21): Jupiter went up a bit since this mention. There’s nothing new to report this week other than the borrowing fee still being high.
Update (6/6/21): Jupiter had a nice week, moving up from the low-$4s to the mid-$4s. There are only 4,000 shares available on iBorrowdesk. With a high borrowing fee, the shorts will have to cover soon.
Update (6/13/21): I nearly scared myself to death when reading the S-1 filing Jupiter released on Friday. I initially saw that they were diluting 5.25 million shares, which would double the public float. However, the real number is 525,000, which is not a big deal. This will allow Jupiter to raise money without screwing the investors.
Update (6/20/21): Jupiter doesn’t have a high short percentage (6%), but the utilzation rate is 100 percent, and the borrowing fee is high. I’m holding on to this one.
Update (6/27/21): As with Exela, there are conflicting data points with this stock. The borrowing fee is high, and there aren’t many shares available to short, but Ortex says that just 7.5 percent of the shares are on loan. It’s frustrating the numbers don’t match, but the people shorting this won’t be able to pay 25-percent interest forever.
Update (7/4/21): This is the opposite of FUBO, as insider Richard Miller bought 35,600 shares of Jupiter. Despite this, there was a 3.4-percent drop during after-hours trading on Friday for some reason.
Update (7/11/21): There was a big buy on Jupiter on Friday, which is why the stock price rose 13 percent, up to $4.44. Hopefully this is the beginning of a huge reversal up to $10-plus.
Update (7/18/21): Jupiter is on sale right now in the low $4s. Remember, this stock has a very low float, so it can move rapidly in either direction.
Update (7/21/21): So much for that low float. I sold Jupiter on Tuesday because of its 8 million share offering. This is a poorly run company that should have waited for an inevitable spike to issue more shares.
I’m jumping in on CCIV at this very low price. I think the EV market is going to be hot, and CCIV has been shorted into oblivion. There are only 300 shares available to short at a 31.7-percent borrowing fee. CCIV is in the top 150 stocks that are most likely to squeeze, according to Fintel, so I expect this stock to jump soon, especially when the merger happens (Churchill Capital Corp IV will become Lucid, and the ticker will change.) (New 5/16/2021)
Update (5/23/21): Lucid briefly eclipsed $20 on Friday. I believe it should be $35 at the very least. Look at this:
The borrowing fee (red line) has skyrocketed, while the shares available to short (blue bars) have disappeared. This is a prime squeeze candidate. I’m increasing this rating to four stars.
Update (5/30/21): The borrowing fee for CCIV was 30 percent last week. It has since risen to 49 percent! This feels like a volcano that is about to erupt because this is a crowded short that is very expensive to maintain. One would think that paying 49 percent interest on a loan would be a deterrent, but apparently not for these idiot short sellers.
Update (6/6/21): The borrowing fee moved to 52 percent at the end of the week, and the stock price moved up a few bucks. This means that the shorts will have to pay even more every single day to hold this stock. I expect to be selling CCIV when it’s around $50.
Update (6/13/21): Nothing really changed this past week. CCIV nearly reached $28, but retraced to $25. The merger with Lucid is coming soon.
Update (6/20/21): Hey, guess what? The hedge funds crushed lots of options here, too! There were a ton of $24 calls that were killed Friday. This will only increase the short numbers, which were already high. Take a look:
Update (6/27/21): There were tons of call options at $25 and even more at $26. We missed out on the $26 options, but at least we were in the money for the $25 strikes. There are now 56 million shares on loan, so finishing above $26 would have caused a gamma squeeze, which would have resulted in a short squeeze. Nevertheless, we’re obviously moving the right way with this price action.
Update (7/4/21): Two weeks ago, CCIV was $23.40, and per the graphic I showed you, there were 58.3 million shares on loan. Now, at $27.02, there are 55.4 million shares on loan, so this remains a very heavily shorted company.
Update (7/11/21): I was so close to buying more CCIV this past week. I was hoping for something below $23. That never happened, as CCIV showed some strength amid a bearish week. Hopfully this means that we’ll approach $30-plus in the near future.
Update (7/18/21): I sold my shares this week. Look at this:
These crooks, who were responsible for the drop from $60 because of their shady tactics regarding warrants, are now trying to dilute close to 15 billion shares! I like Lucid, the car company, but this stock absolutely blows. If approved, this share price is going to be $5.
Marpai is an AI health company that just IPOed a few days ago. The initial public offering closed Friday, which is a good thing for the expected stock price. The volume on this has been nuts, trading above the small float (12 million) each day. Volume typically precedes price, and the volume has been very high. I’m looking for at least $15 in the near future. (New 10/31/2021)
Update (11/7/21): I’m glad to see that Zack Morris is in on this one. I posted this before he announced he was in MRAI. When he did, the stock popped into the $6s, but was shorted back down into the mid-$5s. Those short-selling idiots are currently paying 54.3-percent interest.
Update (11/14/21): The lockup period for this stock is in April 2022. Just something to keep in mind as that time of year approaches. Otherwise, this stock has been walked down due to low volume. I imagine it’s only a matter of time before some institutional buys arrive.
Update (11/21/21): This stock hit my 20-percent threshold for swing trading, so I took the loss. I may get back in after the 30-day period if the price is cheap.
Those of you who invested into SPACs before know that mergers can be hairy. Some brokerages are very incompetent and don’t allow trading for merged companies for a couple of days. This is what happened to MMAT, which is formerly Torchlight. MMAT merged at $10, yet it’s now $6.74 because people couldn’t buy during the merger. There was more selling than buying as a result, which scared others into selling. MMAT is a great bargain now, and it’s also heavily shorted! Look at this absurdity:
MMAT’s borrowing fee is 123 percent, and there are only 7,000 shares available to short, per IBorrowDesk. I could see this having a run up to and perhaps past $20. (New 7/4/2021)
Update (7/11/21): Metamaterial is currently 10th on the Fintel Short Squeeze Explorer. It was buried by the shorts this past week, so I expect that ranking to rise.
Update (7/18/21): This has been crushed along with every other small- and mid-cap stock. The bear market hurt this play, as did its messy merger. I’m not even sure that has been resolved yet.
Update (8/1/21): Alliancebernstein bought 168,700 shares of MMAT on June 30, back when the price was in the $7s. Meanwhile, on the chart, we’re about to go into positive MACD territory, which could signify a reversal soon.
Update (8/8/21): Earnings are this upcoming week, so hopefully we get some good news. Speaking of which, the scuttlebutt on StockTwits is that Nancy Pelosi’s husband bought 200,000 shares of MMAT, but I cannot confirm this at the moment.
Update (8/15/21): Wow. Blackrock bought 3.8 million shares of MMAT at an average price of $4.66. Seems bullish to me!
Update (8/22/21): Here’s another big buy: Invesco bought 685,000 shares of MMAT. This stock has been shorted into oblivion. The lower we go, the higher we’ll squeeze.
Update (8/29/21): This could be a sympathy play to SPRT and BBIG. MMAT is a heavily shorted stock – it’s 43-percent shorted according to Finviz – with a low float (45 million), which has been the formula for the other two squeezes.
Update (9/5/21): It really looked like MMAT was going to squeeze Friday when it was up big during Thursday’s after-hours trading. Instead, it was pinned down to the $5.30-5.50 range by greedy and stubborn short sellers. The good news is that as of Friday afternoon, there are barely any shares left to short:
I bought more shares Friday afternoon.
Update (9/12/21): Some great news. First of all, cost to borrow skyrocketed from the 2-3 percent range to 21.9. Second, utilization, shares on loan and short interest are all way up:
It appears as though a major squeeze is coming.
Update (9/19/21): Utilization and borrowing fee are still much higher than they were a couple of weeks ago. It feels like this could squeeze at any moment.
Update (9/26/21): The borrowing fee has risen again, now in the 15-20% range. I put in some buy orders late in the week, but they didn’t fill. I am looking to pick up more shares below $5.
Update (10/3/21): Short interest and shares on loan have risen from the highs posted on Sept. 12:
I suspect we’re going to have a major squeeze in the future.
Update (10/10/21): Short interest is higher than it was in the graph I posted last week. This will have a huge run one of these days when we least expect it.
Update (10/17/21): Nothing of note this week. MMAT fell into a nice buying range, though I’m looking for shares under $5 to add to my position.
Update (10/24/21): I was happy to get a great dip on MMAT on Friday. I bought more shares at $4.35. Short interest is now the highest it’s ever been:
Update (10/31/21): Believe it or not, some stupid people bought this stock because they confused it with Meta, which is Facebook’s new name for some reason. There was some good news though, as Kingfisher Capital bought 129,900 shares of MMAT, effective Sept. 30. I saw several five-figure purchases as well. If all of these institutions are bullish on MMAT, perhaps we should be as well.
Update (11/7/21): There were some recent big MMAT buys, including several six-figure-share purchases.
Update (11/14/21): This is definitely a candidate for tax selling. That said, Alpine Partners bought 325,000 shares of MMAT, effective Sept. 30.
Update (11/21/21): Bank of New York bought nearly 500,000 shares of MMAT, averaging up to a $3.78 price.
Update (11/28/21): I missed this last week, but State Street bought 2.6 million shares of MMAT at an average price of $3.97. That’s an incredible purchase.
Update (12/5/21): RSI is 26. There’s resistance in the $2.80-$3.09 range, so I put in a buy order toward the lower end.
Update (12/12/21): MMAT’s RSI continues to be low, indicating that it’s extremely oversold. Again, resistance is at $2.80, so I would have a buy order set for that price.
Update (12/19/21): Here’s an indication that MMAT will run soon:
Utilization has risen, while short interest is the highest it has ever been. Who are these idiots shorting at the bottom? That’s like buying at the top! These idiots are going to lose so much money.
Update (12/26/21): The Ortex data I showed you last week hasn’t updated yet, but there’s no sign of the shorts covering. The RSI here is 32, indicating that it’s extremely oversold.
Update (1/9/22): I still like MMAT, and I still have a few shares, but I like other plays more right now.
Outside of GameStop, our top plays have come from bio and pharma companies with huge insider buying. This is another one. Perceptive Advisors is one of the top biotech hedge funds, and they own about 18 percent of this company. What’s even better is that their buy price is above the current price of $1.96! Neptune just raised $55 million shares with an offering at $2, so they have a ton of cash. They also just bought 51 percent of Sprout Foods. There’s a huge gap to fill, and I think we should see this go up to at least $5. (New 2/21/2021)
Update (2/28/21): Again, one of the top biotech hedge funds has a position here of more than $2. This stock price is $1.58. That’s absurd. There’s amazing value available here. I added more to my position this past week.
Update (3/5/21): How smart do you feel that you get to buy a stock at $1.40 ($1.37 in after hours) that one of the top biotech institutions purchased above $2? What a steal!
Update (3/14/21): Neptune rose back to $1.70 by the end of the week. This is still cheaper than the $2 price institutions paid. It won’t last much longer, so enjoy the dip while it lasts.
Update (3/21/21): Again, the price on this stock makes no sense, based on what price the hedge funds were buying. I’m dropping this to two stars because there’s a law firm that is trying to get people to sue Neptune for price losses. This occurs all the time and isn’t a big deal, but it could cause the price to dip.
Update (3/28/21): Look at how much institutions have invested into Neptune at higher average prices:
There’s no way all of these institutions are going to lose this much money.
Update (4/4/21): None of my NEPT shares were borrowed (see CLOV for details.) There’s nothing new to say about Neptune this week, save for it trademarking “Eco Tables.” I’m not sure what this is yet, but there could be positive news on the horizon.
Update (4/11/21): Neptune closed at $1.43 for the week, which is a nice reversal. Hopefully we can move back up closer to $2 soon.
Update (4/18/21): Marijuana stocks continue to be hammered. Fortunately, the house marijuana banking bill received 17 new consponsors Friday, and it’s going to be voted on Monday. The bill being passed will be huge for these marijuana plays.
Update (4/25/21): Another bio that’s been hurt recently. There were some huge buys in the $1.80 range, so this is extremely undervalued right now.
Update (5/8/21): This continues to be undervalued as it drips downward in price. Bios have been hurt by the FDA trying to approve the Covid vaccines, but they’ll bounce back eventually.
Update (5/16/21): Friday was a good day for this stock. Let’s hope it keeps moving with all of the other bios. This has nothing to do with the price movement, but I finally got someone to short my shares, though only 10 percent of my shares of Neptune were shorted.
Update (5/23/21): Perceptive Advisors sold. Not all of their shares, but they decreased their stake from 22.2 million shares to 12.8 million shares. This is disappointing to see. I can’t recommend this as a buy anymore. I still have some shares, but will consider selling them.
Everyone has heard of the FAANG stocks (Facebook, Amazon, Apple, Netflix, Google). Well, the WallStreetBets version of that is BANG. Nokia is the “N” in that acronym, along with Blackberry, AMC and GameStop. Unlike Blackberry, AMC and GameStop, Nokia wasn’t heavily shorted once the spending spree began, but Nokia has been heavily shorted in the past several days. The next short report update will likely confirm this.
Can you imagine how dumb the short sellers felt when they saw that Blackrock owns 333 million shares of Nokia per their Jan. 29 13G filing? Yes, Blackrock believes in this company so much that even though they already owned 300 million shares, they decided to increase their ownership by almost 7 percent!
Nokia dipped below $5 on Friday because heavy shorting wanted to make sure the tons of $5 calls wouldn’t finish in the money. This, of course, was before they knew about Blackrock. The fools will pay. They shouldn’t have shorted Nokia, which is a good company that is heavily involved in 5G technology. (New 1/31/2021)
Update (2/7/21): Nokia beat earnings, yet the stock price went down 50 cents. This looked like manipulation to me because there were so many $4.50 Feb. 5 calls. Nokia has $8 billion cash on hand, and it will dominate the 5G market. Buy the dip and hope NOK finishes above $5 next week because so many calls will be in the money.
Here’s an article about Nokia being free cash-flow positive, which argues that NOK should be worth between $6 and $7.50 at the very moment.
And that doesn’t even take into account that Nokia is discussing buying back 500 million shares and issuing a dividend.
Update (2/15/21): There’s lots of news pending with this company, as referenced in the Feb. 7 update. Can’t wait to see what happens. In the short term, a key price to watch will be $4.50. There are currently 28,741 Feb. 19 calls at that price. By comparison, there were only 11,759 Feb. 12 calls at $4 and $4.50 COMBINED!
Update (2/21/21): We’re still waiting on news. I’m still bullish on this stock.
Update (2/28/21): Nokia plans to give a “long-term” outlook at Capital Markets Day on March 18, so we may get some of the aforementioned updates then.
Update (3/5/21): Nokia is a great buy under $4 (under $3.80 after hours.) They have deals with Google and Japan, and big news will be coming soon.
Update (3/14/21): Nokia is back above $4. The company is planning to announce a renewed strategy on March 18 during its Capital Markets Day event. Hopefully that causes a price spike on this stock.
Update (3/21/21): Nokia signed a 5G eqiupment deal with AT&T. You’d think this would have inflated the stock price, but it has remained stagnant. My guess is that the stock price is being held down so the hedge funds can jump in, but we’ll see.
Update (3/28/21): Here’s a bullish article about Nokia, which includes a $6 price target.
Update (4/4/21): I sold some of my Nokia stock this week. I still like this stock, but I’m worried that some of the hedge funds under fire from GME and AMC are very invested into this company. If they get margin called, they’ll have to sell their Nokia shares. I’ll be interested in buying back the shares I sold once everything calms down.
There’s a ton of insider buying in this stock by many of the big bio players. I wish I had more time to do DD on this, but this price could double or even triple in the near term. (New 12/22/2020)
Update (1/19/21): This stock has risen since the end of December and has met compliance by being over $1 for 10 days. I suspect we’ll get some news on this in the near future that will cause this stock to skyrocket.
Update (1/26/21): This rose quite well on Friday. This has some major potential.
Update (1/31/21): No new news. Still holding full.
Update (2/7/21): This is another Alex Denner bio play. He knows something most of us don’t, so Regulus should rise in the long term.
Update (2/15/21): As I pointed out under ITRM, Alex Denner sold his position, so he could have increased his stake in this company as a result. We wouldn’t know that quite yet, but don’t be surprised if we get some very bullish filings in the near future.
Update (2/21/21): Regulus had some nice movement this past week, and we should hit $2 rather soon.
Update (2/28/21): This stock dropped along with the rest of the market. There are some incredible bargains available at the moment, including this.
Update (3/5/21): This is now $1.15 ($1.10 after hours). Yet, Biotechnology Fund just bought 10 percent of this company a few weeks ago when this price was higher. Not to sound like a broken record, but we’re getting a great bargain at this price.
Update (3/14/21): Friday was great! Regulus hit $2.15 at one point, ultimately finishing at $1.96 on the week. I don’t think the major inside buyers were going to sell at just $2.15, so I expect this to continue to rise.
Update (3/21/21): There were some large buy orders on Regulus at the end of the week. Though we closed a bit lower this week than we did the prior week, I’m still very bullish on this company.
Update (3/28/21): Short interest has risen a lot recently. Regulus used to be 5-percent shorted. Now, short interest is up to 13 percent. This is why the stock price fell from $2.10 to $1.50. Short sellers are a cancer, and the world would be better without them.
Update (4/4/21): None of my RGLS shares were borrowed (see CLOV for details.) This is surprising to me because RGLS has been shorted more recently. We know a press release is coming soon, so a squeeze could happen.
Update (4/11/21): Regulus was $1.46 early on Friday, but the market sell-off dropped it to $1.38. This was all on low volume, so I’m not concerned. Big news is coming at some point in the next few months.
Update (4/18/21): My Regulus shares were finally borrowed. All of them were borrowed on a day in which the share price dropped 7.9 percent. As a reminder, all short sellers are future buyers, so I’m looking forward to when they have to do so in the wake of some impending news.
Update (4/25/21): Fintel identified RGLS as the stock that has the 41st-most potential of a short squeeze. Here’s the link to this information, but you’ll have to pay for it. Fintel has IMAC as the most likely to squeeze, so I bought some shares of that. IMAC has a 95-percent borrowing fee!
Update (5/8/21): Regulus has earnings this week, so perhaps this stock will rebound. It’s been hit hard like other bios, yet Victory Capital Management bought 2.2 million shares at $1.45.
Update (5/16/21): H.C. Wainwright raised their price target from $1.50 to $2 on this undervalued, heavily shorted stock. Vanguard agrees, buying 2.9 million shares at an average price of $1.46.
Update (5/23/21): It’s amazing that this stock is stuck at $1 despite Vanguard buying 2.9 million shares at $1.46. This price could fly on positive test results.
Update (5/30/21): Regulus continues to remain in the $1 area. It’s one of the few bio stocks that didn’t rise this past week, so perhaps that’ll happen soon.
Update (6/6/21): Regulus moved up 12 cents this week, which was nice to see. A Vanguard index fund bought 56,180 shares of this company at $1.56, per a June 1 13F filing.
Update (6/13/21): Regulus rose as high as $1.40 this past week, but then fell back to $1.04. My best guess about what happened centers around Atlas’ announcement that it was buying this stock. As soon as that was announced, someone else may have shorted this stock heavily.
Update (6/20/21): I don’t know what to make of Regulus’ price drop. It could be shorting, but it may also be inside selling. Regulus is 9-percent shorted, but the utilization rate is only 16.7 percent, so this could be shorted much more. I’m holding on for now.
Update (6/27/21): Regulus had a presentation on Friday. The data was solid, and the company believes it’s ready for FDA submission. Short sellers attacked this stock Friday, but I am not concerned.
Update (7/4/21): I don’t know what the USSCX Science & Technology Fund is, but they bought 10.97 million shares of Regulus at $1.19 per a June 24 13F. The shorts continued to attack this stock, but I’m still holding full.
Update (7/11/21): I’m not sure how significant this is, but Zacks increased Regulus to a buy rating. That’s why the stock finally broke its downtrend on Friday. It’s insanely cheap right now.
Update (7/18/21): We had a nice 13F filing, with Focused Wealth Management buying 200,000 shares at an average price of $1.19. The RSI here is 34.6, so it’s obviously oversold.
Update (8/1/21): I don’t have much to say about this at the moment. This company needs to release some news before the price moves up again.
Update (8/8/21): GSA Capital Partners bought 206,000 shares of Regulus. This seems like a great time to buy.
Update (8/15/21): Another big buy: Geode Capital Management bought 208,000 shares of Regulus. Once again, this stock is incredibly cheap.
Update (8/22/21): There were some big buys and some big sells this week, though the two largest orders were Point 72 selling 3.2 million shares of Regulus and Two Sigma Investments selling a million shares of Regulus. And now we know why this stock plummeted at the end of June. Regulus, however, has a drug in Phase 1 and has ample money available, so they seem like a good purchase at this price.
Update (8/29/21): Morgan Stanley tripled their Regulus position, which was nice to see. Regulus is coming off a nice week, so perhaps this is the beginning of a reversal to $1.
Update (9/5/21): Cantor inititated a $2 price target for Regulus. Forget a reversal to $1, perhaps we’ll fly to $2 soon!
Update (9/12/21): Regulus is presenting at the H.C. Wainwright conference on Monday, so maybe we’ll get some exciting news then.
Update (9/19/21): I saw this DD on Stocktwits that I thought I’d share with you:
Update (9/26/21): Zacks Investment Research upgraded RGLS to buy on Tuesday. This stock is very cheap right now.
Update (10/3/21): Regulus saw a spike from 67 to 70 cents on Friday. There was no news, so perhaps it was a substantial purchase.
Update (10/10/21): None of my shares were borrowed for a while, but that changed this past week. That’s a sign that short interest and utilization is increasing. Unfortunately, Zacks Investment Research, which upgraded this to a buy two weeks ago, changed its mind and downgraded it to hold.
Update (10/17/21): I’m sorry for this one, but I sold when the company announced that it would be ceasing its drug and beginning anew. A reverse split is on the horizon, and I don’t want any part of those. I got into this stock because of Alex Denner’s investment, but I have to believe that the big drop early this past week was him selling his shares.
No one hates short sellers more than I do. I hope they all rot in prison, and if they happen to suffer their demise behind bars, I would ask for their skulls so I could drink out of them.
Someone who hates shorts almost as much as I do is the CEO of Rocket Companies. Rocket absolutely destroyed earnings, yet short sellers have infested the stock. As a result, Rocket is 38-percent shorted.
So, what is the Rocket CEO going to do about this? Not only has he ordered a $1 billion buyback of shares; he has issued a dividend that the short sellers will have to pay for! If you hold Rocket through March 8, you will get $1.10 per share. Once you do, the shorts will have to pay $1.10 per share!
Is this devious? Absolutely, but I love it. I’m in favor of anything that makes shorts miserable.
At any rate, Rocket is severely underpriced. Once the short squeeze happens, we could see this move to $100. (New 3/5/2020)
Update (3/14/21): This is still very underpriced and very shorted. With the DTCC rule going into effect on March 19 – as discussed in the AMC entry – there will be more pressure on the shorts to cover, which could cause this stock to rocket (pun intended.)
Update (3/21/21): The alleged presidential administration is offering a $15,000 tax credit to first-time home buyers. There will also be DACA eligibility. All of this should result in more home sales, which will only pump up Rocket’s financial numbers. Rocket is a $100 company that is being heavily shorted right now.
Update (3/24/21): Rocket announced an extended partnership with Mint that will allow people to purchase a home entirely digitally. Rocket is also in the process of paying out its dividend and will re-purchase $1 billion worth of shares in the near future. This is all just a reminder that the people running this company hate short sellers with a passion. They have my full support.
Update (4/4/21): None of my Rocket shares were borrowed (see CLOV for details.) This was surprising to me because Rocket is so manipulated. Just look at the price action this past week. Rocket would always open higher, due to buying enthusiasm, and then it would come crashing down because of shorting. Remember, Rocket’s CEO might be the only person on the planet who hates short sellers more than me, so he will make them pay eventually.
Update (4/11/21): Rocket is in severe oversold territory. Yet, it’s still higher than it was on most occasions prior to March. The next squeeze should send this to $50 or higher.
Update (4/18/21): We’re about a month away from earnings, which are always great for Rocket (especially in the wake of this housing boom.) Amazing earnings could force all the shorts into covering.
Update (4/25/21): Earnings will be on May 5, and I expect them to be good. The shorts have held this company down for quite some time, so they may not be able to stop it when some great news is revealed.
Update (5/8/21): Rocket’s earnings were good. Great, in fact. Look at this:
Despite this, Rocket tanked because there was an EPS loss of a penny. Unreal. The short-selling scum are trying to drive the price into the ground, creating this:
Almost everyone is losing money on Rocket right now, which is crazy because it’s a terrific company with outstanding financials.
Update (5/16/21): Rocket’s great earnings weren’t kind to the stock, pushing it down to the high teens. Think about that for a second. I imagine things will be corrected eventually; this just takes some patience.
Update (5/23/21): For as shorted as this company is, you’d think they’d have a higher borrowing fee, especially in the wake of the stock price drop into the teens. This is still undervalued and oversold.
Update (5/30/21): I saw a headline saying that Dan Gilbert sold 47,000 or so shares, but that is not entirely accurate. He converted those shares into a different class. I’m not sure why he did this, but he’s trying to do everything to clear out the scumbag short sellers.
Update (6/6/21): Rocket moved from the $17.50 range to around $20 this past week, which was nice. The borrowing fee also increased to 1.8 percent. That may not sound significant, but the fee was sub-one for quite a while. Hopefully this is the beginning of a trend. The borrowing fee was 44 percent on Feb. 22, and Rocket squeezed to $40 a couple of weeks later.
Update (6/13/21): Rocket traded between $20 and $22 this past week. I was hoping it would move with the other heavily shorted stocks, but it remained mostly stagnant.
Update (6/20/21): Rocket is 10-percent shorted, but the utilzation rate is 52 percent, and there are only 13 million shares on loan. I love Rocket as a company, but this isn’t something I want to hold during a severe market crash. I may sell and look to buy back at a much lower price.
Update (6/27/21): Rocket’s short interest increased this past week. It’s now 12-percent shorted with 15.4 million shares on loan. The company is also buying back some of its shares, so that should increase the likelihood of a squeeze.
Update (7/4/21): I still haven’t sold any shares. I want to wait until the next earnings report, which should be positive because of the housing market mania.
Update (7/11/21): State Street increased its position in Rocket from 3.7 million shares to 3.9 million shares. Its average share price is $21.66, so you can see how undervalued Rocket is at the moment.
Update (7/18/21): A lawsuit sunk this stock this week, making it extremely oversold (RSI 35.04). Rocket’s market cap is now $2.36 billion, which seems way off to me.
Update (8/1/21): Like some of the other stocks mentioned earlier, Rocket is venturing into positive MACD territory, so hopefully this is a sign that the small- and mid-cap market is about to rebound.
Update (8/8/21): Rocket’s earnings are soon, so perhaps that’ll raise this price. The big catalyst will be the share buyback next year. Either way, it’s a joke that Rocket is selling below its IPO price of $18.
Update (8/15/21): Rocket absolutely destroyed earnings, which is why it rose so much on Friday. It’s still very undervalued. Vanguard bought 1.6 million shares of Rocket at an average price of $21, so they obviously agree!
Update (8/22/21): Invesco bought 1.1 million shares of Rocket at an average price of $21.22. Rocket destroyed earnings, and yet we’re right where we were prior to earnings. This is the type of market we’re in, but it makes for some great opportunities. I bought some shares at the end of the week.
Update (8/29/21): I posted some nice Morgan Stanley buys for other tickers in this week’s update. This is a negative one: Morgan Stanley sold 2.8 million shares of Rocket. This wasn’t great to see, but keep in mind that Morgan Stanley sold at $21.22, and the effective date, June 30, was before Rocket’s great earnings report.
Update (9/5/21): This is anecdotal, but I know some people who sell mortgages for a living, and they’ve been making a killing lately. I expect Rocket’s next earnings report to be great once again. I don’t understand what we’re still doing in the $17 range. Oh, wait, yes I do! It’s because the market is rigged in favor of the short sellers!
Update (9/12/21): Gratus Capital LLC acquired 35,200 shares of Rocket, which closed at a very low price this week. This is a terrific entry or chance to buy low for this great company.
Update (9/19/21): Here’s another big sell, with Virtu Financial selling 278,000 shares of Rocket. This was with the effective date of June 30 though, so perhaps they’d feel differently about the stock at this cheap price.
Update (9/26/21): Fidelity bought 279,000 shares of Rocket as of a July 31 filing.
Update (10/3/21): Invesco, which sold 900,000 shares of Rocket as of an April 30 filing, bought back 210,000 shares as of their July 31 filing.
Update (10/10/21): Look at this position cost distribution:
How is this even legal? Everyone is underwater, and yet the people who bought above $30 aren’t even selling!
Update (10/17/21): Rocket announced that there will be an announcement this upcoming Tuesday, which is one of the reasons why the stock rose this week. The other:
Update (10/24/21): Rocket enjoyed a nice week for once, at least until Friday’s massacre. As usual, the market makers didn’t want a stock to close out the week at a certain price:
Meanwhile, Rocket has earnings on Nov. 4, so hopefully we see some good numbers.
Update (10/31/21): Rocket rose Friday because of announced partnership with Salesforce. Rocket’s earnings report will be on Thursday, so hopefully we keep getting good news.
Update (11/7/21): Rocket had a strong earnings report, and they also announced that they bought back 5.7 million shares. Despite this, it dropped nearly four percent the following day, which makes no sense. Perhaps the news will be absorbed soon so we can once again test resistance in the $18.10-$18.50 range. If so, we’ll approach the high $20/low $21 area before getting stuck in the $23s.
Update (11/14/21): This is probably the No. 1 candidate for tax selling, which I believe played a role once this stock hit $18 just prior to earnings. Speaking of earnings, they were good; EPS beat by $0.09, and revenue beat by $206 million.
Update (11/21/21): Rocket’s price continues to be beaten down despite its positive earnings recently. This is a great price to buy.
Update (11/28/21): Pacific Select Fund bought 122,990 shares of Rocket, holding an average price of $21.59. Rocket remains near all-time lows.
Update (12/5/21): Rocket has held up pretty well during this blood bath of a week, which makes me wonder how high it would have gone if the market didn’t crash.
Update (12/12/21): Rocket rose to $16 and remained there late in the week. Again, if the market were doing better, this would probably be approaching $20.
Update (12/19/21): I took the loss on Rocket. Sorry about this one, guys. Short interest is down to 8 percent, while cost to borrow and utilization are both very low.
Let’s buy some weed stocks before the drug is legal everywhere! This is why lots of people have been bullish on Sundial, which was as high as $1.46 last week. It was shorted down from there, meaning the short interest that FinViz displays (15.2%) could be lower than it is at the moment.
There will be a bit of a gamma squeeze here as well. There were 19,519 50-cent calls that finished in the money on Jan. 29. The true test will be if this can go above $1 on Feb. 5:
If SNDL closes above $1 next Friday – or better yet, $1.50, we will have blast off. Either way, this is a WallStreetBets stock that has been restricted. There will be lots of buying once the Robinhooders move their funds or are allowed to buy again. SNDL had an offering recently, so it can’t have another one until March 29, so don’t worry about anything like that until then. (New 1/31/2021)
Update (2/7/21): SNDL’s offering has closed, and it can’t have another one until the end of March. With the government looking to legalize marijuana everywhere, SNDL should be above $2 sometime soon.
Update (2/15/21): I sold my shares around $2.20. I don’t mind owning this stock through the middle of March, but there are better buying opportunities now.
Update (12/19/21): I’m back in Sundial. I bought shares at 60 cents and then at 55 cents. This is a stock that can always squeeze upon some news, and with marijuana legislation coming soon, I imagine there will be a nice profit opportunity here.
Update (12/26/21): Sundial had a nice run from 53 cents to 67 cents over the past couple of weeks. SunDial was featured in a recent article as a stock to watch as legalization efforts intensify.
Update (1/9/21): Sundial has dropped back down to sub-60 cents, but I expect it to run along with the other highly shorted stocks.
Update (1/16/22): No real update this week. I have a buy order at 51 cents.
Update (1/30/22): Sundial is now the lowest it has been in about a year-and-a-half. There isn’t much to observe from the on-balance volume.
Update (2/6/22): Some volume has come in on Sundial the past couple of days, with the stock moving from 40 cents to 53 cents.
Update (2/13/22): Sundial had a great rally Friday to get to 66 cents. A sign of things to come, or will there be more shorting?
Update (2/20/22): SunDial dropped since its rally last Friday, but only because of short sellers because the on-balance volume didn’t fall very much. Seriously, go look at the volume and tell me why this stock price should’ve fell nearly 10 cents.
Update (2/27/22): SunDial dropped to 46 cents early Thursday, but rebounded a bit. I have nothing else to say about this company at the moment.
Update (3/6/22): Sundial remained around 50 cents for most of the week. We’re in no-man’s land right now as far as the RSI is concerned, so I would wait before buying.
Update (3/13/22): Nothing new here. Still in no-man’s land.
Update (3/27/22): I sold out of SunDial on Friday. Hopefully I didn’t do so too early!
I’ve been monitoring this for quite some time. UWMC is the second-largest mortgage originator in the country. It also offers a 10-cent dividend. And to top it off, UWMC will have a commercial during Super Bowl LV!
UWMC was shorted from $14 down to $10.50 heading into eanings, which were very positive. Despite this, the shorts continued to attack UWMC, which fell below $10. The drop was unwarranted, especially when considering that UWMC’s prior evaluation was based on an income forecast of less than $2 million. Yet, UWMC had $1.37 billion net income in Q4 alone! Based on an evaluation of $5 billion or more, the price of this stock should be $25 at the very least. (New 2/7/2021)
Update (2/15/21): This stock continues to be greatly underpriced. Just be patient with this one. As a bonus, you’ll be able to collect a 4.4-percent dividend while you wait.
Update (2/21/21): This stock continues to be shorted into oblivion. Remember though that every short seller is a future buyer, so some great news will send this flying on a squeeze.
Update (2/28/21): UWMC’s RSI is now 23. That’s insane. This is so undervalued and shorted. It’s only a matter of time before the stock price rises.
Update (3/5/21): This stock rose as a sympathy play to Rocket on Wednesday, but it collapsed because of the market crash. What a shame. I thought this would hit $20 if Rocket kept going. Rocket will fly at some point, so look for the undervalued UWMC to go with it.
Update (3/14/21): Again, this will rise on either Rocket’s movement, or some great financials. UWMC’s previous earnings were positive, so I don’t see why the next earnings report would be worse.
Update (3/21/21): UWMC wasn’t included in the Russell index, which could cause this stock to drop. However, it sounds like there was a technical issue that could be resolved quickly. This reminds me of when Tesla was expected to be included in the S&P 500, but wasn’t. The stock tanked, but then soared when it was included in the S&P 500 months later.
Update (3/28/21): There’s no news of note, but this is a cheap entry. The initial quarterly dividend will pay out for the first time in less than a month.
Update (4/4/21): All of my UWMC shares were borrowed right away, which is hardly a surprise (see CLOV for details.) UWMC will be issuing its dividend at the end of the month, so that’s something the short sellers will have to pay for.
Update (4/11/21): Look at how insane this is:
This represents the average cost of everyone who owns the stock. This means that 99.6 percent of UWMC stockholders are currently losing money (minus the dividend that was just issued.) That’s crazy! This reminds me of what GameStop used to look like last summer.
Update (4/18/21): Another SPAC/former SPAC that is getting hammered. UWMC had great 2020 financial results, so there’s no reason for the stock price to be this low.
Update (4/25/21): Unlike THBR, UWMC already merged, so there are no impending re-filings. Again, there’s no reason why this stock price should be so low. Given the new short-selling rule, we should see a steady increase.
Update (5/8/21): UWMC’s earnings are coming up this week, and I expect the numbers to be great like Rocket’s. Maybe it’ll actually go up, unlike Rocket. It must be noted that Blackrock bought 1.34 million shares of UWMC.
Update (5/16/21): OH, BABY! There’s so much great news regarding this ticker. Not only did UWMC have great earnings; the company declared a 300 million buyback! And if that wasn’t great enough, take a look at this:
Again, the vertical bars are shares available to short, and the red line is the borrowing fee. As you can see at the very bottom, the borrowing fee has shot up to 93.6 percent! This is a sign that this is going to squeeze soon.
Update (5/23/21): The borrowing fee on this stock 59 percent. Shares to short are significantly lower than they were earlier. There’s a share buyback currently in progress. A squeeze should happen soon.
Update (5/30/21): The borrowing fee remains in the same range as last week. Given that, as well as the share buyback, a short squeeze is bound to happen soon. Ihor Dusaniwsky of S3 partners agrees, giving UWMC a 9.25/10 short squeeze score (he’s given 10/10 to AMC and GME.) Take a look:
Update (6/6/21): Three separate June 1 13F filings show that a trio of Vanguard index funds bought a combined 3.1 million shares at $7.93. The borrowing fee has dipped a bit, but it’sstill high at 38.3 percent.
Update (6/13/21): I think we may see a Clover-like squeeze from UWMC in the near future. I’m expecting a jump to $20-25 soon.
Update (6/20/21): UWMC is very heavily shorted. Take a look:
Those numbers should be higher soon because the hedge funds dragged this under $10 to avoid the calls at that price from being in the money.
Update (6/27/21): As predicted, short interest is higher now than it was last week. There are now 24.5 million shares on loan at 29.5 percent.
Update (7/4/21): This stock was beaten down by scumbag shorts this week, but this is a great buying opportunity. I bought more shares on Friday.
Update (7/11/21): State Street Corp bought into UWMC at $7.94, purchasing 26,700 shares at that price. The chart shows some great value, with the RSI at 38 and Slow Stochastics at 16.01.
Update (7/18/21): I don’t know what Hohimer Wealth Management LLC is, but they bought 320,000 shares at an average price of $8.19. UWMC is oversold with a 34.6 RSI.
Update (8/1/21): Here’s another AllianceBernstein purchase, with it buying 10,850 shares of UWMC. We also seem to be heading into positive MACD territory, and the last time that happened, we nearly hit $11 off a $6.18 low.
Update (8/8/21): Swiss National Bank bought 204,000 shares of UWMC as of the June 30 filing. Earnings are on Aug. 16, and all the institutions I’ve been mentioning are expecting good news.
Update (8/15/21): Vanguard Group bought 3.4 million shares of UWMC at an average price of $8.19. UWMC rose at the end of the week as a sympathy play to Rocket. If its earnings are anywhere near as good as Rocket’s, the stock price will rip.
Update (8/22/21): Patrick P. sent me this DD, so I thought I’d share it with you:
I bought more shares this week in the low $7s, which is a ridiculous price for this company.
Update (8/29/21): Marshall Wace bought 116,953 shares of UWMC.
Update (9/5/21): What I said about Rocket, regarding people in mortgages doing extremely well right now, applies here as well. At any rate, if you look at the iBorrowdesk data, you’ll see that the shares available to short have been dwindling recently. Just look at the blue bars:
Perhaps this is a sign that we’re going to squeeze soon.
Update (9/12/21): Utilization is the highest it has been since June, and there continues to be a severe drop in shares available to borrow. IBorrowdesk says that there are just 300 shares remaining to borrow, which seems insane. It’s a great time to buy UWMC because the ex-dividend date has passed, so some peopl have sold shares because they’ll be collecting their dividend in a few weeks.
Update (9/19/21): So much for what I wrote last week. Utilization dropped into the 70s once again. Still, this stock pays a 5-percent dividend, so you can enjoy that while we wait for the price to inevitably rise.
Update (9/26/21): There were lots of green filings at Fintel (new purchases), but nothing crazy. UWMC is super cheap right now and seems like a great buy-low opportunity.
Update (10/3/21): There were some minor, five-figure share filings on Fintel, but nothing very noteworthy. UWMC under $7 is a steal.
Update (10/10/21): I can’t believe UWMC is $6.50. Short interest has steadily climbed over the past couple of months, but it hasn’t risen exponentially like it did back in May. Well, at least we were able to collect our dividend this past week…
Update (10/17/21): Friday was a strong day for this company, closing above $7 for the first time in nearly a month. I didn’t see any news, so there must have been some big buys.
Update (10/24/21): UWMC remained above $7 for most of the week. This had to please Clear Streets Markets because they bought 35,700 shares of UWMC, effective Sept. 30. Earnings are in one month.
Update (10/31/21): I was hoping UWMC would be a sympathy play to Rocket, but it didn’t rise very much. It’s still very cheap, especially considering that there will be a share buy-back at some point in the future.
Update (11/7/21): Rocket had good earnings, so once that rises, UWMC will, too.
Update (11/14/21): This mortgage company has tax-selling implications as well, though not as bad as Rocket’s. I sold 25 percent of my shares and may sell another 25 percent, but I will buy them back eventually.
Update (11/21/21): This stock had a wild week. They announced an offering, which caused the price to plummet to $5.50. However, things completely flipped. Not only did UWMC decide to cancel the offering; they announced that they would accelerate their previously announced share repurchasing program!
Update (11/28/21): The share buyback program saved UWMC from collapsing during a bloody-red week. It finished above $7, and it wouldn’t surprise me if we see $10 in the near future.
Update (12/5/21): Like Rocket, UWMC has held up through the blood bath. Again, I wonder if this would have gone up substantially if there wasn’t a crash.
Update (12/12/21): UWMC has been pinned to around $7 recently, and I don’t see it going much lower because of the share repurchasing program.
Update (12/19/21): Unlike Rocket, UWMC is still heavily shorted (15%) and the cost to borrow and utilization are much higher. This will squeeze when the share purchases begin. That said, I also have a 30-day no-purchasing window here as well.
Update (12/26/21): Investopedia listed UWMC as the top value stock heading into January 2022. UWMC is also doing a buyback of its shares, so 2022 could be a great year for this stock.
Update (1/9/21): UWMC had a great Friday, moving back over $6. I didn’t see any news, so I assume it was a big purchase. UWMC is still too cheap.
Update (1/16/22): UWMC’s annual revenue is nearly $5 billion, yet the market cap is $9.1 billion. This is obviously undervalued.
Update (1/30/22): UWMC’s market cap is now down to $8.1 billion. If the market continues this way, UWMC’s market cap will soon be below its annual revenue. What a joke.
Update (2/6/22): UWMC’s market cap is now under $7 billion, which is insane, given that annual revenue is about $5 billion. Earnings are on Tuesday, so perhaps that’ll shine a light on how undervalued this is.
Update (2/13/22): There was a bunch of insider selling 11 days ago, which is not something you ever want to see. On the bright side, this now pays a 9-percent dividend because the stock price is so low.
Update (2/20/22): Rocket’s earnings are next week, which is important for this stock because UWMC moves with Rocket.
Update (2/27/22): Rocket had some ugly earnings, missing on revenue and EPS, and their guidance wasn’t very good either. That’s not good for UWMC; their earnings are on Tuesday. I’m considering getting out of this one.
Update (3/6/22): Earnings were poor, as expected. I would not recommend purchasing this stock right now.
Update (12/8/20): Looking great! Buy any dips you see!
Update (12/22/20): I sold my shares today as a result of one of the insider selling his shares. I’ll be interested in re-buying at a lower price.
VISL is a very heavily shorted stock (20% at the very least) with a low float of 20.8 million. The space ETF is coming, which means a lot for this company. Furthermore, two companies, Empery Asset Management and Iroquois Capital, just purchased a combined 15 percent of this company. What does that mean besides the float decreasing even further? It could also mean a buyout or a merger. Vislink just hired a new chair who specializes in mergers. I think we can see this stock price rise into the high teens. (New 2/15/2021)
Update (2/21/21): This stock bounced between $4 and $5 this past week. It’s still heavily shorted, and there’s a low float. Big news is coming, which will cause this to skyrocket. As I wrote last week, we’ll see this in the high teens at some point.
Update (2/28/21): Yet another stock that’s super cheap due to the recent crash. Once this goes, it’ll really fly because of the 25-percent short interest.
Update (3/5/21): VISL fell to $2.92 on the Thursday close and then $2.77 after hours. This is insanely cheap, with it expecting to go to double digits when the space ETF arrives.
Update (3/14/21): VISL rose to $3.51 to close the week, and yet it’s still very cheap. This could easily triple in price at some point this year.
Update (3/21/21): There was some major buying in the Friday after hours, with 519,000 shares being purchased. Apparently, some big whale understands how undervalued this stock is.
Update (3/28/21): Short interest is 30 percent now! This is a very low float stock, so this could skyrocket at a moment’s notice.
Update (4/4/21): It should come as no surprise that all of my VISL shares were borrowed (see CLOV for details.) Short interest continues to grow, which is music to my ears.
Update (4/11/21): VISL received a multi-million dollar contract late this past week, and yet the stock price dropped. “Buy the rumor, sell the news” doesn’t apply because there was no rumor. VISL continues to be undervalued.
Update (4/18/21): VISL continues to fall on low volume, as this stock is heavily manipulated. Heavy manipulation often translates to huge pops in the future, so it’s just a matter of waiting.
Update (4/25/21): The CEO of VISL bought 17,000 shares this past week. That would explain the price rising. He’s obviously bullish about the company, so there could be some great news on the horizon.
Update (5/8/21): Here’s another Blackrock purchase, with it purchasing 758,000 shares at an average price of $2.13.
Update (5/16/21): Vanguard followed Blackrock into this, buying 1.7 million shares.
Update (5/23/21): I’m not going to lie, it’s frustrating to see the borrowing fee drop and the shares available to short rise. However, there’s been some more institutional buying, with Goldman Sachs scooping up 11,100 shares. That’s not a huge number – I have nearly as many shares – but it’s at least something.
Update (5/30/21): I don’t have anything new to mention about VISL this week. There weren’t any new institutional buys reported, and the borrowing fee is still around 10 percent.
Update (6/6/21): Two Vanguard index funds bought nearly 1.2 million shares of VISL for $2.93, per a June 1 13F filing. Yet, the price is shy of that, which obviously makes this underpriced.
Update (6/13/21): VISL was in the $3s for a time this past week. They’re some explosive news away from shooting to $5 at some point.
Update (6/20/21): VISL is heavily shorted as well. Here’s the Ortex data:
VISL was also added to the Russell micro cap, which means there should be plenty of buying soon.
Update (6/27/21): There was some covering here this past week, with the free float on loan dropping to 26 percent. VISL had a strong week, so hopefully this trend continues.
Update (7/4/21): I was glad to see this have some great momentum on Friday. It really looks like it could have a breakout sometime soon.
Update (7/11/21): Some of the shorts covered on the recent run to $3.44, but the negative week dropped the price down to $2.65. VISL has great potential and could make a big run soon.
Update (7/18/21): VISL is down to $2.35, but I still like this stock. The RSI is at a nice buying number (37.9).
Update (8/1/21): Something called Ahrens Investment Partners bought 59,000 shares of VISL on June 30. Also, VISL has the highest utilization rate since May 3 (91%). It wasn’t too long ago that the price was in the $3.50-$4 range, so I think we could get there soon.
Update (8/8/21): Earnings will be released Aug. 17, so hopefully we get some good news then!
Update (8/15/21): Earnings are in two days, so hopefully we get some good news. Deutsche Bank bought 86,287 share of VISL.
Update (8/22/21): State Street bought 174,800 shares of VISL, which had positive earnings. Revenues increased 85 percent and there was a significant reduction in net loss. This stock is very undervalued right now. I bought more shares.
Update (8/29/21): Morgan Stanley bought 269,000 shares of VISL at an average price of $2.91. Meanwhile, Vislink tweeted about Starlink early in the week:
This is not the first time Vislink has mentioned Starlink. There’s speculation that there’s an NDA preventing Vislink from mentioning a partnership. If that’s ever revealed, VISL is going to $20.
Update (9/5/21): I have no update at the moment. There weren’t any significant filings this week, and the price looked like it was going to rise until Friday.
Update (9/12/21): Like Regulus, VISL will present at the H.C. Wainwright conference on Monday. Hopefully we’ll get some positive news then.
Update (9/19/21): Nothing new here, as the algos dropped this on small volume. It’s crazy how much volume there was back in February when this stock was trading in the $4-5 range.
Update (9/26/21): VISL had a great close to the week. There was no news that I saw, so it’s likely that institutions were making big purchases.
Update (10/3/21): VISL plummeted with the rest of the market to begin the week, but finished well. Earnings are in a month and a half.
Update (10/10/21): This stock continues to plummet to absurd recent lows, but all it takes is some news about Starlink to send it flying. Earnings are in one month.
Update (10/17/21): No news, but earnings are coming up soon. I’m hoping this gets a boost to close out the year for reasons Will Meade posted in the tweet I shared at the top.
Update (10/24/21): This stock continues to crash, but earnings are around the corner. With all the runners we saw Friday, that should give you an idea of how high this would soar if Starlink news were ever announced.
Update (10/31/21): VISL popped in the middle of this past week because a stock pumper talked about it on Twitter. It predictably came back down. Earnings are soon, however, and we’ll have Starlink news at some point.
Update (11/7/21): We had a huge volume day a couple of weeks ago, but nothing came of it after the stock dropped back down to around where it was in the first place. Perhaps we’ll move after earnings, which is on the 15th.
Update (11/14/21): There are tax-selling implications here for sure, and perhaps that’s what happened when this stock rose to $2.15 and then dropped back down to where it was earlier.
Update (11/21/21): The Kyle Rittenhouse trial could help VISL, which makes camera equipment. VISL is incredibly cheap anyway in the wake of its terrific earnings report.
Update (11/28/21): It’s amazing that this stock has fallen so much in the wake of its brilliant earnings report. Whoever shorting this is in complete control of this stock – for now, that is.
Update (12/5/21): VISL’s RSI is 32. There could be more downside, but you’ll make money buying at this price.
Update (12/12/21): VISL had a rough ending to the week despite all the positive news associated with it. Resistance is at $1.23, so I would buy more at that price.
Update (12/19/21): It was no surprise that VISL ran Friday, as it’s another heavily shorted, oversold stock.
Update (12/26/21): Hopefully the move from $1.18 to $1.29 was the beginning of a trend upward. A year ago at this time, VISL began rising from $1.10 and hit $5.30 by March.
Update (1/9/21): VISL was back down to $1.11 on Friday. As you can see, I have an open buy order at $1.09. The market cap of $52 million is a joke; the company does $29 million in revenue.
Update (1/16/22): VISL’s market cap is $48.2 million, while annual revenue is more than half of that ($29.6 million). I bought more shares.
Update (1/30/22): Another manipulated stock. Seriously, where is the volume to warrant this price drop?
Update (2/6/22): VISL popped up above during the week before closing in the 90-cent range. It’s nice to see some sort of reversal with this stock.
Update (2/13/22): VISL reached $1.06 a one point this past week, but closed at 99 cents. Still, this looks to be the beginning of a reversal. Let’s hope so, at least!
Update (2/20/22): I’d say this is good news:
It’s not quite Ault-type buying, but a higher insider ownership will encourage the company to increase its stock price.
Update (2/27/22): VISL should do well during war time, given that they are a military communications stock.
Update (3/6/22): VISL dropped along with everything else at the end of the week. On-balance volume remained high, though RSI is not at 30 yet, so I didn’t buy more shares.
Update (3/13/22): VISL popped over $1 for most of last week, but fell Friday along with the rest of the market. This was nothing but low-volume sell-off, as on-balance volume is still high.
Update (3/27/22): I sold out of VISL when the RSI was near 70. I’ll repurchase my shares when the RSI drops to near 30.
This is another insider biotech play, like ITRM and RGLS. Perceptive, one of the top biotech hedge funds, bought $10 million worth of shares of VYNE at $2.37. With that purchase, they own nearly 15 percent of the company. VYNE had an offering to accommodate this purchase, which is why the stock price fell from $2.64 to $1.98 a couple of weeks ago. This drop was not warranted, so this stock price should continue to rise. I think this will hit $5 at some point. (New 2/7/2021)
Update (2/15/21): Remember, a top biotech fund bought 15 percent of this company at $2.37. This is currently underpriced at $2.65. Earlier this month, Blackrock purchased seven percent of this company. Again, it’ll be shocking if we don’t see $5.
Update (2/21/21): This stock did a reverse split for some reason. Reverse splits are usually bearish because companies whose shares are under $1 need to do them to regain compliance, but VYNE didn’t need to do that. This reverse split shrank the float considerably, so any positive news will send this stock flying.
Update (2/28/21): One of the top biotech hedge funds bought $10 million worth of shares at a higher price than this is listed for now. Think about that for a second.
Update (3/5/21): Vyne continues to fall ($6.68 close, $6.45 after hours), yet one of the top biotech funds bought $10 million worth of shares at a much higher price. Once things return to normal, this will skyrocket.
Update (3/14/21): Vyne rose to $7.39 to close the week. There’s nothing else to report, outside of this still being cheaper than the price in which some of the top biotech funds purchased shares.
Update (3/21/21): There was some insider buying of VYNE this week with Patrick Lepore purchasing nearly $100,000 worth of shares with an average price of $7.41. This is extremely bullish, obviously.
Update (3/28/21): The inside and institutional buying occurred at higher than the current price. They’re not going to lose money on this.
Update (4/4/21): None of my VYNE shares were shorted (see CLOV for details), perhaps because all of the institutional buying occurred at a higher price. The billionaires won’t lose their money on this.
Update (4/11/21): VYNE was trending on StockTwits late Friday, and I’m not sure why. There was some heavy price action, with short sellers trying to drag the stock under $6 to trigger stop losses. This is a PSA that setting stop losses is a horrible idea because the algos will find them. Having mental stop losses is fine, but do not ever physically set them.
Update (4/18/21): Another bio hurt by the FDA delay. This has fallen on low volume, and the RSI is now 27, the lowest it has been in more than a year.
Update (4/25/21): We’re in a holding pattern right now because of the FDA delay. Again, this is only temporary, so patience will pay off.
Update (5/8/21): I invested into Vyne because Perceptive bought 15 percent of the company. Unfortunately, Perceptive sold a million shares of Vyne. This was not their whole position, but it was not encouraging to see this. Meanwhile, Blackrock sold 8.3 million of their 12 million shares of Vyne. I’m considering just giving up on this and taking a loss, but I may sell just some of my position I’ll let you know what I end up doing in the next update.
Update (5/16/21): I ended up selling half my shares. I still may sell off everything else. Vanguard dumped 5.1 million of its 7.5 million shares.
Update (5/23/21): I’m not sure what 683 Capital Management is, but they dumped their 5.9 million shares of Vyne in a May 17 filing. There was more dumping; I counted 3.6 million shares being sold by numerous institutions across several 13Fs. Keep in mind that the effective date of this was March 31, so that would explain why this stock price fell so much. I imagine none of them were happy with the reverse split Vyne did for no good reason. It just goes to show how important a smart CEO is for a company. Vyne is run by a moron, apparently.
This is another EV stock that could explode. PIC will have a merger soon, and it’s close to 50-percent shorted. And to top it off, the float is only about a million! This is going to explode any day. (New 11/20/2020)
Update (1/19/21): This is formerly PIC. This stock rose to $32, but was shorted heavily down to $20. Citron posted a $60 price target on this stock, which would mean a lot more if I trusted them. However, this stock is 51.7-percent shorted! It should squeeze in the near future.
Update (1/26/21): There’s a new price target on this, with one firm issuing a $30 goal. We saw this rise on Friday, so it should continue to squeeze upward.
Update (1/31/21): Vice President Joe Biden announced that he wants all government vehicles to be EV. This makes me more bullish on XL, which has naturally been shorted into oblivion. According to FinViz.com, 72 percent of the shares are shorted. All short sellers are future buyers, so I’m loving this. Just be patient.
Update (2/7/21): This is still heavily shorted. It will squeeze at some point; you just need to be patient.
Update (2/15/21): The EV sector will be hot at some point in the near future, so we could see this rip. XL has been consolidating tightly, and there are lots of Feb. 19 $22.50 calls (10,064 as of this writing), so we’ll really see this take off if the stock price is above that figure by the end of the week.
Update (2/21/21): No new news to speak of at the moment. I’m still high on XL. There are price targets of $30 and $60 on this company.
Update (2/28/21): This stock has been beaten down like so many. This reminds me of FSR. I expect this to have a big jump soon. It’s heavily shorted, and the RSI is below 30.
Update (3/5/21): Carson Block, a scumbag and traitor to America, runs Muddy Waters, a scam hedge fund. He published a flimsy short report on XL, causing it to plummet. XL’s response wasn’t great, which didn’t help. When I saw this, I knew other shorts would attack this, so I sold my shares. However, I will look to get back in at a much lower price.
Update (3/14/21): As promised, I’m back in XL. The drop from the bogus Muddy Waters report is likely finished.
Update (3/21/21): XL’s earnings are next Tuesday. We could use some good news to make people forget about the Muddy Waters smear.
Update (3/28/21): I bought some shares under $10. This is way too cheap. This stock was once $30 before some smears and short attacks.
Update (4/4/21): You may have noticed that XL plummeted on Thursday. This is because there was a reported 267-percent loss for their quarterly earnings. Except, that wasn’t true. The quarterly results were compared to the annual results accidentally. In reality, XL had a 33-percent EPS beat in the previous quarter! This is great news, yet the stock plunged because of the error. XL is a huge bargain right now, which is why I scooped up so many shares, as seen above.
Update (4/11/21): XL predictably rose this past week, hitting a high of $10.77. However, Friday’s sell-off dropped it to $8.06. It’s unbelievable to me that XL hasn’t reverted to the high teens based on their positive earnings report. You’d think a 33-percent EPS beat would spark some enthusiasm.
Update (4/18/21): Another former SPAC getting crushed. The RSI is 25, which is alarmingly low. And yet, XL beat EPS by 33 percent in their earnings report. What the shorts and market makers have done to this company is criminal, but remember, every short seller is a future buyer.
Update (4/25/21): Again, the SPAC bear market is abating. XL had good earnings, so there’s no reason it shouldn’t rise soon.
Update (5/8/21): XL continues to be undervalued, and Blackrock agrees again. Blackrock bought 745,000 shares to increase their overall stake to 1.745 million. Meanwhile, the borrow rate of XL has risen lately, moving to 10 percent. It was in the 4-5 percent range in April and 1-2 percent range in March. We could have the beginning of a squeeze brewing.
Update (5/16/21): The borrowing fee is steadily rising, reaching 12.9 percent by the end of the week. The best news, however, is that Vanguard bought 7.8 million shares!
Update (5/23/21): We’re venturing into squeeze territory with this company:
The shares to borrow (blue bars) have vanished, while the borrowing fee (red line) is rising. We’re not quite there yet, but I’d love to see the borrowing fee shoot up to 30-plus percent.
Update (5/30/21): There still aren’t many shares remaining to borrow, so XL could squeeze soon. I’d love to see the borrowing fee increase.
Update (6/6/21): XL Fleet’s borrowing fee has risen into double digits, which means that a squeeze is coming soon. It’s getting too expensive for the short sellers to keep their position. Vanguard agrees. Six different index funds of theirs picked up more than five million shares per separate June 1 filings.
Update (6/13/21): XL Fleet’s borrowing fee was as high as 14 percent on Thursday, but dropped a bit on Friday. It looked like XL was moving with the meme stocks, so a huge week for AMC could allow XL to get back into double digits.
Update (6/20/21): XL Fleet is obviously heavily shorted, based on the high number of hit pieces published about them. To verify, here’s the Ortex data:
Update (6/27/21): Short data is about the same as it was last week despite the price increase this past week. We’re still due for a heavy squeeze with this stock.
Update (7/4/21): Nothing has changed in the past week. Yet, the price dropped to below $8 because of a market downtrend at the end of the week. This just creates good buying opportunities, so take advantage of them.
Update (7/11/21): State Street Corp made a nice purchase of XL, buying 61,600 shares at an average price of $8.98. This current price makes absolutely no sense. I’ve been buying the dip.
Update (7/18/21): XL is available at a great bargain, as its RSI is 34.2. This is the lowest it has been since the end of the last bear market for mid- and small-cap stocks in the middle of May. XL was $5.41 back then, and it ran to $9.64.
Update (8/1/21): Alliance Bernstein bought 114,900 shares of XL Fleet on June 30. That’s a huge buy on a stock that has unjustly been in the gutter for far too long.
Update (8/8/21): Swiss National Bank bought 153,000 shares of XL Fleet as of the June 30 filing.
Update (8/15/21): Wow, well, that was an incredibly disappointing earnings report. XL missed on both revenue and earnings, and they failed to provide any sort of forward guidance. This stock is still heavily shorted, but there is more room for the downside, much like LOTZ. I’m going to sell now and perhaps re-purchase these shares in the $3-4 range (waiting more than 30 days of course, so I can declare a loss.) I’m sorry for dragging you into this one.
Zynerba is extremely undervalued, but don’t take my word for it. Here are some price targets:
Yet, ZYNE is trading for just $5 right now. This is a marijuana play with huge upside. I’ve seen some technical analysis that indicates that ZYNE should be trading at $56! (New 2/7/2021)
Update (2/15/21): CNBC published an article about how marijuana stocks were overpriced on Friday morning. When the market opened, the short sellers attacked this stock and others. The SEC will do nothing about this sort of market manipulation, much like they’ll allow Robinhood to prevent who buys what. It’s ridiculous. Anyway, if you’re wondering why this stock plummeted from $8.74 to $5.64, there’s your reason. That said, don’t panic. The greedy short sellers want you to throw away your shares for a loss. Every short seller is a future buyer, and now this low-float stock is heavily shorted. This has the potential to really skyrocket at some point.
Update (2/21/21): Short interest on this stock rose to 14 percent. This was because of the CNBC article I discussed last week. There’s no reason this stock should have crashed the way it did, but we at least found support in the $5 range. We’ll see a nice squeeze in the future.
Update (2/28/21): Another stock that’s way too cheap right now. Remember, this has gotten multiple price targets in the teens.
Update (3/5/21): This is a great bargain at $4.09/$4.00, though the price could continue to drop amid the crash. Remember all of the price targets, and know that Vanguard owns a million shares of this company at a higher price.
Update (3/14/21): Zyne is back to $4.71. I still expect it to hit the mid-teens to match the aforementioned price targets.
Update (3/21/21): Zyne had a fine week, moving to $5.31 by Friday close. It randomly shot up into the $7 range at the end of one day, but plummeted back to normal the following day. I tried to find a reason why that happened, and I couldn’t identify anything. I will say though that the same thing happened to GameStop. When it was stuck in the $4s throughout the month of August, it randomly shot up to $6.50 in one after hours and then returned to normal. This was when Ryan Cohen purchased his shares. Did some big player buy into Zyne? Maybe…
Update (3/28/21): Zyne is back under $5, making it a nice bargain. This stock is now shorted in double digits (11.5%).
Update (4/4/21): All of my Zyne shares were borrowed (see CLOV for details), so no surprise there. Again, this stock is being shorted in the double digits, so a big spike is coming once the scumbags need to cover.
Update (4/11/21): Zyne will present at the Needham Virtual Healthcare Conference on April 12. Hopefully we’ll get some positive news from that.
Update (4/18/21): Check out what I wrote today under Neptune. If the bill is passed, this will see a huge reversal.
Update (4/25/21): There was no news that bumped this stock from $3.80 to $4.40, and then back down to $4.20. I imagine there was a short covering, and then some bag holders sold some shares. Either way, this is still way below the price targets mentioned earlier.
Update (5/8/21): Here’s an encouraging graphic:
There was a ton of buying on Friday, which was great to see.
Update (5/16/21): Vanguard increased their shares from 1.03 million to 1.1 million at an average share price of $3.97.
Update (5/23/21): Goldman Sachs bought here as well. They now own 113,000 shares at an average price of $3.98.
Update (5/30/21): It appears as though Vanguard and Goldman Sachs knew what they were doing because Zyne closed the week at $5.68.
Update (6/6/21): Zyne had a bad week, closing just above $5. It’s unclear if the institutions sold, but if they did, I imagine the price would be much lower.
Update (6/13/21): I missed a 13G filing from last week, as ETF Managers Group increased their ownership of this company from five percent to 11.18. Zyne had a good week and could approach $10 soon.
Update (6/20/21): I sold out of Zyne for a very small profit. It’s disappointing because I wanted to hold on to it for a push to $10, but this company is not heavily shorted, so I may buy in after the market crash.
NFL Picks - Nov. 20
2025 NFL Mock Draft - Nov. 20
NFL Power Rankings - Nov. 19
Fantasy Football Rankings - Sept. 4
